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Scientific Abstract 
 
Cancer is one of the most prevalent diseases affecting the developed world. Breast cancer is a 
particularly common form of this disease affecting women with an estimated 1 in 8 expected to receive 
a diagnosis in her lifetime. Radiation therapy (radiotherapy) involves targeting cancerous cells with a 
high dose of ionising radiation, administered either externally (external beam radiotherapy) or via 
interstitial radioactive sources (brachytherapy) and may be offered as a treatment option in addition to 
surgery, chemotherapy, immunotherapy, or as a standalone treatment.  
 
Despite its efficacy, radiotherapy carries some risk of damaging healthy cells as well as the targeted 
cancerous cells which it aims to destroy. In order to deliver the therapeutic radiation doses required for 
tumour control, a relatively small yet still potentially harmful dose of radiation is inevitably received by 
surrounding healthy tissue located beyond the targeted region. This radiation dose, termed ‘out-of-field’ 
dose, arises from leakage radiation and scatter events within the medical linear accelerator, scatter 
from treatment accessories, and from within the patient. 
 
Modern management strategies as well as trends towards earlier diagnosis have translated to longer 
survival rates for breast cancer patients. The unfortunate corollary is twofold; one, that treatment side 
effects have longer to manifest, and two, patients may live longer with any treatment side effects which 
do present. As a result, increased emphasis is being turned to potential side effects of radiation 
treatment. With 5-year survival rates close to 90% for early stage breast cancer, it is no longer 
appropriate to ignore potential long-term treatment side effects such as second cancer induction. 
Unfortunately, out-of-field doses arising from radiotherapy treatment are not well modelled by 
commercial treatment planning systems. The doses received by untargeted healthy tissues therefore 
are often not well known, let alone optimised. 
 
This thesis addresses the increasingly pressing need to characterise the out-of-field dose received by 
untargeted healthy tissue during external beam radiotherapy for breast cancer. This is achieved through 
in vivo dosimetry whereby out-of-field doses are measured directly on patients as they undergo 
radiotherapy treatment. Specialised thermoluminescent dosimeters (TLDs) sensitive to low radiation 
doses were used, since most commercial detectors lack the sensitivity, dose linearity, and relatively flat 
energy response that is required for accurate dosimetry at out-of-field locations where the radiation 
environment is not precisely known. In vivo measurements were compared to doses calculated from a 
commercial treatment planning system (TPS) in order to assess the extent to which dose calculated 
from a commercial planning system differed from measurements. 
 
In order to further explore individual effects of various treatment parameters, such as the choice of 
beam energy and treatment field size, a series of controlled measurements were performed in a 
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phantom. A customised detector was designed to facilitate direct measurements of leakage radiation 
at the patient plane under various radiotherapy conditions. A correction for leakage radiation was 
derived as a result of phantom and in vivo measurements, providing improved dose estimates at out-
of-field locations. 
 
Skin reactions are a common side effect of breast radiotherapy and skin dose estimates from 
commercial treatment planning systems are often inaccurate. As part of this work, a thin window 
(‘Markus-type’) ionisation chamber was used to systematically characterise surface dose both in- and 
out-of-field. With modern flattening filter free (FFF) beams fast becoming standard on most new linear 
accelerators, it was imperative to characterise the resulting surface dose from FFF as well as standard 
beams which are commonly used to deliver breast radiotherapy in many centres around the world. A 
comparison is presented between surface dose from standard as well as modern FFF beams both in- 
and out-of-field for a typical breast radiotherapy beam geometry. This study demonstrated that FFF 
beams have the potential to reduce the out-of-field dose reaching areas of skin during radiotherapy for 
breast cancer. As this work shows, consequences for surface dose within the radiotherapy field 
depended largely on choice of beam energy and field size.  
 
This thesis provides a comprehensive assessment of the out-of-field dose delivered to untargeted 
healthy tissues during radiotherapy for breast cancer. Various dosimetry techniques were applied, 
requiring specialised TLD materials, thin window ionisation chamber measurements, dose calculations 
from various algorithms within a commercial treatment planning system, and the design and 
implementation of a novel collimated detector system to isolate the leakage component of out-of-field 
dose. Technological as well as patient-specific factors were explored; in vivo dosimetry is applied not 
only to standard breast radiotherapy but also expanded to include state-of-the-art stereotactic ablative 
body radiotherapy, where higher doses per fraction are delivered, to further assess leakage radiation 
in vivo at locations further from the treatment region than would be possible during conventional 
fractionation regimens. FFF beams were studied in detail to provide insight into potential implications 
of modern radiotherapy technologies.  
 
The findings from this work will help to better understand the risks associated with radiotherapy for 
breast cancer, and encourage the use of simple strategies to help minimise these risks, thus translating 
to more favourable outcomes for the large number of patients undergoing radiotherapy every year. 
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Chapter 1 - Introduction 
 
Cancer is one of the most prevalent diseases in the developed world. Since 2003, cancer has overtaken 
cardiovascular disease to become the greatest cause of disease burden in Australia (Begg et al. 2008). 
Breast cancer is one of the most common cancers affecting women along with colorectal and lung 
cancers. Approximately 1 in 8 Australian women will be diagnosed with breast cancer in her lifetime, 
translating to over 16,000 new cases every year.  
 
1.1 Role of radiotherapy 
 
Patients diagnosed with breast cancer often require multi-modality treatment for their disease which 
can include surgery, chemotherapy, hormonal therapy and radiation therapy (radiotherapy). Treatments 
are offered as standalone options or in combination, depending on the extent of the disease and patient-
specific factors. Radiotherapy plays a particularly important role in the treatment of early stage breast 
cancer. There is also a demonstrated survival benefit for locally advanced disease, such as younger 
women in whom disease has extended to the lymph nodes (Van de Steene J 2000). For early stage 
cancers, breast conserving surgery is typically performed to excise the primary site of disease followed 
by whole breast radiotherapy to treat microscopic spread which can manifest as local or distant 
recurrence in the years following original diagnosis. Meta analysis from the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) assessing the outcomes of 10,801 women demonstrated a 
marked reduction in disease recurrence where adjuvant radiotherapy was provided in addition to breast 
conserving surgery compared to surgery alone (Early Breast Cancer Trialists' Collaborative Group 
(EBCTCG) et al. 2011) with a 19.3 % risk of recurrence within 10 years in women who underwent 
radiotherapy plus surgery compared to 35.0 % risk of recurrence for women who only underwent 
surgery. Other studies have similarly demonstrated long-term survival benefits of radiotherapy 
treatment for breast cancer (Fodor, Polgar, and Nemeth 2000; Vinh-Hung and Verschraegen 2004). 
 
Evidence-based estimates of optimal radiotherapy utilisation rates have demonstrated that 83 % of 
breast cancer patients would benefit from at least one course of radiotherapy as part of their overall 
treatment (Shafiq, Delaney, and Barton 2007) making it an important treatment for a large number of 
patients. Based on populations of breast cancer patients, the additional benefit in local control rate is 
estimated to be 11.1 %, with an additional 3.1 % benefit in 10 year overall survival with some variation 
depending on stage of the disease. Thus, per 100,000 women diagnosed with breast cancer, the 
inclusion of radiotherapy as part of overall disease management results in approximately 3000 
additional patients surviving at 10 years after the original diagnosis and 11,000 recurrences avoided. 
Actual utilisation rates however are reported to be well below the estimated optimal rate at between 24 
% and 71 % across Australia, the United Kingdom and the United States (Delaney, Barton, and Jacob 
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2003). With emerging clinical evidence however these rates are reported to be increasing. Radiotherapy 
will therefore continue to play a crucial role in the management of breast cancer well into the future.  
 
Advances in early detection measures in conjunction with modern treatment options have improved 
five-year survival rates from 72 % during the mid-1980s to 90 % between 2008 and 2012 (AIHW 2016) 
(Figure 1.1), presenting a large population of long term survivors. 
 
 
Brachytherapy is another means of delivering ionising radiation to patients with breast cancer. 
Brachytherapy may be administered either via use of ‘stepping’ a radioactive source through needles 
which have been temorarily implanted within the site of disease (as in high dose rate brachytherapy, or 
‘HDR’), or by implanting radioactive seeds which remain inside the breast (low dose rate brachytherapy, 
or LDR). While this thesis only addresses external beam radiotherapy, the interested reader is referred 
to a review on the use of different brachytherapy methods in breast cancer by Skowronek et. Al 
(Skowronek, Wawrzyniak-Hojczyk, and Ambrochowicz 2012). 
 
1.2 Treatment side effects: risks versus benefits 
 
Despite the strong clinical evidence in favour of radiotherapy there is a degree of concern surrounding 
late effects from treatment. Modern radiotherapy techniques enable highly conformal dose distributions 
to sculpt high radiation doses to a target site of disease while sparing surrounding healthy tissue from 
unnecessary exposure. The increasing efficacy of advanced radiotherapy techniques is increasing 
patient life expectancy post-treatment. The unfortunate corollary is that patients may experience late 
effects as a result of treatment. Late effects are of concern for long term survivors firstly because the 
time spent living with side effects is longer, impacting quality of life, and secondly the prolongation of 
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life inherently allows longer time for late effects to develop. This is of particular relevance for the large 
population of long-term survivors who can enjoy a long life expectancy after successful treatment of 
their primary cancer. Young patients in particular may live decades after treatment and radiotherapy 
side effects must be considered in clinical decision making. 
 
Radiotherapy side effects may be classified as either acute or late depending on the time elapsed 
between radiation exposure and the onset of side effects. Acute side effects present in the days or 
weeks following treatment but often subside depending on their severity. They are also usually dose-
dependent and may be an expected but inevitable side effect of treatment. The decision to subject a 
patient to the risk of such effects must be balanced against the need to treat the primary cancer and is 
often deemed an acceptable risk given the cancer posing a more immediate threat to a patients’ health.  
 
Skin reactions are an important acute reaction in breast radiotherapy. It is estimated that one third of 
patients experience significant acute skin toxicity during their radiotherapy treatment (Fisher et al. 
2000), with reactions varying from mild to brisk erythema or moist desquamation in more severe cases. 
The severity of skin reactions depends on the absorbed dose, fractionation regime and the total volume 
of skin irradiated. In cases where there is suspected disease spread to the dermal lymphatics, the skin 
may be included as part of the intended treatment volume, leading to a high but unavoidable skin dose. 
Accurate knowledge of skin dose is therefore important in breast radiotherapy, and several authors 
have published on the use of various detectors suitable for skin dose measurements in radiotherapy 
including film (Cheung, Butson, and Yu 2002), thermoluminescent dosimeters (TLDs) (Gorken et al. 
2002; Kron et al. 1996a; Ostwald et al. 1995; Kron et al. 1993), and optically stimulated luminescent 
dosimeters (OSLDs) (Yusof et al. 2015).  
 
In left sided breast cancer the heart usually lies in close proximity to the treatment target. Conventional 
radiotherapy beam arrangements are oriented in such a way that the primary beam often directly 
traverses the heart in order to cover the entire breast tissue, resulting in incidental exposure of the heart 
to high radiation doses. In a population based study of 2168 women, Darby et al reported an increased 
risk of ischemic heart disease for women who underwent radiotherapy for breast cancer (Darby et al. 
2013). By obtaining heart dose estimates for those women who had undergone radiotherapy, the risk 
of a major coronary event was found to increase with mean heart dose, with no apparent threshold, 
suggesting that any reduction in mean heart dose will lead to a reduced risk of heart disease in the 
years following treatment. Due to the latency period of onset of heart disease, modern clinical evidence 
is based on radiotherapy techniques which are years or even decades old. Interpretation of such 
evidence must therefore take into consideration the recent advances in radiotherapy techniques and 
that dose to untargeted healthy structures from modern techniques may be considerably less than that 
of older techniques. With increased use of image guidance, treatment volumes have since been 
reduced leading to a reduction in exposure of normal tissues. As such the estimated heart dose in 
population based studies from which current clinical evidence is drawn is likely to be conservative. Even 
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so, such studies have demonstrated an increased risk with mean heart dose and therefore mean dose 
must be kept as low as possible.  
 
Such evidence has incentivised radiotherapy practitioners to keep heart doses as low as possible for 
breast cancer patients. Deep inspiration breath hold (DIBH) is a technique which employs the patient 
to take an active role in their radiotherapy treatment and can significantly reduce heart dose particularly 
in left-sided cases. The patient takes a deep breath and holds this position during treatment. This 
causes the diaphragm to relocate inferiorly, thereby drawing the heart away from the radiation beam 
path. DIBH offers promise although relies heavily on patient compliance and capability as well as 
availability of technological requirements such as patient audio-visual feedback and beam gating 
capabilities. Because of these potential limitations DIBH is not standard of care for left sided breast 
cancer patients, although the technique is fast gaining popularity. 
 
Regions of lung are also incidentally exposed during radiotherapy for breast cancer. Due to the 
geometry of breast tissue and its conformity to the shape of chest wall, lung is often unavoidable even 
through use of modern conformal treatment techniques. Furthermore, lung is a key organ at risk for 
right sided as well as left sided breast cancer. The incidence of second lung cancer as a result of breast 
radiotherapy is rare, reportedly occurring in 9 cases for every 10,000 women undergoing breast 
radiotherapy (Inskip, Stovall, and Flannery 1994a). Radiation pneumonitis may also present in women 
who have undergone breast radiotherapy. Reported incidence of radiation pneumonitis varies 
considerably ranging from between 1 and 80 % (Jeba et al. 2015). Such variation arises from vast 
differences in planning techniques and, hence, radiation dose to lungs. Further complications arise from 
variations in patient follow-up and grading criteria for radiation pneumonitis across different studies. 
Recent work however has demonstrated that applying adequate lung dose constraints in conformal 
radiotherapy planning can decrease the incidence of radiation pneumonitis (Blom Goldman et al. 2014), 
making it a rare side effect in breast radiotherapy if the volume of lung receiving 20 Gy is kept below 30 
%. 
  
1.3 Planning strategies to reduce radiation risk 
 
In radiotherapy planning, dose to normal healthy structures may be reduced by judicious choice of beam 
angle, energy, or utilisation of shielding where possible. Modern advances have provided the option of 
modulating the beam as it is being delivered by passing multi leaf collimator (MLC) leaves across the 
treatment field to sculpt the dose distribution to more tightly conform to the shape of the target. These 
techniques are dubbed intensity modulated radiotherapy (IMRT). An IMRT treatment may also be 
delivered while the gantry of the linear accelerator (linac) is rotating about the patient in an arc while 
the MLC leaves are moving in and out of the beam. This is referred to as volumetric modulated arc 
therapy (VMAT). The use of IMRT and VMAT for breast radiotherapy is not widely used, as the low 
dose component extends further into normal structures, namely heart, lung and contralateral breast. 
Furthermore, dose calculations by the treatment planning systems in the low dose and out-of-field 
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regions are known to exhibit reduced accuracy at increasingly larger distances from the treatment field. 
This in turn brings into question the accuracy of dose reported to untargeted healthy structures. This 
additional uncertainty may bring about a degree of reluctance to adopt new treatment techniques which 
increase the dose in an area not modelled well. Nevertheless, research into IMRT and VMAT for breast 
irradiation is ongoing (Beckham et al. 2007a; Popescu et al. 2010a) and these techniques may yet have 
an important role to play for patients requiring radiation treatment to nodal areas where conventional 
tangents are unable to provide sufficient coverage. 
 
1.4 Limitations of out-of-field dose calculations 
 
In external beam radiotherapy the primary beam is collimated to conform to the shape of the treatment 
target. This shields untargeted healthy tissue from the beam and avoids unnecessary radiation 
exposure of regions not intended for treatment. There is, however, a component of radiation which 
unavoidably reaches untargeted peripheral regions during treatment. This ‘out-of-field’ dose arises due 
to scattered radiation from collimating devices, leakage from the treatment machine head, and scattered 
radiation from the patient. A properly commissioned commercial treatment planning system will 
accurately model the dose distribution within the primary beam. Most planning systems will also give 
reasonable dose estimates in the first few centimetres beyond the penumbra, defined as the region 
between 20 % to 80 % of central axis dose at the beam edge. However, several studies have reported 
significant under-estimation of out-of-field dose beyond this region where head leakage and collimator 
scatter dominate as the main contributors to patient dose. These contributions are not explicitly 
modelled by commercial planning systems. Therefore to account for out-of-field dose in radiotherapy 
this dose must be either directly measured during the course of treatment or calculated using Monte 
Carlo simulations that include a complete model of the linear accelerator and accessories as well as 
the patient. Neither method is employed routinely and as such out-of-field dose remains the subject of 
ongoing research in radiotherapy. 
 
1.5 Increasing importance of out-of-field dose 
 
Out-of-field dose in radiotherapy has gained much interest in recent years (Figure 1.2). Although small 
compared to the treatment dose, out-of-field dose in radiotherapy is large enough to elevate the risk of 
a second cancer induction during the years following treatment.  
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Long term studies on atomic bomb survivors following the events at Hiroshima and Nagasaki provide 
gold standard data on the effects of radiation on human health. Recent follow up from the Life Span 
Study has provided strong evidence for the linear no threshold model for solid cancer incidence 
following radiation exposure in humans (Preston et al. 2007a). Increased solid cancer rates were 
observed for most sites including oral cavity, oesophagus, stomach, colon, liver, lung, skin, breast, 
ovary, bladder, nervous system and thyroid. The degree of excess risk however was found to vary with 
age at exposure as well as gender, with women being more susceptible to the harmful effects of 
radiation owing to ovarian and breast cancer incidence, although by restricting the analysis to non-
gender specific cancers this increase disappears. Overall, younger women are at greater risk from 
second cancer induction following exposure to ionising radiation compared to the general population. 
This risk must be considered for the large population of women undergoing radiotherapy for breast 
cancer, particularly those with favourable prognosis. 
 
1.6 Aims of this thesis 
 
The aim of this thesis therefore is to assess the out-of-field radiation dose reaching untargeted healthy 
tissue during radiotherapy for breast cancer. This is achieved through a combination of phantom 
measurements under controlled conditions and measurements conducted in vivo on patients 
undergoing radiotherapy. The problem of out-of-field dose as a whole is divided into key elements; 
patient-related considerations are addressed early in the thesis through an in vivo dosimetric study 
involving a cohort of breast cancer patients. This study is complimented by a technical in vivo dosimetric 
study utilising state-of-the-art stereotactic ablative body radiotherapy for primary kidney cancer to 
address leakage radiation in unique radiotherapy measurement environments only afforded in 
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Figure 1.2 - Total number of publications pertaining to out-of-field dose in 
radiotherapy containing specific reference to second cancers. 
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stereotactic treatments. Out-of-field dose as measured in vivo is then compared to dose calculations 
from a commercial treatment planning system to assess limitations of doses calculated out-of-field. This 
is complimented by a phantom study assessing leakage radiation from a medical linear accelerator in 
which a collimated detector system has been designed and built to isolate leakage radiation at out-of-
field locations. This thesis then explores potential future developments in breast radiotherapy by 
assessing skin dose and out-of-field dose arising from modern flattening filter free treatment beams. A 
comparison of these doses is drawn to conventional beams and the relative benefits are discussed. An 
overview of the contents of this thesis is illustrated in Figure 1.3. 
 
1.7 Thesis structure 
 
An in vivo patient study is presented in Chapter 2. In this work, TLD measurements were conducted on 
breast cancer patients as they underwent radiotherapy treatment. The measurement points chosen 
correspond to anatomy which is considered relevant for long term risk from radiation exposure. These 
locations include the contralateral breast, axilla and thyroid. Dose measured at these locations was 
compared to the dose calculated in a commercial radiotherapy treatment planning system. Multiple 
dose calculation algorithms, each used in routine clinical practice and each with varying levels of 
sophistication in their ability to model radiation transport, were assessed.  
 
In vivo dosimetric measurements conducted under conventional dose fractionation regimens result in 
very low out-of-field measured doses measured for a single fraction out of up to 50 fractions, which are 
scaled up to estimate the final resulting dose over the entire course of radiotherapy. This can raise 
questions about the uncertainties associated with low dose measurements. To overcome this, 
measurements can either be conducted at each treatment fraction or on patients requiring fewer 
fractions. In Chapter 3, in vivo measurements are extended to stereotactic ablative body radiotherapy 
(SABR) patients in order to quantify the leakage dose component in a high dose per fraction scenario. 
This chapter also investigates the appropriateness of TLD as an in vivo dosimeter in a mixed radiation 
field environment, particularly in the context of high energy beams which, in the case of 10 MV and 
above, can generate neutrons which also interact with the TLD material during measurement.  
 
Systematic measurements of out-of-field dose from medical linear accelerators conducted under 
controlled radiation scenarios are presented in Chapter 4. This study utilised a novel collimated detector 
device combined with TLD measurements in order to ‘map’ peripheral dose reaching the patient plane. 
Consequences for leakage dose resulting from changing radiation field size and collimator rotation were 
investigated. Leakage radiation, which is characterised by photons emanating directly from the 
treatment machine, was distinguished from scatter radiation through use of multiple TLDs enclosed 
within the collimated detector. Leakage radiation, although a known contribution to peripheral dose in 
radiotherapy, is not modelled by commercial treatment planning systems and quantifying this 
contribution through direct measurement can inform at least one component of ‘missing’ dose from 
treatment planning system dose calculations. 
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Chapter 5 presents a systematic phantom study using a well-characterised Marcus-type (Exradin A10) 
thin window ionisation chamber to ‘map’ the surface dose both in and out of the primary radiation field 
for various radiation field sizes and beam qualities, including flattening filter free (FFF). Such photon 
beams are a new emerging treatment modality which is fast becoming standard on many new medical 
linear accelerators. Various studies have reported some potential benefits of FFF in breast radiotherapy. 
It was therefore necessary to assess the out-of-field dose associated with FFF, with particular regard 
to how this compares to conventional flattened beams. After characterising the surface dose from 
‘standard’ radiation field sizes (ie, square and symmetric), a half-beam block off-axis rectangular field 
of dimensions typically used for breast radiotherapy was used to characterise the surface dose in and 
out of field. It was found that FFF beams may provide a reduction in out-of-field dose beneath the 
shielding jaw in regions typically corresponding to the contralateral breast compared to conventional 
flat beams. 
 
The four main chapters are followed by a detailed discussion of the results of this work. An updated 
literature review is included and the relevance of the work published herein is discussed. Final 
concluding remarks are provided at the end of the thesis. 
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Figure 1.3 - An overview of the thesis contents. Main outcomes are stated, showing their link to the 
original problem. TLD and ion chamber measurements are employed, as well as patient studies. 
Technological as well as patient-specific considerations are addressed. 
 
 
 
 
 
 
 
 
 
 
 
Unwanted out-of-field dose as a problem in breast radiotherapy 
Technology Patient (in vivo dosimetry) 
Planning strategies 
(example FFF) 
Technical 
evaluation (SABR) 
Clinical evaluation  
(breast radiotherapy) Accelerator design 
Outcomes of thesis: 
 
Application of TLD for out-of-field in vivo dosimetry in breast radiotherapy and comparison 
of measured and calculated dose at key points of concern for long-term risk (Chapter 2) 
 
Assess leakage radiation in high dose treatments & determine the magnitude of over-
response of TLD for out-of-field in vivo dosimetry in mixed photon fields (Chapter 3) 
 
 
Evaluation of out-of-field dose at the patient plane from different beam geometries and 
energies using a collimated TLD measurement system (Chapter 4) 
 
Systematic evaluation of surface dose out-of-field using ion chamber measurements 
comparing flat and FFF beams (Chapter 5) 
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Chapter 2 
 
 
 
Assessment of leakage dose in vivo in patients 
undergoing radiotherapy for breast cancer 
 
 
 
Direct in vivo assessment of out-of-field dose is presented in Chapter 2. In this work, the dose 
measured using thermoluminescence dosimetry (TLD) is compared to calculated doses from a 
commercial treatment planning system. TLD measurements were conducted using customised 
‘buildup domes’ at out-of-field locations on eleven patients as they underwent external beam 
radiotherapy treatment for breast cancer. Different class of dose calculation algorithms were found to 
exhibit varying levels of accuracy at out-of-field locations. Overall, TPS-calculated doses were found 
to under-estimate TLD-measured doses. As a consequence, the resulting risks associated with those 
out-of-field doses are also under-estimated if measurements are not conducted. Since in vivo 
dosimetry is not routine practice at out-of-field locations during radiotherapy this work went on to 
explore potential options for correcting TPS-calculated doses which could translate to a wider patient 
population. At regions peripheral to the radiotherapy field edge, a simple single-valued correction for 
leakage radiation from the medical linear accelerator is feasible as a means of accounting for this 
additional patient exposure. To our knowledge, this is the first patient study to provide a measurement-
based leakage dose correction. Chapter 2 shows that the accuracy of radiation dose calculations 
diminishes at peripheral locations where linear accelerator-specific leakage and head scatter 
components are dominant, and demonstrated that application of a leakage correction, equivalent to 
0.04 % of the primary beam - or ~20 mGy in the context of a 50 Gy breast treatment - in radiation 
treatment planning improves dose calculations at out-of-field locations. 
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A B S T R A C T
Background and purpose: Accurate quantiﬁcation of the relatively small radiation doses delivered to untargeted
regions during breast irradiation in patients with breast cancer is of increasing clinical interest for the purpose of
estimating long-term radiation-related risks. Out-of-ﬁeld dose calculations from commercial planning systems
however may be inaccurate which can impact estimates for long-term risks associated with treatment. This work
compares calculated and measured dose out-of-ﬁeld and explores the application of a correction for leakage
radiation.
Materials and methods: Dose calculations of a Boltzmann transport equation solver, pencil beam-type, and su-
perposition-type algorithms from a commercial treatment planning system (TPS) were compared with in vivo
thermoluminescent dosimetry (TLD) measurements conducted out-of-ﬁeld on the contralateral chest at points
corresponding to the thyroid, axilla and contralateral breast of eleven patients undergoing tangential beam
radiotherapy for breast cancer.
Results: Overall, the TPS was found to under-estimate doses at points distal to the radiation ﬁeld edge with a
modern linear Boltzmann transport equation solver providing the best estimates. Application of an additive
correction for leakage (0.04% of central axis dose) improved correlation between the measured and calculated
doses at points greater than 15 cm from the ﬁeld edge.
Conclusions: Application of a correction for leakage doses within peripheral regions is feasible and could im-
prove accuracy of TPS in estimating out-of-ﬁeld doses in breast radiotherapy.
1. Introduction
With a signiﬁcant reduction in recurrence rates and breast cancer
mortality compared with surgery alone [1,2] whole breast irradiation
following breast conserving surgery is standard practice for patients
with early stage breast cancer. However, there is concern that in-
cidental out-of-ﬁeld radiation doses to the untargeted normal tissues
during breast radiotherapy may be associated with an increased risk of
secondary malignancy [3–7]. The improving survival of patients with
early breast cancer underpins this concern, and adds emphasis to the
need to accurately quantify radiation doses to untargeted healthy tis-
sues during treatment for a more accurate estimation of the risk of
radiation-related second malignancy. In addition, the out-of-ﬁeld ra-
diation received by surrounding healthy tissues during breast irradia-
tion is associated with toxicities of the heart, lung and thyroid [8–10].
Risk of ischemic heart disease in patients following radiotherapy for left
sided breast cancer has been shown to be dose dependent [8]. The
geometry of tangential beam radiotherapy in particular raises questions
regarding the dose delivered to the contralateral breast. This is parti-
cularly important as the breast tissue is assigned a relatively high
weighting factor for radiation protection purposes, reﬂecting its sensi-
tivity to radiation [11]. The risk of radiation-related contralateral
breast cancer following ipsilateral breast radiotherapy is thought to be
dose-dependent [12,13]. Any reduction in out-of-ﬁeld dose to healthy
tissue is therefore important for long term risk reduction, and accurate
calculation of out-of-ﬁeld dose to the contralateral breast is crucial for
informing risk estimates.
The out-of-ﬁeld dose results from leakage radiation from the linear
accelerator scatter from the collimators and beam modiﬁers, and in-
patient scatter. The latter contribution is accounted for by the treatment
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planning system (TPS) at regions relatively close to the beam. However,
linear accelerator-speciﬁc contribution to out-of-ﬁeld dose is largely
unaccounted for by dose calculation algorithms since head leakage
contributions are usually not explicitly considered during beam data
acquisition at commissioning of a new TPS. Thus, radiation dose from
machine leakage and head scatter is not accounted for at peripheral
regions during treatment planning. These are also the dominant con-
tributors to out-of-ﬁeld dose at distances greater than approximately
30 cm from the beam edge depending on treatment parameters [14]
corresponding to regions of untargeted healthy tissue. Others have
shown that neutron contamination also begins to contribute to out-of-
ﬁeld dose in higher energy treatments above approximately 10MV
[15,16], which is also not explicitly modelled.
Previous work has provided systematic analysis of out-of-ﬁeld dose
proﬁles under various treatment parameters in a phantom. Howell et al.
reported a commercial system to have underestimated out-of-ﬁeld dose
by an average of 40% between 3.75 and 11.25 cm from the ﬁeld edge
[17], with the magnitude of this discrepancy increasing at larger dis-
tances. Huang et al. analysed the out-of-ﬁeld dose for IMRT treatments
and similarly concluded the TPS underestimated out-of-ﬁeld dose, in
this case by an average of 50% [18]. The recent AAPM TG 158 pub-
lication [19] discussed the challenges associated with quantifying out-
of-ﬁeld dose in modern radiotherapy, highlighting the importance of
extra target doses as a consideration for long term patient outcomes and
providing physicists and clinicians with guidance for assessing such
doses. A comprehensive review of out-of-ﬁeld dose and risk estimates in
radiotherapy is also provided by Xu et al. [20].
Previous groups have analysed the out-of-ﬁeld dose from diﬀerent
TPS algorithms in water phantoms [21,22], with others using anthro-
pomorphic phantoms to better represent patient treatment [17,23].
Such phantom studies allow treatment parameters to be systematically
altered to study their individual eﬀects on the out-of-ﬁeld dose, and in
turn the ability of the TPS to model these eﬀects. Johansen et al. [24]
measured higher contralateral breast dose with inclusion of a supra-
clavicular fossa ﬁeld in regional nodal irradiation following TLD mea-
surements, concluding that a collapsed cone algorithm was better able
to estimate the out-of-ﬁeld dose compared to a pencil beam algorithm.
Saur et al. used GafChromic ECT ﬁlm in a phantom to assess con-
tralateral breast dose from diﬀerent planning techniques, demon-
strating higher contralateral breast dose from hard wedges compared to
virtual wedges and concluding the TPS algorithms were inadequate for
modelling these doses [25]. Joosten et al. [26] performed Monte Carlo
simulations on patient CT scans to compare out-of-ﬁeld dose from IMRT
and conventional tangent breast irradiation techniques. They found
that out-of-ﬁeld head scatter, which is not adequately modelled by the
TPS, contributed a large portion of the out-of-ﬁeld dose. Similarly to
phantom studies, the TPS was found to under-estimate dose to healthy
tissues beyond the treatment beams. Monte Carlo is the ‘gold standard’
for calculating dose deposition in various media and provides the op-
portunity to compare out-of-ﬁeld dose from diﬀerent planning techni-
ques on a patient CT scan – which cannot be done via in vivo dosimetry
– however, with the peripheral dose shown to vary among diﬀerent
accelerator designs [27], direct measurement is still required to accu-
rately assess patient doses from a given radiotherapy treatment.
In vivo dosimetry at peripheral locations during radiotherapy is not
common practice. As a result, dose calculations by the TPS are usually
the only indication of the dose to peripheral tissues such as the con-
tralateral breast. Thus, the aim of the current study was to assess the
accuracy of dose calculations at peripheral locations using diﬀerent
algorithms from a commercial treatment planning system by comparing
the calculated doses with in vivo thermoluminescent dosimeter (TLD)
measurements conducted out-of-ﬁeld on the contralateral chest of
eleven patients undergoing breast radiotherapy. In addition, the current
study aimed to improve the TPS calculation accuracy with the appli-
cation of a correction for leakage dose.
2. Materials and methods
2.1. Patient cohort
In vivo thermoluminescent dosimetry (TLD) measurements were
performed in eleven patients who underwent ipsilateral whole breast
irradiation following breast conserving surgery for early breast cancer
(Table 1, Supplementary material). All patients provided informed
consent for this study which was approved by the Human Research
Ethics Committee of the Peter MacCallum Cancer Centre in Melbourne,
Australia.
2.2. Treatment planning system calculations
A tangential photon beam treatment plan was created on the
planning CT scan for each patient as per institutional practice. The la-
terality of the treated site, use of a ﬁeld-in-ﬁeld technique, gantry angle,
dynamic wedge angle, ﬁeld size, and number of monitor units used for
each patient are summarised in Table 1 (Supplementary material). Each
patient underwent treatment as planned. The dose at each pre-speciﬁed
measurement point (Fig. 1a) was re-calculated in the TPS software
(Eclipse version 13.6, Varian Medical Systems, Palo Alto, CA) using the
convolution-based Analytical Anisotropic Algorithm (AAA, referred to
as “convolution” herein), Pencil Beam Convolution (PBC, referred to as
“pencil beam” herein), and a more modern linear Boltzmann transport
equation solver Acuros XB (referred to as “Boltzmann solver” herein). A
1.0 cm thick layer of bolus was added to each patient CT dataset to
simulate buildup conditions provided by the TLD perspex holders,
Fig. 1. (a) Diagram depicting measurement Points A, B, C and D on the contralateral breast (3 cm from the nipple in four cardinal directions); Point E at the contralateral mid axilla; and
Point F at the suprasternal notch, and (b) diagram depicting build-up domes used for in vivo measurements, adapted from Lonski et al. 2014 [30].
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which were not applied during the planning CT scan. The dose to each
measurement point was recorded for each algorithm and compared to
the measured dose acquired in vivo.
2.3. In vivo measurements
Measurements were performed using high sensitivity TLD chips
which were placed inside custom-made perspex ‘build-up domes’. The
domes (Fig. 1b) were designed to provide 1 cm build-up material with
minimal directional dependence. LiF:Mg,Cu,P, or “TLD-100H”, chips
(Harshaw, Kansas, USA) were selected for their high sensitivity and
near-tissue radiological equivalence, making them a suitable dosimeter
for in vivo measurements at peripheral locations [28]. Three TLD chips
were used at each measurement location. The chips were calibrated
prior to use in a 6MV photon beam using solid water slabs and each
chip was assigned an individual sensitivity factor according to its in-
dividual response to the batch average following irradiation. TLD chips
were read out using a Harshaw 5500 automatic TLD reader. For TLD-
100H, the combined use of multiple chips for each measurement and a
careful calibration process with tightly controlled handling and readout
process yields an overall measurement uncertainty of± 2% at the 95%
conﬁdence level for each measurement [29]. For in vivo dosimetry,
positioning of the buildup domes and dose gradients across the dome
area increases the measurement uncertainties, estimated here to be
10% (Type B).
All patients were treated on a Varian 21-X medical linear accel-
erator. In vivo measurements were conducted at six pre-deﬁned points
peripheral to the treated region which were nominally identical on all
patients: four on the contralateral breast, one at the contralateral mid
axilla and one at the suprasternal notch, indicating dose to the thyroid
gland (Fig. 1a). Three TLD chips were placed inside each buildup dome
and a single dome was taped to the patients’ skin at each point. Mea-
surements were taken for a single fraction and results extrapolated for a
complete 25-fraction treatment. All patients were treated on a Varian
21-iX medical linear accelerator using 6 MV (TPR20,10= 0.668) photon
beams.
Based on the TLD measurement locations (Fig. 1a), there were three
distinct regions deﬁned as a function of distance from the most prox-
imal edge of the largest ﬁeld (0–5 cm, denoted region 1; 10–15 cm,
denoted region 2; and>15 cm, denoted region 3 herein). Points B and
F were located in region 1, Points C and D were located in region 2, and
Points A and E were located in region 3 (with a maximum distance of
24 cm from the ﬁeld edge).
2.4. Analysis
TLD data was compared to TPS point dose calculations at Points A to
F (Fig. 1a). Discrepancies between the planned and measured doses
were evaluated as a function of distance from the most proximal ra-
diation ﬁeld edge.
2.5. Leakage dose correction
Discrepancies at locations distal to the primary radiation ﬁeld were
assumed to be due to machine leakage radiation. The use of a single-
value correction factor for leakage radiation was assessed to determine
if it improved accuracy of TPS in estimating doses at peripheral sites
where TPS calculations did not explicitly account for leakage con-
tributions. Measured doses which were less than 1 Gy total over the 25
fraction treatment were considered for this leakage correction. The
leakage component was assumed to be additive. The corrected dose,
Dcorr, in Gy, may be expressed as:
= + ×D (Gy) D (Gy) (C 50 Gy prescribed dose)corr calc leak (1)
where Dcalc is the uncorrected calculated TPS dose; and Cleak is the
correction for leakage dose expressed as a percentage of a 50 Gy pre-
scription. The optimal Cleak value was determined mathematically by
considering the discrepancies at each point between measured dose and
calculated dose for the cohort of eleven patients.
For in vivo data, the sensitivity-corrected thermoluminescence signal
was expressed as measured dose (Gy) calibrated against standard TLDs
irradiated to a known dose delivered under standard conditions using a
6MV 10×10 cm2 ﬁeld at the depth of maximum build-up with the
provision of suﬃcient backscatter material. The measured dose for a
single fraction was extrapolated to a measured dose for the entire
treatment course and was accordingly expressed in the following sec-
tions.
3. Results
3.1. TPS accuracy
Measured and calculated doses decreased approximately ex-
ponentially as a function of distance from the ﬁeld edge at peripheral
regions as is shown in Fig. 2a. However, TLD doses decreased less ra-
pidly with distance than the TPS calculated doses in regions beyond
20 cm from the ﬁeld edge. The correlation between calculated and
measured data is shown in Fig. 2b. The ratios of TPS calculated dose:
TLD measured dose are shown as a function of distance from the ﬁeld
Fig. 2. (a) Doses from TPS calculations and TLD measurements as a function of distance from the ﬁeld edge at out-of-ﬁeld regions for eleven breast cancer patients treated with ipsilateral
whole breast radiotherapy; and (b) ratios of TPS calculated dose: TLD measured dose as a function of distance from the ﬁeld edge.
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edge. The Boltzmann solver was shown to be the most accurate algo-
rithm in general across all regions but it under-estimated the measured
dose in region 3.
The average ratios of calculated dose: measured dose in region 1
were 0.84, 1.31 and 1.12 for the convolution-based algorithm, pencil
beam type algorithm and Boltzmann solver, respectively. In region 2,
these ratios were 0.27, 1.32 and 1.01, respectively. In region 3, the
convolution algorithm did not provide an estimate of the dose. The
ratios were 0.74 for the pencil beam and 0.48 for the Boltzmann solver.
The spread of the data can be seen in Fig. 2b.
3.2. Consideration of leakage radiation
The value at which TPS-calculated and TLD-measured dose diﬀer-
ences was at a minimum for all dose points less than 1 Gy was taken as
the leakage correction. Discrepancies between the TPS-calculated and
TLD-measured doses reduced to a minimum for all patients when an
additive leakage correction of 0.04% was applied to the Boltzmann
solver out-of-ﬁeld calculation dose as per Equation 1. A single value
leakage correction was not able to improve the out-of-ﬁeld dose cal-
culations for the convolution based or pencil beam type algorithms.
Without a leakage correction, the Boltzmann solver was found to be the
most accurate algorithm (Fig. 2b). The correlation between the Boltz-
mann solver calculated doses and TLD measured doses before and after
application of leakage correction is shown in Fig. 3.
The addition of a 0.04% leakage correction to the Boltzmann solver
data improved the average ratio of TPS-calculated dose: TLD-measured
dose for this patient cohort in region 3. The correction did not improve
dose calculations in regions closer to the radiation ﬁelds. The average
ratios of TPS-calculated dose: TLD-measured dose for the Boltzmann
solver were 1.12 in region 1, 1.01 in region 2 and 0.48 in region 3
without a leakage correction, and 1.13, 1.10 and 0.66 in the corre-
sponding regions after correction.
4. Discussion
In the present study, accuracy of the out-of-ﬁeld doses calculated by
three TPS algorithms commonly used in clinical practice were com-
pared to measured data acquired in vivo on patients undergoing breast
radiotherapy. The measurement points represented locations of dosi-
metric interest for the purpose of radiation-related risk assessment.
The results showed that accuracy of calculated doses at each mea-
surement point varied amongst the three TPS algorithms. The
discrepancy in calculated doses in comparison to measured doses could
be attributed to varying levels of sophistication of the TPS algorithms.
Overall, the Boltzmann solver data correlated better with in vivo mea-
surements than the convolution-based and pencil beam type algo-
rithms. At measurement points beyond 15 cm from the ﬁeld edge, the
convolution algorithm did not calculate dose. A thorough discussion on
this algorithm is provided by Van Esch et al. [31], who demonstrated
improved accuracy compared to single pencil beam algorithms for in-
ﬁeld locations. The more advanced Boltzmann transport equation
solver was tested by Fogliata et al. [32] in various ﬁeld sizes in the
presence of heterogeneities. It was found to be in close agreement with
Monte Carlo simulations and a marked improvement over convolution-
based methods. Despite varying degrees of sophistication and accuracy
in-ﬁeld, each algorithm in the present work was found to suﬀer in-
accuracies out-of-ﬁeld, and each to varying degrees. This study was not
designed to ascertain the cause of diﬀerences in performance between
algorithms. The Boltzmann solver uses a variable dose calculation grid
size and therefore out-of-ﬁeld dose calculations are averaged over a
larger volume compared with the convolution-based and pencil beam
algorithms. The Boltzmann transport equation solver also models ra-
diation dose distributions in the presence of heterogeneous media with
greater accuracy. A combination of these factors may have contributed
to the improved accuracy at out-of-ﬁeld locations demonstrated in this
study.
Application of a leakage correction improved accuracy of dose
calculations by the Boltzmann solver beyond 19 cm from the ﬁeld edge.
The measured leakage correction of 0.04% is consistent with
International Electrotechnical Commission (IEC) recommendations that
the leakage dose from a medical linear accelerator does not exceed
0.1% of the primary beam at 1m from the source [33]. The leakage
component was likely to be more prominent in distal regions and was
not explicitly modelled by the TPS. However, the correction did not
improve accuracy of calculated doses by the three TPS algorithms at
more proximal measurement points in regions 1 and 2 where the
leakage component was likely to be dominated by head scatter. Out-of-
ﬁeld doses from medical linear accelerators have been shown to vary
with machine design [26,27]. Therefore, leakage corrections would
require experimental veriﬁcation as they are likely to vary depending
on design of the linear accelerators. The single value correction for
leakage dose in the present study did not provide a complete solution
for all measurement regions, as it over-corrected for the discrepancy in
calculated doses by the Boltzmann solver in regions close to the treat-
ment ﬁeld. Nevertheless, an improvement in calculation accuracy was
demonstrated with the added correction for this cohort of patients.
Further work is required to assess the application of this correction to a
wider patient cohort including diﬀerent planning techniques, treatment
sites and linac models. A limitation of this study is that in vivo data is
included from one particular linear accelerator design and calculated
data is a from one TPS vendor. Application of results to a wider patient
population would therefore require further investigation.
The radiation leakage doses, albeit low, are of clinical relevance and
potential signiﬁcance for long term risk-assessment, for example, in a
patient undergoing radiotherapy who is found to be pregnant. The
International Commission on Radiological Protection (ICRP) report 84
[34] states that termination of pregnancy for foetal doses below
100mGy are not recommended, as the risk of foetal complications is
low. For a patient who received a total dose of 50 Gy, the present study
demonstrated that the leakage dose was approximately 20mGy. Al-
though this leakage dose on its own is below the threshold stipulated in
the ICRP guidelines for consideration of termination of pregnancy, in
conjunction with diagnostic imaging and radiation treatment planning
CT scans, the cumulative doses may reach the threshold.
TPS algorithms are not designed nor commissioned to model out-of-
ﬁeld dose. Moreover, the commissioning process can inﬂuence overall
accuracy. The over-estimation of TPS-calculated doses in regions
proximal to the ﬁeld edge may be reduced by modifying the beam
Fig. 3. Comparison of the Boltzmann solver calculations with TLD measured data with
and without application of a leakage dose correction factor of 0.04% of the delivered
dose.
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model in the TPS. However, the present study primarily aimed to im-
prove accuracy of out-of-ﬁeld dose estimates in regions distal from the
ﬁeld edge, which typically corresponded to untargeted healthy tissue.
Thus, accurate quantiﬁcation of radiation doses in these regions is ne-
cessary to improve assessment of the long-term risks associated with
radiotherapy, particularly in patients who are likely to be long-term
survivors including patients with early-stage breast cancer.
The present study showed that the accuracy of radiation dose cal-
culations diminished at peripheral locations where linear accelerator-
speciﬁc leakage and head scatter components were dominant. The ap-
plication of a leakage correction in radiation treatment planning im-
proved TPS dose calculations out-of-ﬁeld. Further investigation into the
application of a leakage dose correction is warranted to improve ac-
curacy of out-of-ﬁeld dose calculations involving critical healthy tissue.
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Chapter 3 
 
 
 
Out-of-field in vivo dosimetry using TLD in SABR for 
primary kidney cancer involving mixed photon fields 
 
 
Chapter 3 builds upon findings presented in the previous chapter by exploring out-of-field dose arising 
in vivo from state-of-the-art stereotactic ablative body radiotherapy (SABR). Features which 
distinguish SABR treatments from conventional radiotherapy include high doses per treatment 
fraction, increased use of image guidance, smaller treatment margins and larger number of beam 
angles such that entrance doses per beam may be reduced. The high dose per fraction and uniform 
distribution of beam angles circumferentially about the patient plane provide unique conditions for 
assessing the leakage component of out-of-field dose in vivo. These conditions allow TLD 
measurements to be conducted further from the field edge than would be conducted in conventional 
treatments since the out-of-field dose per fraction scales with the fractional dose, leading to a higher 
TLD signal. The use of mixed megavoltage photon energies in SABR for primary kidney cancer results 
in varying levels of neutron contamination at out-of-field locations, depending on the relative 
contribution of high energy beams to the overall radiotherapy delivery. The subsequent interpretation 
of photon dose from LiF TLD materials, which have a non-negligible response to neutrons depending 
on the concentration of 6Li, is also discussed. This is an important consideration since the presence 
of neutrons can lead to erroneous interpretation of photon dose from LiF TLD materials, particularly at 
locations far from the treatment field where the neutron component may become significant. The use 
of TLD materials containing 6Li for out-of-field in vivo dosimetry including standard 100H will result in 
over-estimation of photon doses in high energy radiotherapy if additional signal due to neutrons is not 
taken into account, with over-estimates as high as over 400 % for 600H and 60 % for 100H at 50 cm 
from the radiotherapy field.
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Purpose: To assess out-of-field dose using three different variants of LiF thermoluminescence dosimeters
(TLD) for ten patients who underwent stereotactic ablative body radiotherapy (SABR) for primary renal
cell carcinoma (RCC) and compare with treatment planning system (TPS) dose calculations.
Methods and materials: Thermoluminescent dosimeter (TLD) measurements were conducted at 20, 30, 40
and 50 cm from isocentre on ten patients undergoing SABR for primary RCC. Three types of high-
sensitivity LiF:Mg,Cu,P TLD material with different 6Li/7Li isotope ratios were used. Patient plans were
calculated using Eclipse Anisotropic Analytical Algorithm (AAA) for clinical evaluation and recalculated
using Pencil Beam Convolution (PBC) algorithm for comparison.
Results: Both AAA and PBC showed diminished accuracy for photon doses at increasing distance out-of-
field. At 50 cm, measured photon dose was 0.3 cGy normalised to a 10 Gy prescription on average with
only small variation across all patients. This is likely due to the leakage component of the out-of-field
dose. The 6Li-enriched TLD materials showed increased signal attributable to additional neutron contri-
bution.
Conclusion: LiF:Mg,Cu,P TLD containing 6Li is sensitive enough to measure out-of-field dose 50 cm from
isocentre however will over-estimate the photon component of out-of-field dose in high energy treat-
ments due to the presence of thermal neutrons. 7Li enriched materials which are insensitive to neutrons
are therefore required for accurate photon dosimetry. Neutron signal has been shown here to increase
with MUs and is higher for patients treated using certain non coplanar beam arrangements. Further work
is required to convert this additional neutron signal to dose.
! 2017 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.
1. Introduction
With promising rates of local control and acceptable toxicity
[1,2], stereotactic ablative body radiotherapy (SABR) is emerging
as an alternative for treatment of primary renal cell carcinoma
(RCC) in medically inoperable patients. SABR is characterised by
high doses (typically > 8 Gy) per fraction delivered in few (typically
1–5) fractions. Previous work has demonstrated favourable early
outcomes using a minimum of 8 beams with a mix of 6- and 18-
MV photons [2], with 18 MV being important for skin sparing in
many cases. Treatment precision is ensured through the use of
advanced patient setup and immobilisation techniques in conjunc-
tion with image guidance. These immobilisation devices however
are often bulky and can reduce the skin sparing effect. Additionally,
patients with RCC referred for SABR are often not fit for surgery and
may have large abdominal girth resulting in large patient separa-
tion, which can compromise dose conformity and further reduce
skin sparing. Posteriorly located lesions pose additional challenges
in terms of skin sparing. While the use of high energy (>10 MV)
photon beams improves skin sparing, there is a degree of concern
raised regarding incidental neutron production in the medical lin-
ear accelerator.
While modern radiotherapy treatment techniques such as SABR
are able to achieve a high degree of conformality to a targeted
region, a small yet inevitable component of radiation dose reaches
untargeted healthy tissues beyond the useful treatment beam. This
additional radiation, termed ‘out-of-field’ dose, arises from patient
scatter, leakage dose from the medical linear accelerator, and scat-
ter from the machine head and collimating devices. Out-of-field
dose in radiotherapy has gained substantial interest in recent years
http://dx.doi.org/10.1016/j.ejmp.2017.03.022
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[3], owing to improved life expectancies post-treatment with mod-
ern management strategies. The risk of developing a second pri-
mary cancer following radiotherapy has been studied extensively;
the systematic review by Murray et al. [4] showed an increased risk
of radiation induced cancer in prostate radiotherapy across several
studies. Further, this risk was shown to increase over time.
Commercially available radiotherapy treatment planning sys-
tems do not model out-of-field dose accurately. Several groups
have measured out-of-field photon dose for conventional radio-
therapy of various treatment sites, including liver [5], brain [6],
prostate [7] and breast [8]. If accurate knowledge of out-of-field
dose is required, direct measurement is necessary. Out-of-field
dose may have relevance for long term risk assessment particularly
in cases where patient outlook is favourable. This may be the case
in primary kidney cancer, as the 5-year survival for operable
patients with organ-confined disease is above 80% [9].
The high dose per fraction associated with SABR treatments
provided a unique opportunity to explore out of field dose owing
to the higher absolute dose at out-of-field locations compared to
conventional fractionation schedules. The present work describes
the use of highly sensitive TLD material for out-of-field in vivo
dosimetry in SABR treatments involving mixed photon fields. We
demonstrate how this method has been used to assess out-of-
field photon dose and compare with treatment planning system
(TPS) calculations on ten patients undergoing SABR for primary
kidney cancer. The relative contribution of neutron signal is also
assessed.
2. Methods and materials
All reported doses refer to absorbed dose due to photons herein,
as assessed using TLD 700H. TLD measurements were conducted
along midline on ten consecutive patients treated with SABR for
primary kidney cancer. All patients underwent a 4-dimensional
CT scan using a Brilliance 16-slice scanner (Philips Medical Sys-
tems, Eindhoven, Netherlands) for internal target volume (ITV)
determination. Treatment planning was performed using Eclipse
(v11.03, Varian Medical Systems, Palo Alto, CA). Patients were trea-
ted following a clinical protocol approved by the Peter MacCallum
Cancer Centre ethics review board with 3D conformal radiotherapy
to a prescribed dose of 26 Gy in 1 fraction (lesion size < 5 cm) or
42 Gy in 3 fractions using a mix of 6 and 18 MV photon beams.
Non coplanar beams were employed as appropriate to optimise
planning target volume (PTV) coverage and normal tissue sparing.
Treatment parameters are summarised in Table 1. One patient who
was treated to 24 Gy in a single fraction to the sacrum (Patient 11)
is included in Table 1 for comparison to a treatment using only
6 MV photons. TLD measurements for neutrons were performed
on this patient where no neutron signal is expected. This allows
the TLD signal from low-energy irradiation to be compared with
that in a high-energy radiation field where neutrons are present.
Measurements were conducted out-of-field for a single fraction
at 20, 30, 40 and 50 cm from beam central axis (as defined at gan-
try and couch angles of 0 degrees herein) midline along the inferior
direction (ie, beginning at the abdomen with TLDs placed at 10 cm
intervals towards feet). All patients were treated on a Varian 21-iX
medical linear accelerator (Varian Medical Systems, Palo Alto, CA).
The TLD material used in this work was LiF:Mg,Cu,P, which was
chosen for its high sensitivity. This allowed in vivo measurements
to be conducted in low-dose regions (order of cGy or less) at rela-
tively large distances out-of-field. LiF:Mg,Cu,P is approximately 30
times more sensitive than LiF:Mg,Ti [10]. In addition, previous
work using synchrotron radiation has demonstrated minimal
energy dependence for this material, with a maximum deviation
of 15% caused by an over-response to a relatively narrow range
of photon energies at approximately 80 keV in the range between
15 keV and 18 MV, making it a useful detector for out-of-field mea-
surements involving a component of low energy scatter. TLDs were
calibrated in a 6 MV beam (TPR20,10 = 0.67) under reference condi-
tions (10 cm ! 10 cm square field at depth of maximum dose in
solid water with full backscatter provided). The linear accelerator
was calibrated using an ionisation chamber with a calibration
traceable to a primary standards lab. Standard TLDs from the same
batch as patient TLDs were irradiated to a known photon dose.
Sensitivity factor corrections were applied to individual TLD chips.
Photon dose was calculated using a ratio of TLD signal from a
known dose to TLD signal from in vivomeasurements. Patient TLDs
and standard TLDs were read out together using a Harshaw 5500
automatic reader. For LiF:Mg,Cu,P, the use of multiple chips for
each measurement as well as careful calibration is reported to
yield an overall uncertainty of 4% at the 95% confidence level for
a single measurement [11]. This is a Type B uncertainty estimated
from previous experience using our system which includes main-
taining thermal history of TLDs in a batch, use of an automated
reader which performs a pre-read anneal, application of sensitivity
factors for individual chips, and careful handling procedures.
Three different variants of LiF:Mg,Cu,P were used at each
measurement point, each with different 6Li/7Li isotope ratios. The
6Li-enriched, or 6LiF:Mg,Cu,P (‘600H’) variation comprises approx-
imately 95.6% 6Li. The 7Li-enriched, or 7LiF:Mg,Cu,P (‘700H’) mate-
rial contains less than 0.07% 6Li. The response of 600H and 700H
material is almost identical for photons and electrons however
the higher cross-section for thermal neutrons of 6Li makes 600H
more sensitive to thermal and thermalised neutrons, leading to
an additional signal upon readout. The use of 6Li/7Li TLD pairs for
Table 1
Summary of key treatment parameters.
Patient no. (prescription) Treatment fields (non coplanar) Mean jaw field size [X " Y cm] MU at 6 MV per fraction MU at 18 MV per fraction (% of total)
1 (26 Gy/1) 9 (3) 6 ! 6 1782 2695 (60%)
2 (42 Gy/3) 9 (4) 7 ! 6 1082 1136 (51%)
3 (26 Gy/1) 9 (2) 7 ! 4 3652 897 (20 %)
4 (42 Gy/3) 10 (5) 8 ! 7 0 2109 (100%)
5 (42 Gy/3) 10 (3) 7 ! 6 1048 1667 (61%)
6 (26 Gy/1) 10 (2) 5 ! 6 3463 1568 (31%)
7 (42 Gy/3) 9 (4) 7 ! 9 1059 999 (49%)
8 (42 Gy/3) 11 (4) 6 ! 8 1554 889 (36%)
9 (42 Gy/3) 9 (5) 7 ! 7 0 1868 (100%)
10 (42 Gy/3) 10 (4) 6 ! 5 1280 1025 (45%)
11* (24 Gy/1) 8 (5) 6 ! 5 4978 0 (0%)
Mean 10 (4) 7 ! 7 1809 1520 (59%)
* Patient 11 was treated at 24 Gy to the sacrum using only 6 MV photons. This patient is included to compare an 18 MV only treatment with a 6 MV only treatment, since all
RCC patients had at least one 18 MV beam.
10 P. Lonski et al. / Physica Medica 37 (2017) 9–15
25
neutron detection has been discussed by other groups [12–15] who
used TLD 600 and 700 material, comprised of LiF: Mg,Ti. The high
sensitivity material used in this work enabled out-of-field mea-
surements to be conducted in vivo at locations far from the radia-
tion field, up to 50 cm from isocentre. The 700H material is
relatively insensitive to neutrons with the energy spectrum which
reaches the patient plane [16,17], and the small concentration of
6Li in 700Hmaterial has been shown to produce negligible neutron
signal from the spectrum produced by a Varian 21-EX [18]. The
response of the 700H material can therefore be used to assess pho-
ton dose. The third material (‘100H’) contains natural Li (approxi-
mately 7.5% 6Li) and was also included at each measurement
point. The thermoluminescent (TL) response linearity range of
LiF:Mg,Cu,P extends from 10 lGy up to 10 Gy [19]. For photon
dose, TLD signal was converted to dose by comparing the 700H
thermoluminescence signal from in vivo measurements to TLD sig-
nal from chips in the same batch given a known dose under refer-
ence conditions. A pre-read anneal was used to minimise effects of
fading. Photon dose measurements were compared to treatment
planning system calculations at identical measurement locations.
TLDs were placed in custom made Perspex ‘buildup domes’ which
were designed to accommodate three TLD chips (1 ! 3 ! 3 mm in
size) with minimal angular dependence, providing approximately
1 cm buildup material (photons) and moderation (neutrons).
Buildup domes are illustrated in Fig. 1a. A triplet of 600H, 700H
and 100H TLD material was included at each measurement point.
The domes were not oriented in any particular direction when
positioned. The neutron signal was taken as the difference in
response between the 600H and 700H TLDs at each point.
3. Results
3.1. Limit of detection
The limit of detection was assessed for each TLD material using
readings from 5 un-irradiated chips from each set, several days
after being annealed in a TLD oven. The limit of detection may be
expressed as:
xL ¼ !xþ k " s
where xL is the smallest measure that can be detected with reason-
able certainty, !x is the mean of blank (un-irradiated) readings, s is
the standard deviation of the blank readings. The coverage factor
k was chosen to be 3 for a confidence of 99%. Background readings
were of the order of 10 ± 5 nC, reflecting environmental radiation
over one to two days, which was typical for in vivo measurement
readout delay time. The limit of detection for each material type
is estimated to be approximately 1 mGy, well below the dose levels
measured in vivo.
3.2. Reproducibility
Measurement reproducibility was investigated at identical
points for a fractionated treatment of 42 Gy in 3 fractions. Fig. 1b
shows mean TLD signal for all three fractions and the standard
uncertainty is shown by the error bars. The relative standard
uncertainty for each TL material was within 18, 14, 18 and 8% over
3 fractions at 20, 30, 40 and 50 cm from beam central axis respec-
tively. From the measurements on the example patient from
Fig. 1b, the dose gradient can be estimated to be 0.15 cGy/cm
between 20 and 30 cm, 0.04 cGy/cm between 30 and 40 cm, and
0.02 cGy/cm between 40 and 50 cm. Positioning accuracy of the
TLD domes is estimated to be within ±2 mm. The inset shows the
mean resulting neutron signal measured for 3 fractions, which
showed a relative standard uncertainty of 15, 10, 9 and 6% over 3
fractions at 20, 30, 40 and 50 cm respectively, indicated by the
error bars.
3.3. TLD response in 6, 18 MV treatments
TLD measurements conducted on an example patient treated
using only 18 MV photons (Patient 4) were compared with mea-
surements for a sacrum patient treated with only 6 MV photons
(Patient 11). The TL signal from each material is shown in Fig. 2
for these patients. The difference between the 600H and 700H
material was found to be negligible within the measurement
uncertainties for the patient treated using 6 MV, which is consis-
tent with the absence of neutrons as expected for this energy.
For the patient treated with only 18 MV photons, an increased
response attributable to neutrons can be seen from the 600H and
100H materials. 600H produced the greatest signal due to its
higher concentration of 6Li. Comparing the relative TL signal from
these two patients demonstrates a non-negligible neutron compo-
nent of the TL signal for the 18 MV case, making 700H essential for
Fig. 1. a. Schematic of Perspex buildup domes used to accommodate three TLDs at each measurement location. The concentration of 6Li isotope, which has a higher cross
section for thermal neutrons, is indicated for each material. b. Mean TL response over 3 fractions for one patient. Error bars show the standard error at each point for all TL
materials (not visible at 50 cm due to the small standard error). The mean resulting neutron signal and standard error (error bars) is shown in the inset.
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accurate assessment of photon dose in high energy photon dosime-
try. Photon dose can be determined using the 700H material and
for the example patients shown in Fig. 2, the measured doses at
20, 30, 40 and 50 cm were 1.48, 0.45, 0.34 and 0.35 cGy per
10 Gy prescribed dose for the patient treated with only 6 MV and
2.48, 1.28, 0.67 and 0.65 cGy per 10 Gy prescribed dose for the
patient treated using only 18 MV. For these two patients, the
out-of-field dose for 18 MV was on average a factor of 2 higher
than for 6 MV, though this does not take into consideration differ-
ences in field sizes, patient geometry, couch or gantry angles.
3.4. Photon doses
The out-of-field photon component was assessed using the
response of the 700H material, which is insensitive to neutrons.
Both PBC and AAA were found to under estimate the out of field
photon dose. In most cases, no dose estimate was provided by
the treatment planning system at the measurement points owing
to the large distance from the treatment volume. Fig. 3 shows a
dose pattern out-of-field comparing Eclipse calculations to out-
of-field TLD measurements for a typical patient. Both AAA and
PBC can be seen to underestimate photon dose out-of-field at
points beyond approximately 22 cm. The degree by which the
planning system underestimates out-of-field dose increases at lar-
ger distances. The 700H material provides a measurement of pho-
ton dose while the 600H and 100H material show increased
response due to their increased sensitivity to thermal neutrons.
If not accounted for, additional TLD signal due to neutrons
increased the apparent photon dose. Using the response of the
700H material to calculate ‘true’ photon dose, apparent photon
dose from the 100H and 600H material was calculated. Over
response of the natural Li (100H) material was 22% (range 2–51),
40% (range 9–99), 59% (range 27–92) and 66% (range 24–120) on
average at 20, 30, 40 and 50 cm from isocentre, respectively. The
over response for the 600H material was higher at 54 (range 11–
94), 117 (range 50–224), 196 (range 85–324) and 231 (range 92–
418) % respectively. The measured photon doses as assessed using
700H are shown for all patients in Fig. 4b.
Out-of-field photon dose as measured using 700H was assessed
as a function of relative contribution of 18 MV monitor units to the
overall treatment. Measured doses were scaled to a common pre-
scribed dose of 10 Gy and are shown in Fig. 4a with the unscaled
doses shown in Fig. 4b. At 50 cm, the measured dose for a 10 Gy
prescription was 0.3 cGy on average with only small variation
across all patients. The trendline for 50 cm demonstrates a near-
constant dose ‘bath’ that may be attributable to leakage radiation
from the linear accelerator, which is largely independent of field
size and the magnitude of the measured dose would be consistent
with International Electrotechnical Commission (IEC) recommen-
dations for maximum allowable leakage radiation for medical lin-
ear accelerators.
3.5. Assessment of neutron signal
The difference between the raw 700H and 600H TLD response is
taken as an additional signal due to neutrons. Fig. 5 shows neutron
signal detected in vivo for ten SABR patients as a function of num-
ber of monitor units (MU) delivered at 18 MV. The measured neu-
tron signal is shown for points at 20, 30, 40 and 50 cm from beam
central axis. Neutron signal increases with number of MUs for each
measurement location. No such correlation between neutron
Fig. 2. TL signal measured out-of-field for each material as a function of distance from beam central axis for two SABR patients, one treated using only 6 MV (a) and the other
with only 18 MV photons (b). TL signal is scaled per 1000 monitor units and readout uncertainties of 3% are indicated by symbol size.
Fig. 3. Out-of field dose measurements for a single fraction comparing 700 H TLD
measurements with the PBC and AAA dose calculation algorithms for Patient 4. Both
the 100 H and 600 Hmaterials can be seen to over-estimate out-of-field dose due to
their higher 6Li concentrations, making them sensitive to thermal neutrons.
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signal and either field size or source-surface distance was observed
within the patient cohort.
The photon contribution to TL signal out-of-field (TLD 700H),
relative to neutron signal (difference of the TLD 600H reading
and TLD 700H reading), is shown in Fig. 6 as a function of distance
from the beam central axis. Relative photon signal can be seen to
decrease with increasing distance from the treatment field. The
cross-over point where neutron TLD signal begins to dominate over
photon TLD signal occurs at distances >30 cm from beam central
axis.
Per thousandmonitor units, the mean jaw-defined field size and
patient size as assessed in terms of anterior-posterior as well as
left-right separation at the level of the PTV did not make a signif-
icant difference to neutron signal (two-tail p = 0.97 and 0.91,
respectively). The work of Sohrabi et al. (2016) [20] also shows that
for out-of-field neutron measurements, field size does not correlate
with neutron equivalent dose. Neutrons are not well collimated by
field-shaping components made from high atomic number materi-
als with low neutron absorption cross sections. Neutrons tend to
be scattered elastically with little energy loss to the recoil nuclei.
There was a slight increase in neutron signal for shorter mean
SSD but this was not significant (p = 0.07). Geometrical assessment
of non coplanar beams showed that neutron signal was generally
higher for patients who received at least one non coplanar beam
delivered anteriorly from the patient inferior direction (i.e., side
of the linac head positioned directly above the TLDs, creating an
acute angle between linac gantry and the patient plane) at
18 MV. In this arrangement the side of the linac head is in close
proximity to the TLDs. On average, mean neutron signal across
all measurement locations was a factor of 2 greater received at
least one 18 MV beam delivered at an anterior-inferior gantry
angle, which was significant (two-tail t = 2.57, p < 0.001).
To further investigate this apparent correlation between angle,
TLD measurements were made in the linac gantry and treatment
couch geometries outlined in Fig. 7. TLD buildup domes were
aligned along the couch with solid water backscatter material pro-
vided. Increased neutron signal was detected with the linac head
Fig. 4. (a) Measured photon dose at 20, 30, 40 and 50 cm from isocentre for 10 SABR patients as a function of relative contribution of 18 MV monitor units, scaled to a 10 Gy
prescription. Trend line is included for 50 cm and (b) unscaled photon doses for all patients measured using 700 H, with treatment parameters for each patient shown in
Table 1. Lines for patients measuring the highest dose (Patient 6), lowest dose (Patient 9) are shown along with the mean dose for all patients (dashed line).
Fig. 5. Neutron signal measured in vivo along midline at 20, 30, 40 and 50 cm from
beam central axis on ten patients undergoing SABR. Neutron signal is taken as the
difference between 600 H and 700 H TLD response and increases with number of
monitor units (MU) delivered at 18 MV.
Fig. 6. Photon TL signal relative to neutron signal as a function of increasing
distance from beam central axis for 10 SABR patients.
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forming an acute angle with the patient couch, as was observed
within the patient cohort. The measured photon dose was found
to decrease exponentially for all three geometries. Photon dose
from the gantry 45 degree geometry (ie, obtuse angle) was found
to have the highest dose overall. An increase in photon dose
between 40 cm and 80 cm was observed for the gantry 315 degree
geometry but to a much smaller extent compared to the reported
neutron signal; ratios of photon dose measured at 60 and 80 cm
to that measured at 40 cm were 1.3 and 1.7 for photons. For neu-
trons, the ratios were 1.7 and 26.4 (Fig. 7a), indicating a stronger
increase in neutron signal compared to photons.
4. Discussion
Modern management strategies and sophisticated radiotherapy
techniques have led to improved patient outcomes and longer life
expectancies. As such, increased attention has been turned to the
potentially harmful long-term effects of incidental irradiation of
untargeted healthy tissues during radiotherapy. Neutrons are of
particular concern owing to the higher biological damage, up to a
factor of 20 [21], compared to photons. Neutron production occurs
within high atomic number materials contained within the medi-
cal linear accelerator when operated above %10 MV. The use of
treatment beams at these higher energies is necessary in many
cases particularly in SABR for RCC where immobilisation devices
can compromise the skin sparing effect.
High sensitivity LiF:Mg,Cu,P TLD material allowed assessment
of out-of-field dose at locations far from the treatment field. For
in vivo photon dosimetry, the use of TLD materials containing 6Li
including standard 100H leads to an over-response in high energy
photon treatments where neutrons are produced [22]. Isolation of
the neutron component using combinations of 6Li and 7Li enriched
TLDs allows distinction of neutron and photon associated signal in
mixed neutron and photon fields. An increased neutron signal with
number of monitor units delivered at 18 MV has been demon-
strated in vivo in the current patient cohort (Fig. 5). This finding
is consistent with the work by Romero-Exposito et al., who have
demonstrated a linear increase in measured neutrons with linac
MU for different accelerator models [23]. This work demonstrates
this application in vivo. Interpretation of the measured signal, how-
ever, is complex. Calibration factors for neutron dosimetry are
strongly dependent on the incident energy spectrum. Thus, for
dosimetry of photo-neutrons produced by a medical linear acceler-
ator where the neutron spectrum differs significantly from those
produced by standard neutron sources, determining an accurate
dose response calibration factor experimentally presents a signifi-
cant challenge. It should be emphasised that the results shown in
the present work do not explicitly account for differences in TLD
sensitivity with changing neutron spectrum. Patterns in neutron
signal at out-of-field locations may change when a correction can
be derived for changes in sensitivity. Further work is required to
determine the thermal neutron spectrum out-of-field for the mea-
surement scenarios in the present work.
Aside from being a neutron detector, rather than dosimeter, TLD
has some additional advantages and drawbacks. The key advantage
is assessment of out-of-field photon dose, arising from linac leak-
age and scatter, obtained in the same measurement. It is only in
the context of this photon dose that the neutron component can
be interpreted. Drawbacks however include the laborious nature
of proper TLD handling and readout, delayed readout, requirement
of specialist procedures and in particular the requirement of spe-
cialised TLD material. With careful handling and readout proce-
dures, TLD was shown to be very reproducible for photon
dosimetry at out-of-field locations, with the largest variation
occurring at measurement points closest to the primary beam
(see Fig. 1b). With the reproducibility improving at larger dis-
tances, positioning uncertainties may be assumed to be the domi-
nant contributor to inter-fraction variations, since the dose
gradient is steeper closer to the beam.
Within this patient cohort, the use of 6 or 18 MV showed no
trend in out-of-field dose at 20 cm, where scatter is dominant
(Fig. 4). Measured dose at 50 cm from isocentre was 0.4 cGy (stan-
dard deviation of 0.1 cGy) for a 10 Gy prescription regardless of
beam energy, consistent in magnitude with 0.1% of the primary
beam at 1.0 m distance from the target stated in IEC recommenda-
tions [24] for leakage from the linear accelerator. This is further
supported by the similar doses measured for both 6- and 18-MV
treatments in this region. Leakage was observed to be the main
contributor to out-of-field dose beyond 40 cm from isocentre.
The use of oblique gantry angles was found to be associated with
increased neutron signal. Fig. 7 shows a phantom irradiation repli-
cating a similar geometry, further demonstrating that increased
neutron signal is observed beneath the side of the linac head. From
Fig. 7. a. Neutron signal measured along the patient plane at increasing distance from linac isocentre for three different linac/couch angle configurations. b. Schematic
depicting the acute and obtuse configurations used. A considerable increase in neutron signal is observed in the case of an acute angle between linac gantry and patient plane,
with the side of the linac head in closer proximity to the TLDs.
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the patient data, this increase is not observed in the case of pho-
tons. It is unclear why this increase beneath the linac head occurs
for neutrons but not for photons however one may speculate that
different interactions within materials in the linac head may play a
role, since photons are attenuated by high atomic number materi-
als but these same materials have a low neutron absorption cross
section.
TLD 700H material was found to be essential for assessing out-
of-field dose at locations, particularly at 40 cm and beyond from
treatment isocentre. The over-response of 600H due to neutrons
in high energy treatments was demonstrated, with an over-
estimation of photon dose by a factor of 4 in some cases. These
findings are similar in magnitude to the work by Kry et al. [22]
who demonstrated an over-response of 487% on average for TLD
100 at out-of-field locations up to 50 cm from central axis using
18 MV fields. The use of multiple TLD compositions enabled assess-
ment of the relative neutron signal along the patient plane com-
pared with that of photons. From our measurements we
conclude that linac gantry and couch combinations which place
the patient directly beneath the side of the linac head could be
avoided or assigned lower beam weighting where possible at high
energies, since the detected neutron signal was highest for these
beam arrangements. However this should only be considered in
cases where comparable PTV coverage and acceptable doses to
critical structures can still be achieved. This is a relatively simple
planning strategy which could be implemented clinically to reduce
overall neutron exposure at no real cost to plan quality or delivery.
5. Conclusion
This work demonstrates that LiF:Mg,Cu,P exhibits sufficient
sensitivity to assess out-of-field dose at locations far from the radi-
ation treatment field in vivo for patients treated with SABR using 6
and 18 MV photons. The use of TLD materials containing 6Li for
out-of-field in vivo dosimetry including standard 100H will result
in over-estimation of photon doses in high energy radiotherapy if
additional signal due to neutrons is not taken into account, with
over-estimates as high as 418% for 600H and 66% for 100H at
50 cm from the field reported in this work. 700H can be used to
discern photon dose in vivo during high energy SABR with ade-
quate spatial resolution at distances far from the treatment field
without additional signal from neutrons, and is essential in order
to accurately assess photon dose in high energy radiotherapy using
LiF-type TLD. Out-of-field photon doses have been presented for 10
SABR patients at locations up to 50 cm from the treatment field. In
these regions, the treatment planning system was found to under-
estimate the photon dose. 6Li/7Li TLD pairs may be used to discern
additional signal due to neutron interactions within the TLD mate-
rial, although interpretation of measured TL signal is complex and
further work is required to better understand the link between
neutron energy deposition and dose in TL materials.
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Chapter 4 
 
 
 
A collimated detection system for assessing leakage 
dose from medical linear accelerators at the patient 
plane 
 
 
Having established the magnitude of out-of-field dose in vivo, Chapter 4 then shifts focus from the 
patient plane to the linear accelerator in order to isolate the origins of leakage radiation. To facilitate 
such measurements, a customised collimated detector system was designed which would allow 
focused measurements to be conducted at the patient plane aimed at points of interest on the linear 
accelerator. Chapter 4 presents the design, validation and results obtained from this system. A dual 
layer of TLD chips housed within a lead cone was used to quantify the magnitude of leakage and 
scatter radiation at a given point at the linear accelerator as well as determine whether the detector 
system was aimed at a source of radiation, such as a leakage radiation hot spot. Focused cone 
measurements facilitated leakage dose measurements from the linac head directly at the patient plane 
The fraction of leakage due to ‘direct’ photons (along the raypath from the bremsstrahlung target) and 
that due to scattered photons was established. This work not only established a novel means of 
assessing leakage radiation from a medical linear accelerator, but was also able to provide leakage 
and scatter dose profiles at the linear accelerator for varying field sizes and collimator rotations. It was 
determined that leakage was on average 0.01% of the primary beam for the irradiation conditions 
investigated. This level is below regulatory requirements and consistent in magnitude with the leakage 
dose measured in vivo as presented in this work.  
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Abstract Leakage radiation from linear accelerators can
make a significant contribution to healthy tissue dose in
patients undergoing radiotherapy. In this work thermolu-
minescent dosimeters (LiF:Mg,Cu,P TLD chips) were used
in a focused lead cone loaded with TLD chips for the
purpose of evaluating leakage dose at the patient plane. By
placing the TLDs at one end of a stereotactic cone, a
focused measurement device is created; this was tested
both in and out of the primary beam of a Varian 21-iX linac
using 6 MV photons. Acrylic build up material of 1.2 cm
thickness was used inside the cone and measurements
made with either one or three TLD chips at a given dis-
tance from the target. Comparing the readings of three
dosimeters in one plane inside the cone offered information
regarding the orientation of the cone relative to a radiation
source. Measurements in the patient plane with the linac
gantry at various angles demonstrated that leakage dose
was approximately 0.01 % of the primary beam out of field
when the cone was pointed directly towards the target and
0.0025 % elsewhere (due to scatter within the gantry). No
specific ‘hot spots’ (e.g., insufficient shielding or gaps at
abutments) were observed. Focused cone measurements
facilitate leakage dose measurements from the linac head
directly at the patient plane and allow one to infer the
fraction of leakage due to ‘direct’ photons (along the ray-
path from the bremsstrahlung target) and that due to scat-
tered photons.
Keywords Leakage dose  Radiotherapy  TLD 
Patient safety
Introduction
Clinical interest into leakage radiation extends beyond
linac commissioning, with a growing number of publica-
tions on leakage dose and radiocarcinogenesis produced
since the 1970s [1]. Interest in leakage and out-of-field
doses was prompted around this time by the introduction of
higher energy linacs, the use of which gradually gained
popularity in preference to their lower-energy 60Co unit
and betatron predecessors. Assessment of leakage and out-
of-field radiation is important from the perspective of
patient safety. Out-of-field dose may be subdivided into
three categories depending upon the origin of ionising
radiation: (i) the scatter component from collimators and
accessories, (ii) in-patient or phantom scatter, and (iii) head
leakage from the linac gantry. Much work has been done to
map and quantify out-of-field dose as a whole [2–7] or
utilise modelling for head scatter [8]; however, it is often
challenging to separate these components and, in particu-
lar, isolate and identify the leakage contribution.
Existing methodologies for assessment of out-of-field
dose traditionally employ point dose ion chamber mea-
surements within a water phantom [9–11]. Such work
thoroughly maps the integral out-of-field dose at the patient
plane but cannot, however, offer information pertaining to
the spatial origin of the dose nor therefore facilitate
localisation of leakage ‘hot spots’ at the linac. Monte Carlo
radiation transport calculations may provide an alternative
to direct measurement and the capability for ‘tracking’
photons so as to determine leakage and so forth, though a
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full linac model (including all shielding, joints, and any
missing shielding etc.) would be necessary; i.e., common
approaches for linac modelling as with the BEAMnrc code
(NRCC) would not be appropriate, since they are designed
to model the primary beam only. Furthermore, such
methods are often not accessible to clinics not heavily
engaged in research, and a simplistic experimental method
for leakage determination would be a much more prefera-
ble alternative. Previous work by the authors has investi-
gated leakage and scatter dose at the linac surface [12]. It is
the aim of the present study to validate the use of a colli-
mated thermoluminescence dosimetry (TLD) detection
system for the purpose of conducting point measurements
at the patient plane.
The present work systematically evaluates the effec-
tiveness of a novel measurement technique that utilises
readily available (and reusable) TLD chips and a stereo-
tactic cone to isolate leakage radiation produced by a
Varian 21-iX linac at the patient plane. By placing TLD
chips inside a stereotactic cone, the influence of scatter
radiation is minimised and therefore the system can mea-
sure the leakage component directly. Using multiple TLDs
at a measurement plane, information regarding the spatial
location of the source of such leakage radiation may also
be inferred.
Methods and materials
A varian 21-iX medical linear accelerator (Varian Medical
Systems, Palo Alto, CA) was used for all measurements
using a 6 MV photon beam. Several experimental scenar-
ios were used to investigate the suitability of the proposed
measurement technique:
• Characterisation of the dose distribution within the
cone using Gafchromic EBT2 film
• Variation in dose with changing SDD
• Measurements across the beam penumbra
• Leakage measurements from the linac head with
changing collimated detector system (CDS) position
• Leakage measurements from the linac head with
changing linac gantry rotation
These scenarios are described in more detail in ‘‘Experi-
ments performed’’ section.
Collimated detection system (CDS)
LiF:Mg,Cu,P thermoluminescent dosimeter (TLD-100H)
chips (Harshaw, USA) were used to take measurements
from within a lead cone to create a collimated detector
system (CDS). This is illustrated in Fig. 1, which shows the
dimensions of the CDS. The TLDs were reproducibly
located in purpose-designed acrylic (Perspex, q = 1.16 g/
cm3) holders that also provide build-up material. Each
holder was 12 mm thick to provide buildup (*14 mm
water equivalent per holder) and backscatter material. Four
TLDs were used for each measurement. A single dosimeter
holder (SDH) housed one chip sitting in the centre of the
stack below a buildup layer, and a triple dosimeter holder
(TDH) housed three chips located at the bottom. This
arrangement is shown in Fig. 1.
Radiochromic film
The dose distribution within the finite sized cone varies
according to its alignment with a radiation source, which
may thus be exploited to identify hot-spots. Small film
sections were used to illustrate the effect of beam
obstruction at oblique angles. Gafchromic EBT2 (Interna-
tional Specialty Products, NJ, USA) radiochromic film was
used to characterise the dose distribution within the CDS.
Film was scanned *24 h following irradiation using an
Epson Perfection V700 scanner following a half hour
scanner warm up time. Film scans were acquired at 300 dpi
at the centre of the scanner bed.
TL dosimetry
The advantage of LiF:Mg,Cu,P is the high sensitivity to
relatively low doses. TLDs were calibrated prior to use at
50 cGy using a 6 MV beam in a 10 9 10 cm2 field at
depth of maximum dose with sufficient backscatter pro-
vided. The chips were read out using a Harshaw 5500
automatic TLD reader. Sensitivity factors were applied
following a batch calibration to correct the reading of each
chip following a measurement. For LiF:Mg,Cu,P TLDs, the
27.5 mm 
128.0 mm 
12.0 mm 
12.0 mm 
12.0 mm 
lead Perspex 
SDH 
TDH 
Fig. 1 Schematic depicting collimated detector system (CDS).
LiF:Mg,Cu,P TLD chips were placed in custom made Perspex
holders designed to fit inside a lead cone. The single dosimeter holder
(SDH) housed a single chip, while the triple dosimeter holder (TDH)
housed three chips
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use of multiple chips for each measurement as well as
careful calibration yields an overall uncertainty of 4 % at
the 95 % confidence level for a single measurement [13].
Results for each measurement are expressed as a percent-
age of ‘reference’ TLDs (irradiated to a known dose in the
primary beam under full buildup and backscatter condi-
tions as per standard reference calibration). The energy
dependence of this type of TLD, with respect to the energy
spectrum out-of-field, was not corrected for in this work
since the out-of-field spectrum is not well known. The
energy dependence of LiF:Mg,Cu,P is negligible down to
*100 kV photons and was therefore not assessed in detail
for this work. At lower energies response can vary by up to
30 % [14].
Experiments performed
Film characterisation of CDS
Film measurements were conducted to characterise the
dose distribution within the CDS. One film was retained as
a zero dose reading while a second piece of film was
irradiated to 5 Gy at isocentre using a 10 9 10 cm2 6 MV
photon beam. A further three films were used for a mea-
surement within the cone; a 6 MV 10 9 10 cm2 field was
delivered to the cone containing TLD holders (without any
TLDs present). A piece of film was placed at the top of the
stack of holders, another between the top and middle
(SDH) holders, and the third placed between the middle
and base (TDH) holders. This measurement was then
repeated with the cone placed at the edge of a 10 9 10 cm2
field. In this way it was possible to observe the dose dis-
tribution at each layer and also to observe shadowing
effects from the inner walls of the cone when placed at the
field edge. By observing the dose distribution within the
cone both at the centre of a clinical photon beam and again
at the field edge, it is possible to gain insight into the
angular dependence of the dose distribution inside the
cone, relative to the target. The purpose of this was to
illustrate the spread in thermoluminescent (TL) signal
when the primary radiation source is not axially aligned
(see Fig. 1, which shows the SDH and TDH arrangements).
As the cone is oriented at increasing angles relative to the
target, the dose distribution inside the cone changes due to
partial shadowing effects as the target becomes partially
obscured. The results of film measurements are shown in
Fig. 3.
Dose variation with changing SDD
Measurements were taken at various source-to-detector
distances (SDDs) with the CDS placed in the centre of a
6 MV 10 x 10 cm2 field. The height of the patient
treatment couch was varied to alter the SDD (where the
detector was chosen to be the SDH TLD chip in the central
holder). SDD of 96, 100, 120 and 140 cm were used. By
conducting measurements at varying distances from the
target it may be shown that the measurement system
exhibits a response which is consistent with the inverse
square law. Any significant deviation from this would
indicate that the response of the measurement system is
influenced by sources of radiation other than the source at
which it is aimed, for example scatter from the inner walls
of the collimating cone.
Measurements across the penumbra
300 monitor units were delivered with a 6 MV
20 9 20 cm2 field with a SDD of 100 cm to the SDH TLD
chip in the central holder in the manner illustrated sche-
matically in Fig. 2a. The CDS was gradually shifted out-
of-field (labelled ‘‘d1’’ in Fig. 2a) from central axis in
5.0 cm increments. In this way, the response of the system
from central axis to locations at increasingly oblique angles
relative to the target may be determined. Determining the
system dependence on angle of orientation relative to a
known source is important for measurement interpretation
when using the cone for leakage measurements; i.e., once a
peak in TLD signal is detected, the location of the source of
the hot spot may then be isolated.
Leakage measurements from the linac head with changing
CDS position
Measurements were made to test the ability of the proposed
measurement technique to discern an anticipated radiation
peak due to ‘direct’ leakage (i.e., that due primarily to
photons from the bremsstrahlung target as opposed to
scatter). With the linac gantry fixed at 270 rotation
(Fig. 2b), the detector system was oriented toward the
bremsstrahlung target. Here, the contribution of brems-
strahlung photons (albeit small when perpendicular to the
electron beam on the target) is anticipated to result in a
peak above the leakage due to internal scatter, since one
would expect internal scatter to behave in a more uniform
fashion as a function of spatial location. As shown sche-
matically in Fig. 2b, the detector system was shifted along
the couch at increasing distances from what is central axis
at a gantry rotation of 0 to map leakage dose along the
side of the linac. From these measurements, the spatial
resolution of the cone and TLD system can be investigated.
Further measurements were made in a similar manner
with an alternative choice of gantry orientation in order to
see whether the CDS is a suitable tool for isolating sources
of leakage dose which arise, for example, from shielding
gaps. With the linac gantry fixed at a 30 incline to the
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patient plane, the detector system was placed on the
treatment couch and moved along the couch (indicated by
‘‘d3’’ in Fig. 2c) for two orthogonal collimator rotations.
The open end of the cone was vertically aligned facing the
linac gantry. Measurements were taken with a collimator
rotation of 0 for both a 4 9 4 cm2 (‘small’) and a
40 9 40 cm2 (‘large’) treatment field. Measurements were
then repeated for a collimator rotation of 270, again for
small and large field sizes. The couch was maintained at
50 cm vertical distance below isocentre. The results are
shown in Fig. 7. From simple trigonometric considerations,
one would expect the maximum dose to be observed at a
distance d3 of 83 cm from the central axis, i.e., when
located such that the cone is oriented along a direct ray-
path to the target. If this is not the case, there may be
shielding deficiencies allowing leakage and scatter radia-
tion toward the patient plane.
Leakage measurements from the linac head with changing
gantry orientation
The detector system was placed 15 cm from central axis, a
10 9 10 cm2 field size was set and the gantry rotated about
the detector system in one degree increments. This
arrangement is shown in Fig. 2d. Measurements were made
at each gantry angle. The change in gantry rotation is
geometrically similar to variation of the angle of the
detector system axis relative to a stationary linac gantry.
d1 (cm) 
(a) 
d2 (cm) 
(b) 
d3 (cm) 
30°
(c) (d)
θ
Fig. 2 Schematic depicting the
experimental setup for a dose
variation with increasing
distance (d1) from central axis
(dashed line), b measured dose
variation beneath a known dose
peak (bremsstrahlung target) as
the cone is shifted along the
patient couch by distance d2,
c dose variation along the
patient treatment couch with
distance d3 with the linac gantry
at 30 to the couch plane, and
d cone remaining stationary
15 cm from central axis (as
defined at 0 gantry rotation) as
the gantry is gradually rotated
overhead in 2 increments
(a)
top
SDH
TDH
(b)
top
SDH
TDH
Fig. 3 Results of film measurements made at the top of the stack of
TLD holders, on the middle holder, and on the bottom holder. Film
scans shown in a were irradiated at the centre of a 10 9 10 cm2 field;
those shown in b were irradiated at the edge of a 10 9 10 cm2 field
(indicated by the shaded region; not to scale)
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Such rotation of the gantry around the detector system
facilitates measurement of the leakage dose arising due to
collimator transmission or shielding gaps.
Results
Film characterisation of collimated detector system
Results of film measurements (described in ‘‘Film
characterisation of CDS’’ section) are shown in Fig. 3.
Dose variation with changing SDD
In order to investigate dosimetric consequences of using a
lead collimator as part of the CDS, measurements were
conducted under various conditions and results related
back to a standard geometry. This ‘standard’ geometry was
defined as a 10 9 10 cm2 field and 6 MV photon beam,
with the cone containing TLDs placed in the centre of the
beam. The SDH TLD chip was set at 100 cm source to
detector distance (SDD). The TL signal under these
conditions is shown in Table 1, along with results of test
(i.e., non-standard) measurements, for comparison.
Measurements conducted at varying SDD show the TL
response varies according to the inverse square law (ISL).
This is shown in Fig. 4. These measurements indicate that
the primary beam is the main source of TLD dose (i.e.,
scatter from the inner walls of the cone is not a significant
contribution). Inverse square law corrections were not
applied to measured data for this work.
Measurements across the penumbra
Figure 5 shows the results of measurements taken at
increasing distance from central axis, as depicted in the
insert. This arrangement is shown in Fig. 2a. The vertical
axis shows TL signal as a percentage of reference TLDs
Table 1 Measured dose under various set up parameters, expressed as a ratio relative to ‘standard’ (10 9 10 cm2, 6 MV photon beam, 100 cm
SDD to the SDH chip) TLDs
6 MV
10 9 10
4 9 4 20 9 20 40 9 40 96 cm
SDD
120 cm
SDD
140 cm
SDD
SDH 1.00 0.91 1.03 1.02 1.10 0.69 0.50
TDHave 0.90 1.01 0.94 0.89 1.00 0.63 0.46
RSD of TDH (%) 2.4 1.8 2.3 3.5 2.2 0.7 1.8
The TL signal of the SDH chip is shown along with the average of the TDH arrangement (‘TDHave’). ‘Standard condition’ measurements were
conducted three times; the results presented are an average of these. The relative standard deviation (RSD) of the TDH arrangement is also shown,
as a percentage
Fig. 4 TL signal as a function of varying SDD for the SDH and TDH
arrangements. Results are normalised to standard irradiation of the
SDH TLDs Fig. 5 TL signal expressed as a percentage of ‘reference’ conditions
(known dose delivered at dmax) as a function of increased distance
from central axis (arrangement depicted in Fig. 2a). The field size was
set to 20 9 20 cm2. The TL signal of each chip in the TDH
arrangement is depicted by the shaded dots with the connecting line
indicating the spread of results. The dashed line shows the average TL
signal of the TDH arrangement. The TL signal of each SDH chip
(crosses) is also shown
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(irradiated to a known dose at dmax). The horizontal axis
shows increasing distance from isocentre, d1, as illustrated
in Fig. 2a. A 20 9 20 cm2 field was used, and distances
(x-axis) are expressed in centimetres from central axis. As
such, the cone is within the treatment field at points up to
10 cm. The apparent reduction in TL signal within the field
at 15 and 20 cm occurs due to the collimating walls of the
detector system obscuring TLDs from the source.
Figure 5 also shows the difference in TL signal for both
the SDH and the TDH TLD arrangements. At central axis
the TL signal from each of the three chips in the TDH
arrangement show good agreement. As the CDS is shifted
away from central axis, the TL signals of the three chips
begin to show considerable deviation due to partial shad-
owing by the collimator. This deviation was greatest at the
field edge (10 cm from central axis), with a relative stan-
dard deviation of 45 % in the TL signal of the three TLD
chips. The agreement of the three dosimeters improves at
peripheral points 15 cm and beyond, that is, where the
contribution of the primary beam is considerably reduced
and head scatter begins to dominate.
The results of measurements conducted at a fixed gantry
rotation of 270 (depicted in Fig. 2b) are shown in Fig. 6.
The vertical axis represents TL signal as a percentage of
reference TLDs irradiated with a known dose while the
horizontal axis shows cone distance from central axis at
gantry 0 (corresponding to d2 in Fig. 2b). An increase in
TL signal is initially observed at 80 cm, attributable to
head scatter from the secondary collimators. A relatively
high signal is also seen at 90 cm, this point being directly
beneath the flattening filter. A peak of magnitude 5 times
the response at other points was discernible at 100 cm from
isocentre, corresponding to the point at which the cone was
directly beneath the target. This ‘peak’ in dose is not
symmetrical about 100 cm. Instead, the response is greater
at 90 cm (corresponding to the production side of the tar-
get) than at 110 cm (corresponding to the incident side of
the target). Fig. 7 shows the dose patterns detected along
the side of the linac gantry with the gantry angle fixed at a
30 incline to the patient plane (depicted in Fig. 2c).
Figure 8 shows the TL signal of the dosimeters in the
detector system as the linac gantry was passed overhead.
The detector system remained fixed at 15 cm off central
axis (a 10 x 10 cm2 field was set) and the gantry was
passed over in single degree increments. The vertical axis
shows the TL signal as a percentage of reference TL signal.
The horizontal axis shows the rotation of the linac gantry as
it was passed over the CDS.
Discussion
The present work demonstrates the feasibility of the use of
a collimated detector system for the purpose of assessing
leakage dose from medical linear accelerators at the patient
plane. The materials required are readily available
throughout many radiotherapy departments and are reus-
able. The technique is simple and effective for various
linac arrangements which are used for patient treatment.
From Fig. 6, the measurement system was able to dis-
cern a dose peak of magnitude 5 times that of background
leakage at the side of the linac head, suggesting that any
leakage hot spots (for instance due to shielding gaps) are
able to be clearly distinguished from ‘background’ leakage,
such as low level scatter.
The difference between the average TL signal of chips
in the TDH holder compared to the SDH in Fig. 7d may be
a consequence of the differences in detector height within
the collimating cone, since a similar effect was also
observed in Fig. 6 (at 100 cm). From Table 1, this effect
was as much as *10 % for a 40 x 40 field. This detector
height difference would result in differing radiation dose,
specifically the amount of collimator scatter reaching each
TLD arrangement.
The spread of the TL signal of chips in the TDH
arrangement, resulting from shadowing effects within the
CDS, offers information regarding the relative location of a
leakage radiation source. This effect is illustrated in Fig. 8
which shows a large spread in the TL signal of chips in the
TDH arrangement over a range of angles. This arises due to
shadowing effects whereby at least one TLD is obscured
Fig. 6 TL signal expressed as a percentage of ‘reference’ conditions
(known dose delivered at dmax) as a function of increasing distance,
d2, from fixed vertical central axis with the linac gantry rotated to
270 (arrangement depicted in Fig. 2b). The TL signal of each TLD in
the TDH arrangement is depicted by the shaded dots with the
connecting line indicating the spread of results. The dashed line
shows the average TL signal of the TDH arrangement. The TL signal
of each SDH TLD (crosses) is also shown
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from the source at oblique angles between the cone and the
radiation source. The differences between the SDH and
TDH TLD arrangements may be influenced by the different
heights at which they were placed inside the cone, which
would leave the SDH chip in view of a radiation source
over a greater range of angles than the TDH arrangement.
From the geometry of the setup (see Fig. 2d), the target
was directly above the cone at a gantry rotation of *8.5.
A peak in dose was observed at *12–13 for the SDH
TLD and at 11 for the TDH arrangement. At a gantry
rotation of 11 the spread of the results of the TDH
arrangement becomes smaller, since the walls of the cone
are no longer obscuring the radiation source; therefore each
TLD receives a similar dose. From the geometry of the
arrangement (refer to Fig. 2d), the cone was in alignment
with the target at a gantry rotation of 8.5. That a peak was
not observed until a gantry rotation of 11 suggests that the
target may not be the most significant source of leakage
radiation under these conditions.
Figure 9 illustrates the ‘shadowing’ effects observed
using film measurements, the results of which were shown
in Fig. 3. Shadowing effects have obscured part of the
detection region inside the CDS from radiation. This
illustrates the spread in response of TLD chips in the TDH
which was found when assessing doses in out-of-field
regions. Specifically, one would expect the spread in TL
Fig. 7 TL signal of chips for both small (4 9 4 cm2) and large
(40 9 40 cm2) treatment field sizes with varying distance (d3) from
isocentre, as depicted in Fig. 2c. The vertical axis shows TL signal
expressed as a percentage of the reference TLDs irradiated in the
primary beam with a known dose at depth of maximum buildup. The
horizontal axis shows cone distance from isocentre as it is shifted
along the patient treatment couch. Results are shown for a a small
field size with collimator rotation of 0, b small field with collimator
rotation of 270, c large field size at collimator 0, and d large field at
collimator 270. In each case the spread of the TL signal of chips in
the TDH arrangement is indicated by the solid line, where the TL
signal of each chip is indicated by shaded circles. The TL signal of
each SDH TLD is indicated by crosses
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signal at the TDH layer to be greatest when the primary
(strongest) leakage source is oriented obliquely to the
detector system axis. Conversely, the spread in TL signal
when the system is directed towards a source will likely be
small (convergent). Shadowing effects, and the resulting
standard deviation of TLD chips in the TDH arrangement,
are useful in determining whether the cone was directly
oriented at a radiation source. In principle, one could use
film for all measurements in the present study, however the
number of monitor units required to observe a measurable
dose would be prohibitively high. Consequently, the use of
TLD is preferable since multiple point-dose measurements
may be achieved at a single measurement plane within the
CDS for a relatively low number of MUs.
For all measurements made with the detector system
aimed at the linac gantry, TL signal indicates leakage dose
at the patient plane did not exceed 0.1 % of the primary
beam at 1 m (extrapolating) from the source, in accordance
with international requirements [15–17]. The use of
LiF:Mg,Cu,P chips allows a small number of monitor units
to be used for a single measurement, since this type of TLD
is highly sensitive. The use of multiple TLDs at a single
plane within the cone offers a quantitative means by which
the detector alignment relative to a radiation source may be
determined. When in direct alignment with a source, the
TL signal of the TDH arrangement of TLDs showed a
relative standard deviation (RSD) of 6.4 % (Fig. 5),
whereas at locations either side of the source the RSD
becomes considerably larger (up to 39 %). This effect may
be seen qualitatively in Fig. 3.
Conclusions
The present study describes and tests a novel method by
which leakage dose at the patient plane may be systemat-
ically mapped. This directionally sensitive technique may
be used for simple or more complex treatment setup
options and can quantify both the magnitude and location
of leakage ‘hot spots’ from the linac surface at the patient
plane. The methods discussed may be used to quantify
leakage dose hot spots by eliminating contributions from
other radiation sources, such as scatter. High sensitivity
TLD chips were used for these measurements, minimising
the required number of monitor units and enabling multiple
point-dose measurements at a single measurement plane
which may be exploited to localise the source of leakage.
The proposed methodology, while labour intensive due to
the need to assess each point individually, is cheap and
simple to use, particularly for radiotherapy centres which
already possess the required equipment.
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Chapter 5 
 
 
 
Surface dose measurements in and out of field: 
Implications for breast radiotherapy with megavoltage 
photon beams 
 
 
The final chapter of this thesis attempts to look towards future technologies in breast radiotherapy. 
More specifically, Chapter 5 explores the dosimetric implications for skin both in and out-of-field from 
new Flattening Filter Free (FFF) beams. Challenges of measuring surface doses are addressed, with 
a thin window ‘Advanced Markus’-type chamber chosen for its thin entrance window and wide guard 
ring, and with an effective measurement depth which corresponds to the average depth of the basal 
cell layer in human skin. Surface dose from conventional flattened beams and newly introduced FFF 
beams are compared for different photon beam energies. The chapter begins by characterising the 
surface dose from generic square fields comparing flat and FFF beams, and then expands to include 
measurements in and out-of-field for a conventional breast radiotherapy field. This work demonstrated 
that surface dose at out-of-field locations is lower in FFF beams compared to a conventional flattened 
beam of similar quality. These findings have implications for breast radiotherapy in future, offering a 
potential means of reducing out-of-field dose to untargeted healthy tissue. 
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Abstract
This study examines the difference in surface dose between
ﬂat and ﬂattening ﬁlter free (FFF) photon beams in the
context of breast radiotherapy. The surface dose was mea-
sured for 6 MV, 6 MV FFF, 10 MV, 10 MV FFF and 18 MV
photon beams using a thin window ionisation chamber for
various ﬁeld sizes. Proﬁles were acquired to ascertain the
change in surface dose off-axis. Out-of-ﬁeld measurements
were included in a clinically representative half beamblock
tangential breast ﬁeld. In the ﬁeld centres of FFF beams
the surface dose was found to be increased for small ﬁelds
and decreased for large ﬁelds compared to ﬂat beams. For
FFF beams, surface dose was found to decrease off-axis
and resulted in lower surface dose out-of-ﬁeld compared
to ﬂat beams.
Oberﬂächen-Dosismessungen innerhalb und
außerhalb des Feldes: Implikationen für die
Mammakarzinom Bestrahlung mit
Megavolt-Photonenstrahlen
Zusammenfassung
Zusammenfassung: Unsere Studie untersucht die Ober-
ﬂächendosis in ausgleichsﬁlterfreien (FFF) Photonen-
strahlen eines Linearbeschleunigers im Zusammenhang
mit Mammakarzinom-Bestrahlungen. Die Oberﬂächendo-
sis wurde mit einer Ionisationskammer vom ‘advanced
Markus’ Typ für 6 MV, 6 MV FFF, 10 MV, 10 MV FFF
und 18 MV Photonenstrahlen für verschiedene Feld-
größen gemessen. Es wurden Dosisproﬁle gemessen, um
Änderungen der Oberﬂächendosis außerhalb des Zen-
tralstrahls zu bestimmen. Dosismessungen außerhalb des
Strahlenfeldes wurden ebenfalls für ein für die Mamma-
Tangentialbestrahlung repräsentatives Halbblock-Feld
durchgeführt. Die Oberﬂächendosis in der Feldmitte ist bei
kleinen FFF-Feldern höher, bei großen Feldern niedriger,
als bei normalen Feldern. Für FFF-Felder nimmt mit
zunehmendemAbstand vomZentralstrahl dieOberﬂächen-
dosis ab und ist außerhalb des nominellen Feldes kleiner
als bei normalen Feldern.Keywords: Surface dose, Flattening filter free,
Out-of-field, Breast radiotherapy
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1 Introduction
Flattening filter free (FFF) beams are fast becoming
standard on new linear accelerators and their use may have
benefits in breast radiotherapy. These benefits include higher
dose rates associated with shorter treatment times, lower
peripheral dose, and reduced monitor units which can reduce
patient exposure to machine head leakage. The removal of the
flattening filter leads to more efficient X-ray delivery, which
in turn increases the dose rate along the beam central axis.
The high dose rates and shorter beam-on time of FFF beams
also allows more comfortable treatment delivery for patients
undergoing respiratory gated treatments. With deep inspira-
tion breath-hold becoming a popular treatment option, this
may have implications for breast radiotherapy in a 3D con-
formal setting, particularly for patients who struggle to hold
their breath for the duration of treatment delivery and may
therefore be disqualified from receiving radiotherapy using
deep inspiration breath hold. Furthermore, the peaked beam
shape may be exploited to improve dose homogeneity within
the PTV where field-in-field techniques are currently used to
boost under-dosed areas within the breast. Planning studies
assessing the appropriateness of FFF for breast irradiations
have suggested similar plan quality between flat and FFF
beams for markedly lower beam delivery times in the case
of FFF beams [1,2].
The process of generating FFF beams varies between linac
vendors. In the case of Varian, the softer beam spectrum result-
ing from the removal of the flattening filter is not compensated
for by any adjustments to the energy of the accelerated elec-
tron beam. The resulting bremsstrahlung photons generated
in the linac target are likewise unaffected. FFF beam qualities
are therefore lower than their corresponding flattened beams
of the same nominal energy. In Elekta machines, the elec-
tron energy is tuned so that resulting flat and FFF beams are
‘matched’ to be of similar beam quality at a reference field
size, though discrepancies in beam quality become obvious at
larger field sizes as demonstrated by Fogliata et al. [3]. The
removal of the flattening filter has been attributed to a reduc-
tion in the peripheral or ‘out-of-field’ dose in FFF beams.
This is owing to the reduction in scatter from the flattening
filter, which is a major source of scattered photons, and overall
lower beam quality (in the case of Varian machines [4–6]. The
reduced beam current required to produce FFF beams has also
been attributed to a reduction in head leakage [7]. This poten-
tial reduction in out-of-field dose from the treatment head is of
particular interest in breast radiotherapy where the contralat-
eral breast is at risk of incidental irradiation during treatment.
Furthermore, the in-field surface dose is of clinical interest
for assessing the likelihood of adverse skin reactions to the
treated breast. The in-field surface dose has been reported to
be higher in FFF beams. Wang et al. [8] measured higher sur-
face dose for FFF beams up to a field size of 10 cm × 10 cm.
The increase was small, and was reported for square fields
at central axis. Javedan et al. [9] reported similar findings
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in a Monte-Carlo study assessing superficial doses for head
and neck as well as breast cases comparing treatment plans
using flat and FFF beams. De Puysseleyr et al. [10] reported
slightly higher dose at central axis in the buildup region for
energy-matched FFF compared to flattened beams. The dose
from clinically representative fields at off-axis locations how-
ever has not been reported. Since most commercial treatment
planning systems do not model skin dose accurately, mea-
surements are required to quantify surface dose from a linear
accelerator. Thus it was the aim of the present study to mea-
sure surface dose from FFF beams both in and out-of-field
and compare with flattened beams for field sizes of clinical
interest in breast radiotherapy.
2 Methods
A thin window parallel plate Exradin A10 chamber
(“advanced Markus design”) with a nominal effective mea-
surement depth of 70 microns was used to measure surface
dose in a solid water phantom on a Varian TrueBeam linear
accelerator.
Point measurements were conducted at 2 cm intervals at
the surface across a 20 × 20 cm2 and 40 × 40 cm2 field using
6 MV (TPR20,10 = 0.668), 6 MV FFF (TPR20,10 = 0.632),
10 MV (TPR20,10 = 0.739), 10 MV FFF (TPR20,10 = 0.710)
and 18 MV (TPR20,10 = 0.784) to construct a surface dose
profile across the open field of flat versus FFF beams. A
custom-made 30 cm × 30 cm solid water slab phantom (Fig. 1)
was cut to snugly accommodate the chamber such that its sur-
face was flush with the surface of the phantom. The phantom
was irradiated at normal incidence. Additional slabs of solid
water were placed beneath the chamber holder to provide full
backscatter. Surface dose is reported relative to integrated ion
chamber readings acquired at depth of maximum dose for
each beam quality. Measurements were conducted at 100 cm
source-to-surface distance (SSD). To determine the surface
dose variation with field size, measurements were conducted
at central axis for 4 × 4 cm2, 10 × 10 cm2, 20 × 20 cm2 and
40 × 40 cm2 jaw-defined field sizes. Surface dose was then
measured in a 10 × 20 cm2 half beam blocked field at the
field centre, at 5 and 7 cm off-axis, and at 2 and 5 cm out-of-
field beneath the shielding jaw. This geometry is illustrated
in Fig. 4(b). The slab phantom was irradiated at normal inci-
dence to characterise the beam. This field represents typical
dimensions used for breast radiotherapy, and measurement
points beneath the shielding jaw correspond to the approxi-
mate location of the contralateral breast.
3 Results
Surface dose profiles measured across the open area of6 MV FFF, 10 MV, 10 MV FFF and 18 MV. Integrated charge
readings at the surface of a solid water phantom are expressed
relative to integrated readings collected under reference
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Figure 1. Schematic depicting measurement geometry with dashed lines representing the radiation field size and red lines depicting beam
ith
bercentral axis. A beam’s eye view of the 30 cm × 30 cm slab phantom w
(a) chamber and phantom centred in a 10 cm × 10 cm field, (b) cham
phantom and chamber centred in a 40 cm × 40 cm field.
conditions for each beam quality, that is, at depth of maximum
dose (d-max) for the same number of treatment monitor units
at 100 cm SSD for the same field size. The magnitude of mea-
sured surface dose varies for different beam qualities; 6 MV
FFF as the softest beam quality produced the highest surface
dose near the field centre and 10 MV FFF produced the lowest
surface dose. Profiles from 6 MV FFF and 10 MV FFF beams
demonstrated a marked surface dose falloff at increasing dis-
tance from the beam central axis, reflecting the peaked shape
of the clinical beam profile at depth. Conversely, surface dose
profiles from flattened beams exhibited little change across the
field region. Surface dose as a function of field size at 100 cm
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Figure 2. (a) Surface dose profiles measured up to 8 cm distance from
field for five photon beam qualities from a Varian TrueBeam linear acc
jaw-defined field size. Both figures are normalised such that 100% is th
central axis for each field size at d-max at 100 cm SSD for a given beam
44ion chamber in the centre is shown for three measurement scenarios;
centred in an off-axis 10 cm × 20 cm half beam block field, and (c)
SSD is shown in Fig. 2(b) for a 4 × 4 cm2, 10 × 10 cm2,
20 × 20 cm2 and 40 × 40 cm2 jaw-defined field sizes.
Fig. 3 shows surface dose measured for 20 × 20 cm2 (a,
b) and 40 × 40 cm2 (c, d) fields expressed as a percentage of
the dose measured at depth across the beam profile using a
scanning water tank during beam commissioning. Beam pro-
files from commissioning were normalised to 100% at beam
central axis for profiles at d-max. Profiles at 10 cm depth
were not scaled to 100%, and are instead expressed relative
to depth of maximum dose (for example, 66.5% at central
axis in the case of 6 MV). Beam divergence was not explic-
itly accounted for in any way. Measurements using the largest
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elerator, and (b) surface dose at beam central axis as a function of
e integrated charge for a given number of treatment monitor units at
quality.
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Figure 3. Surface dose across the open field expressed as a percent of dose at depth across the beam profile. Profiles at depth of maximum
dose (d-max, inserts (a) and (c)) and 10 cm depth (d-10 cm, inserts (b) and (d)) were measured using a scanning water tank during beam
commissioning. Profiles show surface dose as a percent of (a) normalised dose at d-max for a 20 × 20 cm2 field, (b) normalised dose at
10 cm depth for a 20 × 20 cm2 field, (c) normalised dose at d-max for a 40 × 40 cm2 field, and (d) normalised dose at 10 cm depth for a
e a
n fi40 × 40 cm2 field. Profiles are normalised such that 100% is the dos
off-axis distance as the corresponding distance at surface, for a give
available clinical field size were included to explore influence
of the linac target and primary collimator. Clinical photon
beams have an inherent shape from beam production in the
linac head, be it the flattening filter which produces character-
istic horns at d-max or the peaked shape of a flattening filter
free beam profile. Expressing surface dose relative to the pro-
file at depth removes the inherent beam shape from primary
photons and allows identification of additional contributions
across the profile which are not associated with the primary
beam at depth, such as low energy photon scatter or electron
contamination.
Surface dose measurements from a clinically representative
breast treatment field are shown in Fig. 4(a) and are expressed
as a percentage of reference measurements acquired at d-max
in a 10 × 10 cm2 field at 100 cm SSD (conditions in which
100 MU = 1 Gy) for each beam. The schematic in Fig. 4(b)
45t d-max at the same number of treatment monitor units at the same
eld size and beam quality.
illustrates the measurement points used. Surface dose in
the field centre was largest for 6 MV FFF and lowest for
10 MV FFF. Variations in surface dose off-axis were more
pronounced for FFF beams. Dose measured out-of-field
beneath the shielding jaw was lowest for 10 MV FFF but
largest for 18 MV. For out-of-field measurements, surface
dose was reduced by 1.5% of dose at d-max for 6 FFF
compared to 6 MV for each of the 2 and 5 cm OOF points.
Out-of-field dose was reduced by 3.1% at 2 cm OOF and
2.6% at 5 cm OOF for 10 MV FFF compared to 10 MV.
4 DiscussionThe presence of low energy photons and electron con-
tamination in external beam radiotherapy contribute to dose
deposited at the surface of a phantom or patient. These
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Figure 4. (a) Surface dose measured relative to depth of maximum dose at central axis for various photon beam qualities and (b) beam’s eye
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contributions originate upstream in the beam from media
comprising the linac target and flattening filter as well as colli-
mating jaws and beam modifying devices. Radiation field size
and beam energy inherently affect surface dose which is not
accurately modelled by commercial treatment planning sys-
tems [11] with accuracy even depending to an extent on beam
configuration [12]. Therefore measurements are required to
ascertain the surface dose in external beam radiotherapy. With
the ever increasing popularity of FFF beams, investigation of
the consequences for surface dose is warranted.
Dose measurements in the buildup region are complicated
by non-equilibrium conditions. This presents particular dosi-
metric challenges requiring careful interpretation of detector
response. Other authors have demonstrated use of TLD
[13,14] and film [15] extrapolation techniques for surface dose
measurements while others have reported on the use of MOS-
FETs [16]. Ion chambers have the advantage of instant readout
and are well characterised. The advanced Markus chamber
design includes a thin entrance window, small electrode sepa-
ration and wide guard ring making it an appropriate dosimeter
for surface dose measurements. Further, the effective mea-
surement depth corresponds to the approximate average depth
of the basal cell layer in human skin. Previous work has
demonstrated that the advanced Markus chamber is appro-
priate for surface dose measurements in megavoltage photon
beams with reduced over-response compared to the Markus
chamber design [17].
Considering the consequences of removing the flattening
filter it may be anticipated that the surface dose is affected in
different ways; firstly, that contaminant electrons and photon
scatter originating in the flattening filter are reduced, thus low-
ering the surface dose, and secondly, that the beam hardening
46geometry used. Machine isocentre is blocked by the Y1 jaw with a
ns of out-of-field (‘OOF’) measurement points beneath the jaw are
effects are removed, resulting in a softer beam which would
therefore increase the surface dose. The overall consequence
to surface dose will be a complex balance of these compet-
ing effects. In addition, vendors add a thin metal plate in FFF
beams which serves to both reduce the low energy contami-
nant electrons generated in the target and primary collimator,
and also to provide a small amount of buildup dose which can
be detected by the monitor chambers [7]. The addition of this
filter may serve to remove some of the additional low energy
contaminant radiation from the surface. The consequences for
surface dose are therefore non trivial.
In this study surface dose was found to vary with field size
for flat as well as FFF beams, though for FFF this field size
dependence was less pronounced. Similar to the findings by
Wang et al. [8], smaller FFF fields were found to result in
higher surface dose at beam central axis, however for larger
fields it was found that FFF resulted in smaller surface dose
compared to flat beams in the beam centre. With the removal
of the flattening filter as a source of electron contamination
and low energy scattered photons, this likely indicates that the
flattening filter is the dominant contributor to surface dose at
larger field sizes, leading to the marked reduction observed in
the case of FFF. Direct comparison however is made difficult
since the removal of the flattening filter also changes the beam
quality (TPR20,10 = 0.668 for 6 MV compared to 0.632 for
6 MV FFF and TPR20,10 = 0.739 for 10 MV compared to 0.710
for 10 MV FFF).
The conical shape of the flattening filter results in dif-
ferential beam hardening across the profile for flat beams,
with maximum effect occurring along central axis. The result
is a relatively flat beam at 10 cm depth with profile horns
appearing at d-max. Fig. 3 shows the ratio of measured surface
hy
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dose to dose at both d-max and 10 cm depth. The ratio enables
assessment of the surface dose profile relative to the clinical
primary beam profile at clinically relevant depths. Surface
dose relative to dose at both depths was found to increase off-
axis for FFF beams. This reflects the peaked shape of the beam
profile for FFF beams. In the case of flat beams it was shown
that the ratio is relatively flat with a slight reduction off-axis.
To determine the surface dose in breast radiotherapy, cen-
tral axis data is not necessarily relevant since patients are often
treated using a half beam block to achieve a non-divergent
edge on parallel opposed tangents, which shifts the radiation
beam off-axis. Therefore measurements were conducted for a
10 × 20 cm2 half beam blocked field. 6 MV FFF was shown
to produce the highest surface dose in the field centre, with
the lowest dose measured for 10 MV FFF. Out-of-field surface
dose was lower in the case of FFF, which supports previous
work by Kry et al. [6], suggesting that incidental irradiation
of normal tissue, particularly the contralateral breast, may be
reduced through the use of FFF beams. With a lower surface
dose at the beam centre as well as out-of-field, 10 MV FFF
may prove useful in reducing unwanted treatment side effects
both in and out of field. This has been demonstrated for open
fields in a phantom measurement however further work is
required to demonstrate a reduction in a clinical setting. In
cases where the dermal lymphatics are included in the treat-
ment target and full dose to skin is required, 6 MV FFF may
prove a more appropriate alternative, as the measured surface
dose was demonstrated to be higher.
5 Conclusion
FFF beams were associated with a higher surface dose for
smaller field sizes. At larger fields, FFF beams produced less
surface dose in the field centre. Surface dose profiles have
been presented across the open area of large fields to examine
the change in surface dose at off-axis locations. A clinically
representative breast treatment field has been used to compare
surface dose from different beam qualities. This study demon-
strates that for tangential breast radiotherapy FFF has potential
to reduce surface dose out-of-field at points corresponding to
the contralateral breast and in cases where similar plan qual-
ity can be achieved the use of FFF should be considered for
reducing out-of-field dose to normal healthy structures.Acknowledgements
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Chapter 6 - Discussion 
 
6.1 Chapter overview 
 
This chapter begins by providing an overview of the scope of this thesis wherein the aims and objectives 
are re-iterated. This is followed by detailed chapter discussions which link each chapter to the thesis 
aims, beginning with a clinical out-of-field dose study in which limitations of out-of-field dose calculations 
from commercial planning systems are explored and the problem of under-estimating peripheral dose 
is addressed through a leakage dose correction derived directly from patient measurements. This is 
followed by further in vivo dosimetry work assessing the technical aspects of TLD measurements out-
of-field wherein the unique radiation conditions afforded by stereotactic treatments are exploited to 
address issues associated with low TLD signal at very peripheral locations. Interpretation of photon 
dose in the presence of neutron contamination from high energy photon beams is also addressed. 
Implications for out-of-field TLD measurements in breast radiotherapy and subsequent impact on the 
proposed measurement-derived leakage correction are discussed. Challenges associated with direct 
leakage radiation assessment from a medical linear accelerator are then addressed through a novel 
collimated detector system, the design and use of which was presented in Chapter 4. A discussion of 
second cancer incidence is then provided for clinical context including evidence of cancer risk based 
on current literature. Future technology is then considered through a discussion of the consequences 
to skin dose from the implementation of flattening filter free beams in breast radiotherapy based on 
measurements presented in Chapter 5. Deep inspiration breath hold as a technique for reducing heart 
dose is then discussed including implications for lung dose from this technique. Other means of 
quantifying out-of-field dose are discussed including a comparison of the relative merits of Monte Carlo 
calculations to the methods used in this thesis. The discussion concludes with comments on incidental 
findings from this work which arose throughout the course of this work, including comments on the 
effect of neutron contamination to interpretation of TLD dose, and finally a review of the increasing 
importance of out-of-field dose in radiotherapy and current trends in patient in vivo dosimetry.  
 
6.2 Scope 
 
In the context of this work, ‘out-of-field’ dose pertains to locations beyond the primary radiation beam. 
Although important for assessment of long term risk of radiocarcinogenesis, dose in these regions is 
not accurately modelled by commercial treatment planning systems (TPS), primarily because these 
systems are not specifically designed to model such doses. Furthermore this thesis has also assessed 
radiation dose at the skin surface which, despite being geometrically encompassed by the primary 
photon beam lies dosimetrically beyond the region of charged particle equilibrium and as such is also 
affected by limited calculation accuracy. Surface dose is affected by treatment-specific factors such as 
accessories and collimator scatter, leading to varying degrees of accuracy for skin dose calculations 
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from commercial treatment planning systems. However these doses are important for assessing a 
patient’s risk of adverse reactions from treatment both short- and long-term. This is particularly relevant 
for breast cancer; modern management strategies and sophisticated treatment options have translated 
to favourable long term survival outcomes for breast cancer patients, which does therefore necessitate 
an understanding of the associated risks from treatment. This thesis addresses these known TPS 
limitations by providing a comprehensive peripheral dose assessment from breast cancer radiotherapy. 
Assessment of peripheral dose and leakage radiation is achieved through patient in vivo dosimetry 
including routine breast cancer radiotherapy and state-of-the-art stereotactic ablative body radiotherapy 
in combination with controlled measurements conducted within a novel collimated detector system. 
Systematic ion chamber measurements in a phantom are used to assess skin dose both in and out-of-
field from conventional flattened and modern flattening-filter-free radiotherapy beams used in the 
treatment of breast cancer. 
 
6.3 Statement of Aims 
 
The aim of this thesis was to assess the out-of-field radiation dose which is inevitably delivered to 
untargeted healthy tissue during radiotherapy for breast cancer, specifically: 
 Assess the magnitude of out-of-field dose reaching untargeted healthy tissue through a clinical 
in vivo dosimetry study and compare to dose calculations from a commercial treatment planning 
system. 
 Explore technical aspects of thermoluminescence dosimetry techniques far out-of-field within 
the unique radiotherapy conditions afforded by state-of-the-art stereotactic ablative body 
radiotherapy.  
 Design and implement a novel collimated detector system to facilitate leakage radiation 
measurements at the patient plane. 
 Assess the implications to out-of-field dose from modern technology in breast radiotherapy, 
specifically, assess skin doses arising in- and out-of-field from modern flattening filter free 
beams, compare to conventional flattened beams, and determine the benefits of these modern 
beams in the treatment of breast cancer. 
 
 
6.4 Impact of this work: how the aims have been addressed 
 
This thesis has demonstrated that commercial treatment planning systems under-estimate radiation 
dose beyond the primary beam and has ventured to quantify out-of-field radiation doses associated 
specifically with breast radiotherapy. This was achieved through in vivo dosimetry conducted on breast 
cancer patients as they underwent radiotherapy treatment. Thermoluminescence dosimetry (TLD) was 
used to measure the absorbed dose at locations of interest for the purpose of long-term risk assessment 
including the contralateral breast, axilla, and thyroid. Further analysis of TPS limitations showed that 
the application of a correction for linac-specific leakage radiation provided improvements in dose 
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calculation accuracy at out-of-field locations where leakage radiation is dominant. A further study was 
conducted to assess leakage dose patterns from a medical linear accelerator which revealed no specific 
shielding deficiencies and suggested the linac target to be the key source of leakage radiation reaching 
the patient plane. These findings were compared with an in vivo dosimetric study performed on patients 
receiving state-of-the-art stereotactic ablative body radiotherapy (SABR) which enabled assessment of 
out-of-field dose in a hypofractionated treatment setting using uniformly distributed beam angles. A 
common feature of SABR, higher energy beams are often required to achieve skin sparing through 
bulky immobilisation devices which are a necessary component of SABR. This provided a unique 
opportunity to assess the effects of neutrons in the context of TLD measurements, particularly with 
regard to the interpretation of photon dose in mixed field environments, which was then related back to 
the in vivo study performed on breast cancer patients. The leakage dose as assessed in vivo in these 
two separate studies was found to be in agreement. Risks of developing a second solid cancer as a 
result of exposure to the measured leakage radiation are estimated, along with a discussion of the 
assumptions used. State-of-the-art technology was also considered specifically in the context of breast 
radiotherapy. To that end, this body of work concludes with a systematic assessment of the effects of 
skin dose in breast radiotherapy from modern flattening filter free (FFF) beams which are fast becoming 
standard on modern linear accelerators and may, as the results presented herein suggest, reduce the 
out-of-field dose deposited to untargeted healthy tissue in regions adjacent to the radiation field 
compared to conventional flattened beams.  
 
6.5 Assessment of leakage dose in vivo in breast radiotherapy 
 
A clinical study is presented in Chapter 2 in which TLD measurements were conducted on eleven breast 
cancer patients who underwent external beam radiotherapy treatment. The six common measurement 
locations in this study were chosen to correspond with anatomical locations which are of interest for 
long term risk assessment, namely the thyroid, contralateral breast and axilla. Assessment of radiation 
doses at out-of-field locations particularly in the context of clinical fractionation regimens requires 
specialised dosimeters which are sensitive to low radiation doses and exhibit small variations to different 
radiation qualities since the radiation quality out-of-field is often not precisely known. A specialised TLD 
material, LiF:Mg,Cu,P, was therefore chosen for its high sensitivity and relatively flat energy response 
over a wide energy range compared to conventional TLD materials. To facilitate sufficient levels of 
measurement accuracy, customised ‘buildup domes’ were designed to accommodate three TLD chips 
per measurement point. The geometry of the domes was such that they provided a hemisphere shaped 
buildup region to the TLD chips. In this way, angular dependence of the incident radiation at each point 
was minimised. The geometry of TLD position resulted in dose averaging over the area of the domes 
which, considering the dose gradients across the domes and associated positioning uncertainties, 
increased the measurement uncertainties to an estimated 10 % (Type B). In a low radiation dose setting, 
this would generally be regarded as acceptable for the purposes of in vivo dosimetry. 
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Limitations of the TPS were evident at locations distant from the radiotherapy fields with dose at distal 
points under-estimated for all algorithm types, though to varying degrees. Patient-related factors were 
not found to be a predictor for calculation accuracy out-of-field when variables such as field size, beam 
energy, linac gantry angles and treatment laterality were considered. Three different class of dose 
calculation algorithm were compared as part of this study. Each class of algorithm has varying levels of 
sophistication in calculating in-field doses and their accuracy in-field in the presence of different media 
typical of human tissues are well documented (Van Esch et al. 2006; Fogliata et al. 2011) and thoroughly 
investigated at commissioning before clinical use. Their respective accuracy at out-of-field locations 
however is typically not assessed during commissioning beyond a few centimetres from the radiation 
field edge. 
 
The impact which increasing distance from the radiotherapy fields exhibited on calculation accuracy 
suggested that linac-specific contributions were not explicitly accounted for. Using the most modern 
algorithm the application of a leakage correction was explored that would add a missing out-of-field 
dose component to calculation data as measured in vivo. Addition of a 0.04% correction for leakage 
radiation was found to improve dose calculations at points distal to the radiotherapy fields on average 
for all patients. This measured value is consistent with international guidelines (IEC, 1990) for the 
maximum allowable leakage radiation from a medical linear accelerator. This correction compensates 
for a measured deficiency in treatment planning system calculations and is derived directly from in vivo 
dosimetric assessment; the proposed correction is therefore feasible in a wider cohort of breast cancer 
patients since it is not patient-specific.  
 
Given the labour intensive nature of in vivo dosimetry it is unlikely that similar TLD measurements would 
ever become standard practice. A leakage correction which is independent of patient factors is therefore 
a desirable feature in the context of wider clinical implementation. This work does however have some 
limitations in that it is specific to one particular linear accelerator design and treatment planning system 
combination. A comparison of leakage dose from different accelerator designs is presented by Lonski 
et at (Lonski et al. 2012) where it was demonstrated that leakage dose varied by up to a factor of 5 
between different linac designs. It was also demonstrated that a single-energy linear accelerator (Varian 
600C) produced less leakage radiation than its higher energy multi-modality counterparts (Varian 21-
X, Elekta Synergy-II and Siemens Primus). Intuitively, one may anticipate that the absence of a bending 
magnet is a contributor to the reduced leakage radiation seen in the single mode design. Even amongst 
the higher energy models, differences in collimator design were shown to have a considerable impact 
on the leakage radiation, with a combination of thicker jaws and MLC leaf bank in the Varian 21-X 
design producing the least amount of leakage radiation. Leakage dose assessment is therefore required 
for each accelerator model and its application to a wider patient cohort should be assessed before 
clinical implementation, particularly for different treatment planning system and linac combinations.  
 
Since the in vivo study was performed for patients treated on a Varian 21-X machine, the 0.04 % 
leakage dose correction is likely to be lower than would be required if these patients were treated on a 
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machine model shown to produce higher leakage radiation. Assuming a well-shielded linear accelerator 
whose leakage component is 0.04 % of the primary beam, for a 50 Gy typical breast treatment this 
leakage dose would add 20 mGy unaccounted dose from radiotherapy treatment. This dose may be 
considered low, however if one were to consider an example case of a patient who was found to be 
pregnant during the course of her treatment, 20 mGy becomes an important addition to other sources 
of radiation exposure for radiotherapy patients, including for example diagnostic imaging and planning 
CT scans. According to the International Commission on Radiation Protection (ICRP) report 84 
('International Commission on Radiological Protection. Pregnancy and medical radiation'  2000), 100 
mGy would be a dose threshold above which foetal risk becomes important. In this context an additional 
20 mGy from radiotherapy treatment is an important consideration and not accounted for in commercial 
treatment planning.  
 
6.6 Limitations of TLD 
 
While TLD appears favourable for its low energy dependence in unknown radiation environments and, 
for LiF:Mg,cu,P, high sensitivity to low out-of-field doses, associated measurement uncertainties are 
strongly dependent on handling procedures. Careful handling, reproducible readout and annealing, 
cleanliness of TLDs and associated equipment, and careful calibration are critical to measurement 
accuracy. A key advantage of TLD though is the lack of cables required, such as would be required for 
MOSFETs or diodes. TLD also requires no voltage as in the case of ion chamber measurements. The 
small size also provides an advantage for patient comfort during measurement. An alternative strategy 
to in vivo dosimetry, and one which occurs more frequently in the literature, is the application of Monte 
Carlo simulations to acquire out-of-field doses to peripheral healthy tissue. Previous groups have 
applied Monte Carlo modelling to breast radiotherapy (Berris et al. 2013; Joosten, Bochud, and Moeckli 
2014; Joosten et al. 2013) in order to obtain organ specific doses and thus calculate absolute lifetime 
attributable risk estimates. Monte Carlo is considered the ‘gold standard’ in modelling radiation 
interactions within matter. Such studies therefore provide highly accurate dose calculations within 
inhomogenous media. Dosimetric validation however is required with the radiotherapy fields they are 
intended to simulate. Furthermore, modelling of specific components within the linear accelerator poses 
some challenges, namely obtaining the exact dimensions and compositions of each component, 
particularly shielding. Such details may not always be readily available from the manufacturer and 
simplifications are usually necessary which also has the advantage of increasing calculation speed. 
Monte Carlo modelling also requires skills and computing resources which may not be available to many 
radiotherapy facilities without academic affiliations. 
 
6.7 Stereotactic ablative body radiotherapy for assessment of leakage dose in vivo 
 
The relatively close proximity to the primary radiation field for some measurement points in Chapter 2 
results in a complex amalgam of leakage, patient scatter and collimator scatter contributing to doses 
measured in vivo. Indeed, measurement locations immediately adjacent to the treated breast were 
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necessarily excluded from the leakage dose correction as these locations were overwhelmingly 
dominated by patient scatter. Since leakage radiation dominates at larger distances from the primary 
beam, a second in vivo dosimetric study was employed to study the leakage component in further detail. 
This work, presented in Chapter 3, explores the out-of-field dose in the context of state-of-the-art 
stereotactic body radiotherapy (SABR) treatments for primary renal cell carcinoma.  
 
SABR treatments offer unique radiotherapy conditions prime for analysing machine leakage since beam 
angles are often uniformly distributed circumferentially about the patient plane. More significantly, 
higher treatment doses per fraction results in a higher radiation dose out-of-field per treatment session, 
thereby resulting in a stronger signal from radiation detectors placed out-of-field. High sensitivity TLDs 
can therefore be placed at further distances from the treated site than would be typical under 
conventional fractionation regimens. TLDs were placed along midline at increasing distances up to 50 
cm from beam central axis for a cohort of SABR patients as described in Chapter 3. In this way, the 
leakage component was able to be measured in regions of minimal head scatter and patient scatter 
contributions. Leakage dose was measured to be 0.03 % of the primary beam in this work. This is 
consistent with the 0.04 % correction proposed for breast radiotherapy in Chapter 2. Patients were 
treated on the same linear accelerator model in both studies.  
 
6.8 Effects of beam energy on leakage dose out-of-field 
 
An interesting finding of this study was the use of 6- or 18 MV photon beams did not show a trend in 
out-of-field dose at near-field locations (20 cm from isocentre) within this patient cohort (compare Figure 
4a, Chapter 3). Considering the accelerator design and interactions of charged particles within, it may 
be anticipated that there would be subsequent differences in the out-of-field dose from a linac operating 
at various megavoltage photon energies. For instance, the angular dependence of bremsstrahlung 
photons would lead to increased leakage radiation when operated at lower energy modes owing to the 
less forward peaked nature of the beam. In addition, the lower conversion efficiency at 6 MV compared 
to 18 MV within the target material requires a higher beam current in order to produce the same dose 
rate. Conversely, at locations beneath the collimators, an 18 MV beam will produce more scatter 
radiation owing to the greater penetrative ability of the higher energy photons through shielding and 
collimator materials. The similarities in out-of-field doses observed in vivo in this study comparing 6- 
and 18 MV SABR plans may suggest these competing effects balance out somewhat. However, patient 
related factors may also have an impact. A comparison of peripheral dose was also presented by Fraas 
et al (Fraass and van de Geijn 1983), who similarly concluded that out-of-field dose did not change 
considerably between different beam energies. Their study however was conducted on different linear 
accelerator models, ranging from a Co-60 machine to a 10 MV accelerator. Interpretation of these 
results is therefore complicated by differences in machine design which may be a confounding factor. 
Van der Giessen (Van der Giessen 1996) came to similar conclusions by collating published data from 
various machines. Energy dependence of peripheral dose was small enough, it was found, that a 
generalised model covering a range of energies from Co-60 up to 25 MV could be applied to estimate 
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peripheral dose with an accuracy of ± 33 %. The findings of this thesis therefore appear to be supported 
by current literature, and peripheral photon dose has only a small dependence on the energy of the 
primary beam. This is not to be confused with total absorbed dose, however, since the production of 
photoneutrons at higher energies increases the biological dose further and must also be taken into 
account. 
 
6.9 Assessment of machine leakage using a collimated detector system 
 
The in vivo dosimetric studies presented thus far address the issue of leakage dose at the patient plane. 
This has clear clinical applications and is of interest for patient risk assessment. A natural extension of 
this work is to ascertain the origin of such leakage dose at the linear accelerator. To this end, a 
collimated detection system utilising high sensitivity TLD material was devised which would enable 
focused measurements to map leakage dose patterns from a linear accelerator head. This study is 
presented in Chapter 4 and demonstrated that the spatial origin of leakage dose hot spots within the 
treatment head may be identified using multiple detectors embedded within a stereotactic cone. The 
spread of TLD signal from multiple chips embedded at the same measurement plane was shown to 
indicate whether the cone was oriented towards a source of leakage dose, as indicated by a low 
standard deviation, or adjacent to a radiation source, as indicated by a larger standard deviation. 
Leakage dose may be directly measured in this way since the collimated measurement system shields 
TLDs against multi-directional sources of radiation such as scatter.  
 
Measurements conducted along one side of the treatment head revealed a leakage dose peak of 
magnitude five times higher than surrounding scatter doses at the level of the bremsstrahlung target. A 
discernible signal was identified at the level of the flattening filter though was less than the dose 
measured at the level of the target. Furthermore, leakage dose measured at the production side of the 
target was higher than the incident side of the target, as would be expected. Leakage dose at the side 
of the linac head was shown to be invariable with jaw-defined field size when comparing a small (4 cm 
x 4 cm) and large (40 cm x 40 cm) fields though a dose reduction was noted when the collimator was 
oriented such that the MLC leaf bank was situated between the bremsstrahlung target and detector 
system. This study demonstrated that the leakage dose did not exceed 0.01 % of the primary beam 
with the collimated detector system aimed at the linac target. Out-of-field dose elsewhere arising from 
scatter contributions within the gantry was measured to be 0.0025 % with no discernible shielding 
deficiencies identified.  
 
Perhaps its most obvious drawback, the methodology employed to facilitate collimated measurements 
is labour intensive. Alternative methods however are scarce, with conventional film-wrap techniques no 
longer routinely used due to the high cost of modern radiochromic film and the reduced availability of 
film processing facilities for cheaper radiographic film. Monte Carlo methods may provide an alternative, 
owing to the ability to track photon interactions in a linear accelerator. However, a full linac model 
including precise location and dimensions of shielding would be required, and shielding deficiencies 
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during manufacturing cannot necessarily be anticipated. Furthermore, common approaches for linac 
modelling such as BEAMncr code (NRCC) are designed to model the primary beam, and not the head 
components of the accelerator. Direct measurement is therefore required. Common methods for 
assessing out-of-field dose typically employ ion chamber measurements within a water phantom 
(Chofor et al. 2010; Cashmore 2008; Kase et al. 1983). Under these conditions the origins of dose 
contributions to the detector cannot be distinguished between head scatter, phantom scatter and 
leakage radiation, nor can they therefore distinguish specific radiation ‘hot-spots’ from the treatment 
head. While labour-intensive, a collimated detector system may be the only practical solution. 
 
6.10 Second cancers from radiotherapy 
 
Whole breast irradiation following breast conserving surgery has been demonstrated to provide 
significant reduction in recurrence rates and breast cancer mortality for patients with early stage breast 
cancer compared to surgery alone (Fisher et al. 2002; Group 2012), making it an important treatment 
option for a large number of patients. The incidental exposure of healthy tissue beyond the radiotherapy 
fields however may carry some risk of second cancers later in life (Abo-Madyan et al. 2014; Gao, Fisher, 
and Emami 2003a; Grantzau and Overgaard 2015a; Ng et al. 2012). Current scientific evidence links 
absorbed radiation dose to long-term health risk according to the linear-no-threshold model (Preston et 
al. 2007b; McGregor et al. 1977). For breast cancer patients, accurate knowledge of radiation dose 
both in and beyond the primary treatment region is therefore important for assessing these risks.  
 
Long-term epidemiological studies provide quality scientific evidence for risks of radiocarcinogenesis 
resulting from exposure to ionising radiation. Data from radiotherapy patients is particularly valuable 
owing to the large number of cases and dosimetric information is often well documented. Studies 
reporting on short-term follow up have reported insignificant elevated risk of second cancer following 
radiotherapy (Gao, Fisher, and Emami 2003b). This is perhaps unsurprising since long-term follow up 
is required in order to allow sufficient time for second cancers to manifest (Bartkowiak et al. 2012). 
Indeed, studies reporting outcomes at least 10 years following radiotherapy have reported elevated risk 
of second solid cancer induction, particularly in patients who were irradiated at a younger age with 
elevated risks of second cancer induction being well established for patients who undergo radiotherapy 
during childhood (Friedman et al. 2010; Hawkins 1990; Kaldor 1990; Olsen et al. 1993; Schwartz et al. 
2014). The importance of sufficient follow-up time cannot be understated for such studies – in a review 
article on the incidence of second primary cancers in irradiated patients, Tubiana (Tubiana 2009) 
reported that the time delay between irradiation and cancer induction is often greater than ten years, 
and can manifest up to 50 years post radiotherapy. Studies which report cancer incidence at shorter 
follow up times likely under-estimate the risk of cancer incidence. Cumulative incidence of second 
primary cancers were found to be as high as 20 % for radiotherapy patients, however the locations of 
these events occurred in moderate to high dose regions. For low doses received beyond the treatment 
region, Tubiana claims that while dose estimations are complicated, they are nonetheless essential 
since more data is required to link radiation effects to absorbed dose in lower dose regions - a topic 
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currently under much debate. The discussion is unlikely to be resolved however if inaccurate low-dose 
estimates are applied to long-term follow up data. Accurate data in the low dose region is required, as 
this thesis has aimed to address. 
 
Inskip et al analysed the incidence of lung cancer in patients who underwent radiotherapy for breast 
cancer, reporting an estimated ERR of 0.2 Gy-1 for the affected lung after a 10-year follow up period 
(Inskip, Stovall, and Flannery 1994b). This epidemiological data however is based on older radiotherapy 
techniques between 1935 and 1971, with an estimated mean combined lung dose of 9.8 Gy, much 
higher than doses typically achieved with modern techniques. These reported risks are therefore 
associated with outdated planning strategies and associated ERR estimates may not extend to modern 
planning techniques where lower mean lung doses are readily achievable. The value of such data may 
well be brought into question in light of the ever evolving nature of radiotherapy. On the contrary, the 
long-term follow up times required will always inherently result in a lag time between emerging 
epidemiological evidence and current radiotherapy practices and epidemiological evidence should not 
be discounted. Indeed, as electronic treatment records become prevalent the ability to link long term 
outcomes with dosimetric parameters will translate to a better understanding of the risks associated 
with radiotherapy. The dose estimates from the treatment planning system however must first be 
sufficiently accurate to ensure the validity and quality of future long-term follow-up studies.  
 
Boice et al (Boice et al. 1992) assessed the risk of second solid cancer induction in the contralateral 
breast of women who underwent breast radiotherapy. In their case-controlled study consisting of over 
41,000 patients a small increase in risk was reported at 10 years after treatment. Though only 3 % of 
observed second cancers were attributable to radiotherapy, the risk was higher for women exposed at 
age < 45 years and increased with the estimated absorbed dose to the contralateral breast.  
 
More recently, a large meta-analysis containing data from 762,468 patients demonstrated that 
radiotherapy was significantly associated with increased risk of second cancer induction (Grantzau and 
Overgaard 2015a). Relative risk of second cancers for irradiated women was compared to those who 
did not receive radiotherapy. The authors demonstrated elevated risks of cancer induction for lung and 
oesophagus - organs which are in close proximity to the radiation field - and reported that the risk 
increased over time, peaking at 15 years post radiotherapy. This work received some attention upon its 
publication; one letter in particular was submitted to the journal editor (Mallick, Giridhar, and Prasad 
Venkatesulu 2015) expressing concern that the article would create confusion for clinicians. In their 
response (Grantzau and Overgaard 2015b), the authors stressed the clear benefits of radiotherapy for 
reducing recurrences and mortality, despite the associated risks which they had demonstrated, though 
added that the decision to treat with radiation must be weighed against such risks. In order to extrapolate 
associated risks from radiation treatment however, the dose must first be quantified with sufficient 
accuracy; long-term outcomes based on inaccurate dosimetric information are inherently misleading. 
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6.11 Risk of second cancer from leakage radiation in breast radiotherapy 
 
Having directly measured the leakage component of the out-of-field dose through in vivo dosimetry, 
results of this thesis can be used to estimate risks of developing a second fatal cancer after radiotherapy 
for breast cancer from exposure to this leakage radiation. ICRP guidelines stipulate a  5 % risk per 
Sievert absorbed radiation dose (ICRP 2007). This work has demonstrated that patients are exposed 
to 0.04 % of the prescribed dose in the form of leakage radiation, or 20 mGy for a typical prescribed 
dose of 50 Gy. This equates to a 0.1 % risk of second fatal cancer as a result of exposure to this leakage 
radiation. With 16,000 new cases of breast cancer are diagnosed in Australia every year, and if one 
assumes an optimal radiotherapy utilisation rate of 83 % as calculated by Delaney et al, (Delaney, 
Barton, and Jacob 2003) this translates to approximately 13 cancer inductions per year across Australia 
as a result of exposure to leakage radiation, which is not accounted for in commercial treatment 
planning systems. This does not account for other risks arising from intermediate and high doses to 
which patients are also exposed. The associated uncertainties in this estimate are large, relying heavily 
on an assumed dose response as stated by the ICRP and assumes optimal radiotherapy utilisation 
which in practice over-estimate true utilisation rates at present, however this figure is useful as an 
indicator as to the number of breast cancer patients potentially affected by exposure to leakage radiation 
every year which is unaccounted for and largely unknown, except in rare cases where in vivo dosimetry 
is performed out-of-field. This figure also assumes conventional treatment delivery using standard 
tangents. If IMRT or VMAT is used, the relative contribution of leakage radiation increases due to the 
increased modulation, although the degree to which this applies is highly dependent on planning 
technique. For low modulation, the leakage component may be double. For highly modulated treatments 
however, and for the purposes of bunker design, an IMRT factor of 5 is often assumed. Therefore the 
relative merits of IMRT of VMAT for breast radiotherapy should be carefully considered along with the 
associated increased risk from additional exposure to leakage radiation. For complex treatment 
volumes IMRT or VMAT may be necessary to achieve clinically acceptable dose distributions. For 
simple volumes however, if similar plan quality is achievable, standard tangents used in preference to 
modulated techniques. 
 
6.12 Skin doses in breast radiotherapy 
 
The leakage dose described in Chapters 2, 3 and 4 is of interest for patient long-term risk assessment. 
These lower radiation doses are associated with stochastic effects, whereby the probability of a post-
treatment event - which may take years to manifest - increases with absorbed radiation dose. 
Therapeutic radiation doses may be several orders of magnitude higher and are associated with acute 
reactions, in which case the severity of a reaction increases with absorbed dose. Acute effects are more 
immediate and may occur in the hours, days or weeks following treatment. Skin reactions are one such 
concern in breast radiotherapy and can range from mild skin reddening to more severe reactions such 
as moist desquamation.  
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Skin sparing may be afforded in some cases by judicious choice of beam energy however in cases 
where the dermal lymphatics are intended for treatment the skin will unavoidably receive prescribed 
dose. Depending on the extent of the radiotherapy fields, a patients’ history of sun exposure can also 
affect the likelihood of skin reactions during a course of radiotherapy treatment, particularly about the 
neckline. It is therefore important to quantify skin dose at the radiotherapy treatment planning stage.  
Despite being geometrically contained within the primary radiotherapy fields, the surface of a patient or 
phantom is within a region of charged particle disequilibrium. Detector size poses a particular challenge 
due to their finite thickness; larger detectors may perturb the radiation field, and dose averaging occurs 
over a thicker measurement depth than desired. An alternative method has been proposed by others, 
whereby decreasing thickness of TLD (Kron et al. 1996b; Kron et al. 1993) or film (Butson, Yu, and 
Metcalfe 1999) enables interpolation of skin dose at depth of the basal cell layer, or approximately 70 
microns. Interpolation techniques are well suited for determining skin doses from radiotherapy beams 
and lend themselves to in vivo dosimetry. Ion chamber measurements provide an alternative solution, 
having the advantage of instant readout and are well-characterised, providing means of systematically 
mapping surface dose from radiotherapy fields. The Exradin A10 chamber used for the study presented 
in Chapter 5 has an effective measurement depth of approximately 70 microns. It is also characterised 
by a small electrode separation and wide guard ring to reduce perturbation effects.  
 
Dose contributions to skin arise primarily from scatter radiation and electron contamination, the latter 
originating from interactions upstream in the primary beam within the treatment head, accessories and 
other media. Skin doses are therefore not well modelled by commercial treatment planning systems 
(Kim, Hill, and Kuncic 2012) and measurements are required to accurately predict skin dose in 
megavoltage radiotherapy. Surface dose from radiotherapy fields typical of breast treatments was 
studied as part of this work and is presented in Chapter 5. A thin window ionisation chamber was used 
to systematically map the surface dose across a half blocked beam using dose measurements relative 
to local reference conditions (depth of maximum dose at 100 cm source-to-surface distance in a 10cm 
x 10cm jaw-defined field). The dimensions of the experiment field were chosen to represent average 
field sizes used for breast radiotherapy. Choice of beam energy was similarly chosen to be 
representative of current common practice, including 6, 10 and 18 MV.  
 
6.13 Advancing technology: the introduction of Flattening Filter Free beams 
 
Flattening filter free (FFF) modalities have recently become standard on many modern linear 
accelerators. These modalities may have potential applications in breast radiotherapy. Removal of the 
flattening filter, which traditionally serves to flatten the primary beam by selectively attenuating the 
higher photon fluence at central axis, results in a higher dose rate in the field centre and a peaked dose 
profile. Additionally, it may be anticipated that removal of the flattening filter has consequences for out-
of-field dose and skin dose since the flattening filter is a source of scatter as well as contaminant 
electrons. Conversely, removal of the flattening filter also reduces the beam hardening effects normally 
afforded by the additional attenuation, thereby reducing the beam quality which would be expected to 
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increase the surface dose. The final resulting skin dose is therefore a complex balance between 
competing effects.  
 
Beam tuning may be performed by adjusting electron energy to achieve similar beam quality between 
flat and FFF beams of the same nominal energy (as in the case of Elekta machines) or a reduction in 
beam quality can be accepted without tuning (as in the case of Varian machines). Vendors may add a 
thin metal plate for FFF beams to absorb low energy contaminant electrons which originate within the 
target and primary collimator and to also provide a small buildup dose for the purpose of increasing the 
proportion of detectable secondary electrons in the monitor chamber. The consequences for surface 
dose are therefore not readily estimated and systematic measurements are required.  
 
The study presented in Chapter 5 demonstrated that the absolute surface dose at beam central axis 
varies with jaw-defined radiation field size for flat as well as FFF beams. Field size dependence was 
shown to be less pronounced for FFF modes. A higher surface dose was measured at central axis in 
smaller jaw-defined fields when using FFF. For larger radiation fields this trend was reversed, with 
flattened beams producing higher surface dose in the largest available field. This suggests the flattening 
filter may be a dominant contributor to skin dose in larger treatment fields. Surface dose was also found 
to reduce at off-axis locations in the case of FFF. For breast radiotherapy, a half-beam block technique 
is often used to achieve a non-divergent field edge from two opposing tangents. The surface dose from 
such fields was similarly studied and for these clinical geometries, the lowest available megavoltage 
beam (6 MV) operated in FFF mode was found to produce the highest surface dose in the field centre. 
Interestingly, the lowest surface dose was produced by a 10 MV FFF beam.  
 
Dose measurements out-of-field at locations corresponding to the contralateral breast demonstrated 
that FFF beams delivered lower out-of-field dose compared to flat beams of similar nominal beam 
quality, suggesting that modern FFF modalities may provide options to reduce scatter dose to the 
contralateral breast. Furthermore, this study demonstrated that surface dose across a radiotherapy field 
can vary considerably depending on the choice of photon beam used. For breast radiotherapy, 6 MV 
FFF was shown to produce the highest surface dose in the field centre (27 % of the primary beam) with 
10 MV FFF producing the lowest surface dose (17 % of the primary beam). 10 MV FFF was also the 
lowest at off-axis locations. In cases where skin dose is of concern, this work has demonstrated that 
judicious choice of beam energy and modality can result in considerable differences for surface dose, 
providing useful data for radiotherapy treatment planning. The usefulness of FFF for breast radiotherapy 
remains to be seen, with some authors already reporting similar plan quality with conventional flat 
beams (Spruijt et al. 2013; Lai et al. 2016) and in some cases suggesting a benefit of FFF for DIBH 
(Koivumaki et al. 2016). FFF has potential to be an important option for breast radiotherapy in the future. 
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6.14 Planning strategies: conforming to the modern era 
 
Since the beginning of this thesis the issue of peripheral dose in breast radiotherapy has gained 
considerable research interest with various groups attempting to quantify radiation doses and 
associated health risks. Heterogeneity in treatment practice amongst radiotherapy institutions presents 
a particular challenge in attempting to apply ‘typical’ patient doses to risk models. Breast radiotherapy 
may be delivered using intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy 
(VMAT), 3-D conformal radiotherapy (3DCRT), tomotherapy and electron fields amongst others. 
Furthermore, emerging evidence from clinical trials such as MA.20 (Whelan et al. 2015) may translate 
to use of larger radiotherapy fields in some patients to encompass surrounding lymph nodes within the 
treatment field.  
 
Planning studies have been used in response to emerging techniques to compare second cancer risk 
from different treatment planning approaches. For locoregional radiotherapy, Popescu et al (Popescu 
et al. 2010b) demonstrated the relative merits of VMAT techniques over IMRT in achieving dose 
coverage in left sided breast cancer including the internal mammary nodes. Beckham et al (Beckham 
et al. 2007b) similarly compared IMRT to standard plans and determined that while IMRT was able to 
achieve improved conformity to targeted regions, this came at the cost of increased volumes of normal 
tissue receiving low doses. Abo-Madyan et al (Abo-Madyan et al. 2014) simulated 3DCRT, IMRT and 
VMAT techniques on CT scans of 10 ‘representative’ patients to compare the associated risks of lung 
and contralateral breast cancer using different risk models. The increased risk of second cancers was 
determined to be between 34 and 50 % for modern techniques including IMRT and VMAT compared to 
3DCRT, though emphasised that the risk of second cancers should be balanced against potential 
benefits from heart sparing afforded from these techniques. Such studies are a valuable source of 
relative risk comparisons however do not necessarily afford absolute risk data for a larger population 
due to some limitations, namely, accuracy of the commercial dose calculation algorithm used, the use 
of representative patient CT scans, and sensitivity of treatment plan quality to optimisation engines. 
Nevertheless, on a patient-specific basis such planning studies can provide invaluable information to 
clinicians who may opt for one treatment strategy over another based on individual prognosis. Lee et al 
(Lee et al. 2014) performed a similar planning study though complimented their risk estimation data 
with dose measurements performed in an anthropomorphic phantom. Again it was found that the risk 
of second cancer was higher in the case of VMAT and IMRT, though this study is specific to an 
anthropomorphic phantom whose geometry, it may be argued, would be considered somewhat 
unrealistic. Results of similar planning studies are again subject to how the optimiser is used in the 
treatment planning system though nevertheless provides a useful relative comparison of out-of-field 
doses from different planning strategies. 
 
As radiotherapy technology continues to evolve several groups have investigated whether breast 
radiotherapy can benefit from modern developments such as volumetric modulated arc therapy (VMAT) 
and flattening filter free (FFF) modalities. With generally higher integral dose inverse-planned 
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treatments such as VMAT offer little benefit for breast patients, and are often contra-indicated for 
concerns of dose to adjacent organs at risk (Badakhshi et al. 2013).  
 
6.15 Deep Inspiration Breath Hold for cardiac sparing 
 
One technique which shows promise particularly in the management of left sided breast cancer is deep 
inspiration breath hold (DIBH). In women treated for left sided breast cancer, the heart lies immediately 
adjacent or in many cases partially within the radiation field. Darby et al (Darby et al. 2013) reported an 
increased risk of ischaemic heat disease in women who underwent radiotherapy for breast cancer, with 
the risk reported to be dependent on the mean dose to the heart. Crucially, there was no threshold 
reported below which the mean heart dose was thought not to carry a risk. Reducing heart dose in 
breast radiotherapy therefore carries potentially significant benefits to patients. Several studies have 
reported on the benefits of DIBH for reducing dose to the heart during radiotherapy treatment (Dincoglan 
et al. 2013; Hayden, Rains, and Tiver 2012; Hjelstuen et al. 2012; Remouchamps et al. 2003; Vikstrom 
et al. 2011).  
 
6.16 Consequences for lung dose in DIBH 
 
There is a degree of concern that lung expansion during DIBH increases the volume of lung within 
radiotherapy fields and may result in an increase in lung dose. As part of this thesis a sub-study was 
conducted to investigate the effects of changing lung volume, and therefore dose, arising from lung 
expansion in DIBH (Lonski, Jolly, Chua, et al. 2015; Lonski, Jolly, Siva, et al. 2015). CT scans of ten 
consecutive patients were retrospectively evaluated. Patients underwent a free breathing (FB) and 
DIBH CT scan. The relative change in lung volume that occurred in DIBH was assessed. Change in 
lung volume was defined relative to free breathing lung volume.  
 
While an increase in absolute volume of lung was observed within the radiation beams, results 
suggested that although the lung volume present within the radiotherapy fields increases during DIBH, 
a decrease in tissue density was observed as the lungs expand. The resulting lung dose-volume 
histogram metrics when analysed in terms of relative rather than absolute lung tissue showed no 
significant difference comparing DIBH to free breathing. The relative lung volume receiving 5 Gy, 20 Gy 
and 30 Gy (V5, V20 and V30 Gy) was comparable in FB and in DIBH, despite the absolute volumes 
being higher in DIBH. Concern for lung dose therefore should not be a contra indicator for DIBH, though 
lung metrics should still be considered by clinicians on an individual patient basis. 
 
6.17 Dose calculation methods: the role of Monte Carlo modelling 
 
Monte Carlo radiation transport modelling is considered the gold standard in dose calculation, since 
interactions of primary radiation as well as subsequent particles are explicitly modelled. Studies utilising 
Monte Carlo derived organ doses are labour intensive to establish. However, after initial verification, 
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Monte Carlo has substantial value as a research tool can be useful in establishing accurate dose 
distributions to adjacent organs from a radiotherapy treatment simulation. Joosten et al (Joosten et al. 
2013) compared peripheral dose calculations from a commercial treatment planning system to Monte 
Carlo simulations for a breast radiotherapy patient and found large discrepancies in calculated organ 
doses, even for organs adjacent to the field. They concluded that a significant portion of the out-of-field 
dose emanated from head scatter, which is not modelled by commercial planning systems. Their study 
however consisted of only one patient and therefore extrapolating findings to the wider patient 
population has limited scope; however the study nicely illustrated limitations of commercial planning 
systems. 
 
Prohibitively long calculation times however tend to restrict the use of Monte Carlo to research 
environments. Furthermore expert knowledge is required for modelling and often only larger research 
centres possess the required resources and expertise. Furthermore, Monte Carlo modelling may not 
include all relevant treatment accessories such as block trays and wedges, and detailed information 
about the componentry within the linear accelerator head must be included in the model for accurate 
dose calculation. Therefore, while Monte Carlo offers the best means of modelling particle interactions 
and resulting dose deposition in various media, it is not a comprehensive solution for investigating out-
of-field dose and should be seen rather as a complimentary tool. 
 
6.18 Increasing importance of out-of-field dose in radiotherapy 
 
Throughout the earlier days of radiation therapy out-of-field dose was generally not considered to be of 
major concern. Betatrons and 60Co machines were commonly used for external beam radiotherapy and 
it was not until the transition to higher energy linear accelerators in the 1970s that concerns were raised 
about potential neutron generation during high energy photon treatments. This lead to a number of 
studies over the coming decades assessing neutron doses in high energy radiotherapy, many of which 
focused on risk to treatment staff (McCall, Jenkins, and Shore 1979; McGinley et al. 1976; LaRiviere 
1985)  suggesting that, at the time, long term risks to patients arising from out-of-field doses during 
treatment were not as much of a concern as they are today, possibly reflecting the differences in long-
term patient survival. However it was not long before the associated peripheral photon dose also gained 
interest. Some of the first work assessing out-of-field photon doses in radiotherapy began to emerge in 
the early 1980s (Fraass and van de Geijn 1983; Kase et al. 1983). Long-term risk to patients was cited 
as the key driver for this work, and since then out-of-field dose in radiotherapy has been a topic of 
ongoing interest.  
 
As the methods and technology behind radiotherapy treatment evolves, so too does the out-of-field 
dose associated with radiotherapy, and even comprehensive datasets do not necessarily translate to 
modern techniques, nor do they account for patient-specific treatment scenarios. It is therefore no 
surprise that the topic of out-of-field dose continues to draw much research interest. Figure 6.1 shows 
the number of publications pertaining to out-of-field dose in radiotherapy since the 1980s. Very few 
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publications existed until the mid-2000s, when a surge of work began to emerge. At around the same 
time, the topic of second cancer in radiotherapy also gained substantial interest.  
 
 
Figure 6.1 – Number of PubMed search results pertaining to out-of-field dose in radiotherapy and 
second cancer from radiotherapy from 1980 to present. 
 
 
Although in vivo dosimetry in radiotherapy had been performed since the 1960’s, its application was not 
immediately extended to breast treatments. Figure 6.2 shows the number of publications reporting on 
the use of in vivo dosimetry in radiotherapy since external beam radiotherapy began. The number of 
publications reporting on in vivo dosimetry for breast radiotherapy can be seen to increase with the total 
count, averaging around 8% of the available literature. 
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Figure 6.2 – Total publication count between 1959 and 2017 for PubMed search containing “in vivo” 
and “radiotherapy” and “dosimetry”. Publications within the search results specifically related to breast 
radiotherapy including post mastectomy chest wall irradiation are duplicated separately to illustrate the 
proportion of the total publications related specifically to breast radiotherapy. 
 
In practice, routine in vivo dosimetry can place prohibitive resource demands on a radiotherapy 
department, particularly in larger centres. Measurements are often either performed on select patients 
or not at all. Recent efforts to automate in vivo dosimetry using electronic portal imaging devices 
(EPIDs) show promise for future routine use (MacDougall et al. 2017; Mijnheer et al. 2015; Olaciregui-
Ruiz et al. 2013). With most modern linear accelerators already equipped with EPI, and limited 
additional time required of treatment staff, this option appears particularly attractive for routine use and 
can be used for most megavoltage photon treatments under standard setup conditions. Furthermore 
the addition of 2D spatial information provides an advantage over point dose measurements. Obvious 
exceptions where EPI cannot be used in vivo include total body irradiation and electron treatments. 
Furthermore, measurements are only possible within the primary beam, and the field size is limited to 
the dimensions of the detector panel. This somewhat limits the scope of EPID dosimetry to in-field 
megavoltage photon treatment verification, and currently clinical implementation of routine EPID in vivo 
treatment verification is only performed in a small number of advanced centres worldwide. Other 
methods for performing in vivo dosimetry include ionisation chambers, diodes, TLD, radiosensitive gels, 
metal oxide field effect transistors (MOSFETS) and radiochromic film. Use of these detectors for in vivo 
dosimetry requires additional resources and training and can limit the number of patients for whom 
measurements are performed during treatment. Some restrictions of EPID however do not apply to 
these detectors, since they can be used for electron treatments, extended source-to-surface distance 
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treatments and large fields. They can also be placed out-of-field if their response to low doses in areas 
dominated by leakage and scatter is well characterised. With a linear dose response and minimal 
energy dependence, this makes LiF:Mg,Cu,P thermoluminescence materials particularly attractive as 
an out-of-field dosimeter material. 
 
6.19 Consideration of neutron contributions 
 
The in vivo study presented in Chapter 3 investigated possible influence of stray neutrons on TLD 
measured dose. Neutrons are an unwanted by-product in high energy radiotherapy generated within 
high atomic number materials comprising the linear accelerator and other treatment accessories. In an 
extensive review paper on out-of-field photon and neutrons in radiotherapy, Takam et al (Takam et al. 
2011) demonstrated that the reported neutron dose equivalent per unit photon dose varies considerably 
in the literature, ranging from 0.1 mSv/Gy to 20.4 mSv/Gy for an 18 MV linac beam. While neutrons are 
of concern for biological damage to untargeted healthy structures, there is also concern of neutron 
contribution to TLD materials while attempting to assess photon dose. Specifically, TLD materials 
enriched with 6Li will exhibit a greater interaction rate and therefore detector response due to the higher 
cross-section for thermal neutrons compared with 7Li, leading to erroneous interpretation of photon 
dose. Since the material used for in vivo dosimetry has a natural 6Li concentration of approximately 7% 
it was prudent to investigate its over-response while assessing photon doses in the presence of stray 
neutrons produced from high energy radiotherapy, specifically the 18 MV photon beams often employed 
not only for breast radiotherapy but also in the context of SABR for primary renal cell carcinoma. Using 
a combination of three different types of TLD material, each with varying concentrations of 6Li and 7Li, 
it was determined in this work that the over-response due to photons was potentially significant if not 
accounted for. This over-response increases with distance from the primary beam and was most 
pronounced for the 6Li-enriched material.  
 
For the high sensitivity material used in the work presented in Chapter 2, the over-response due to the 
presence of neutrons was measured to be 22%, 40%, 59% and 66% on average at 20, 30, 40 and 50 
cm from isocentre, respectively. These figures are, in the context of neutron contamination from high 
energy radiotherapy, within reasonable agreement with results reported by Kry et al (Kry et al. 2007). 
In the context of breast radiotherapy, measurement locations for the in vivo dosimetry presented in 
Chapter 2 were within 30 cm from the primary beam. Therefore the over-response could be expected 
to be as high as 40 % at the most peripheral measurement locations. However, the relative contribution 
of 18 MV photon beams to the overall radiotherapy treatment was significantly lower in the cohort of 
breast patients compared to SABR patients, with a maximum 30 % relative contribution of overall 
treatment monitor units. Thus for any given point the maximum over-response due to neutrons is 
estimated here to be approximately 12 % and is expected to be significantly less for the majority of 
measurement points located closer to the primary beam. Furthermore, only three of the eleven breast 
patients were treated using 18 MV photon beams as part of their radiotherapy. Additional TLD signal 
due to neutrons therefore did not have a significant impact on the out-of-field doses reported in Chapter 
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2. Future in vivo studies using LiF TLD materials should however take this additional signal into account. 
Where possible, the use of 6Li enriched materials should be avoided when assessing photon doses 
from high energy photon beam treatments, particularly at out-of-field locations, since the additional TL 
signal due to neutrons can be significant. 
 
A limitation of this work is that potential exposure to neutrons from other forms of radiotherapy such as 
protons are not assessed. In addition to posing dosimetric challenges, neutrons are often of concern 
for their potential of higher biological damage (ICRP 2007) compared to photons. Although proton 
facilities are not yet available in Australia, other groups have applied proton beams and conventional 
photon beams to accelerated partial breast irradiation (APBI) to compare resulting dose distributions. 
Despite the limitations of planning studies, there are suggestions that while similar target coverage is 
achievable for the two delivery methods, there may be considerable gains in normal tissue sparing from 
proton beam radiotherapy in a APBI setting (Moon et al. 2009). Resulting neutron doses from proton 
radiotherapy however must also be considered. In their review article on the topic of secondary neutrons 
in proton radiotherapy, Brenner and Hall (Brenner and Hall 2008) estimate similar second cancer risks 
from proton and photon radiotherapy. One key difference however is the secondary neutrons associated 
with proton beams have higher uncertainties compared to out-of-field photon doses from conventional 
photon beams. Kaderka et al (Kaderka et al. 2012) compared peripheral dose from megavolt photons, 
protons and carbon ions and found significantly higher peripheral dose from photons compared to 
charged particles. Furthermore, they concluded that the generation of biologically harmful 
photoneutrons resulted in increased out-of-field dose with increasing energy of the primary photon 
beam. Photoneutron contributions from high energy photons were found to contribute approximately 
the same order of magnitude as out-of-field photon dose. Out-of-field dose is also of concern for its 
effect on pacemakers, although with some conflicting evidence in the literature. A recent study in 
Denmark reported no increased risk to pacemaker function in patients treated for early stage breast 
cancer (Rehammar et al. 2017), however Zaremba et al report 3% malfunction rate for these devices 
from radiotherapy. Furthermore, malfunction rates were found to be associated with beam energy. The 
reason for conflicting data may well be the nature of reported device failure – for those events which 
were detected, Zaremba et al report transient software disturbances, which may in some cases go 
undetected. Recent case reports indicate that in the case of proton treatments there may be concerns 
for patients who have implanted cardiac devices (Ueyama et al. 2016). The use of charged particles 
has potential to reduce integral dose to untargeted healthy tissue though the absolute risks and benefits 
of protons versus photons remain to be seen.  
 
6.20 Outlook 
 
Radiotherapy is an important treatment option for many cancer patients worldwide. It is estimated that 
approximately 50 % of all patients diagnosed with cancer would benefit from radiotherapy (Delaney et 
al. 2005). Early diagnosis and improving treatment options are translating to increasingly favourable 
outcomes for many patients, particularly for early stage breast cancer where five-year survival rates 
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have improved from 72 % to 90 % over the past 30 years. This translates to a large number of long-
term survivors in whom treatment related effects are becoming increasingly important. This body of 
work has assessed the out-of-field dose reaching untargeted healthy tissue during radiotherapy for 
breast cancer, requiring the use of specialised clinical dosimeters which are sensitive to low doses and 
have dosimetric characteristics desirable for dosimetry in radiation environments out-of-field, where the 
energy spectrum is not well known. In the case of higher energy radiotherapy the use of 18 MV beams 
also poses the challenge of interpretation of photon doses in the presence of neutrons, the influence of 
which has been examined in this thesis. This work has broader implications for other radiotherapy 
treatments, since the leakage component of the out-of-field dose has been shown to be linac-specific, 
as was demonstrated in a comparison between breast radiotherapy and out-of-field dosimetry in a state 
of the art SABR programme for primary kidney cancer. The leakage correction which was derived 
directly from in vivo dosimetry is applicable to a large number of patients treated on a make of linear 
accelerator commonly used in many radiotherapy departments. Emerging treatment technology is also 
likely to have an impact on patient outcomes, as has been explored in the context of flattening filter free 
beams. The conclusions drawn herein can be applied to other treatment modalities where long term 
cancer risk is of clinical importance, such as radiotherapy in the management of younger patients. 
Patient-related technology such as deep inspiration breath hold shows promise for significantly reducing 
treatment related risks, and was shown not to significantly increase lung dose. As new technologies 
become available it is essential that each be evaluated to fully realise their potential to achieve 
maximum benefit for patients.  
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Chapter 7 - Conclusions 
 
The objective of this thesis has been to characterise the peripheral or ‘out-of-field’ dose reaching 
untargeted healthy tissue in radiotherapy treatment of breast cancer. Motivation for this work stems 
from the increasing prevalence of breast cancer and the important role of radiotherapy treatment in the 
management of the disease; approximately 16,000 new cases are diagnosed every year in Australia 
alone and with 5 year survival rates currently at 90%, this presents a large cohort of long term survivors. 
As improved treatment technology increasingly translates to more favourable outcomes, understanding 
the associated risks of radiotherapy treatment becomes increasingly important. 
 
Assessment of radiotherapy risk is complicated; while there are a host of underlying patient-related 
factors such as genetics, sex, age at time of radiotherapy treatment, previous exposure to ionising 
radiation and so on, the absorbed dose is generally used to estimate the risk of treatment side effects. 
Unfortunately, dose estimates for radiation not in the primary treatment region from commercially 
available treatment planning systems are inaccurate, often under-estimating the dose in these regions, 
and therefore by extension underestimating the associated risks of long-term side effects including 
radiocarcinogenesis. Determination of out-of-field dose therefore often requires direct measurement, 
which was the focus of this thesis. 
 
Although labour-intensive, and therefore not routinely employed, in vivo dosimetry currently stands as 
the most immediate and reliable means of assessing out-of-field dose. Patient-related factors can 
dramatically affect the out-of-field dose, particularly in regions adjacent to the treatment target. The size 
of the target will determine the size of the radiation fields to be used, with larger field sizes resulting in 
a higher portion of internal scatter within the patient. Patient geometry will further influence the 
treatment, particularly in breast radiotherapy where patient shape varies considerably, influencing the 
choice of beam angle, energy, field size and use of accessories such as wedges. Technical 
considerations further add to the complexity with some clinics employing state-of-the-art treatment 
techniques such as inverse-planned intensity modulated radiotherapy (IMRT) or volumetric modulated 
arc therapies (VMAT). Assessment of out-of-field dose is therefore highly case specific, thereby 
necessitating in vivo dosimetry. The thermoluminescence dosimetry (TLD) study presented in Chapter 
2 highlighted the differences in accuracy of various dose calculation algorithms in out-of-field regions. 
Despite being developed from the same manufacturer, these algorithms exhibited varying degrees of 
accuracy in regions near the treatment field. This stems from the fundamental differences in approach 
to radiation transport modelling between the different algorithms which in turn leads to differences in 
the final dose distribution between algorithms for the same radiation field. The commissioning of a new 
algorithm can also affect its accuracy. Differences are mainly evident in scenarios involving 
inhomogeneities or in regions at or beyond the field edge. This was observed in Chapter 2 where, for 
the same treatment, different algorithms estimated substantially different dose out-of-field, even in 
regions close to the field edge. A common finding from all algorithms though was the failure to predict 
any dose at all beyond a given distance from the treatment field edge. At such distances, leakage and 
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scatter from the treatment head begin to dominate. It was found that a simple correction for leakage 
radiation was able to improve dose estimates at out-of-field locations. As algorithms were developed 
by the manufacturer however, this leakage correction did not fully account for the discrepancy in dose. 
This is despite the findings shown in Chapter 4 which discussed leakage dose measured using a 
collimated detector that determined a leakage contribution of 0.01 % of the primary beam. The 
measurement points used in the cohort of breast radiotherapy patients however were likely too close to 
the treatment field for leakage dose alone to be dominant; therefore a simple leakage dose correction 
was not appropriate at these regions. Further measurements were conducted on patients who were 
undergoing stereotactic ablative body radiotherapy (SABR) treatment for primary kidney cancer. This 
advanced technique, characterised by high doses per fraction and tight margins requiring stringent 
image-guidance, provided a unique opportunity to assess leakage dose far out-of-field. This work was 
presented in Chapter 3  and demonstrated that at regions beyond 40 cm from isocentre the out-of-field 
dose is nearly constant. Furthermore, the magnitude of the dose measured in these regions was 
approximately 0.05 % of the prescription dose. This finding is consistent in magnitude with 
measurements conducted using the collimated detector presented in Chapter 4, and is consistent with 
IEC recommendations for maximum allowable leakage radiation from medical linear accelerators. 
 
In properly commissioned commercial radiotherapy treatment planning systems high dose regions 
within the radiation field are typically well modelled. Surface dose however is typically not modelled 
accurately despite being within the high dose region, even within a system which has been properly 
commissioned. This is because surface dose is affected by not only primary photons in the beam but 
also electron contamination and photon scatter from the treatment machine. Again, direct measurement 
is therefore required in order to provide dose estimates to skin regions in breast cancer radiotherapy. 
Surface doses for various high-energy photon beams was presented Chapter 5. This chapter discussed 
the differences in surface dose both in- and out-of-field for a ‘typical’ breast radiotherapy treatment field, 
such as would be used clinically. With a scarcity of published data on surface dose of modern photon 
beams, particularly flattening filter free (FFF) modalities, this work provided important new data which 
can be readily used to compare the surface dose between different photon beams. In addition, it was 
found that the surface dose from FFF beams at out-of-field regions was less than that from flattened 
beam of similar nominal beam quality. During treatment these regions correspond to normal healthy 
tissue particularly the contralateral breast. As such this provides some potential to reduce the dose to 
the contralateral breast should FFF treatments gain popularity in breast radiotherapy. The relative 
merits of such beams in the treatment of breast cancer remains to be seen and is the focus of various 
other research efforts. 
 
Full assessment of the technical or ‘machine-specific’ aspects of peripheral dose in radiotherapy is 
made complicated by various factors with one of the greatest challenges being that out-of-field dose 
will change depending on the treatment machine used, since manufacturers incorporate different head 
designs in their linear accelerators and therefore measurements conducted on one machine do not 
necessarily translate to another machine type, even from the same manufacturer. A systematic effort 
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to ‘map’ out-of-field dose from medical linear accelerators will therefore only apply to the machine on 
which the measurements were taken. This was discussed in a paper in which leakage dose at the 
treatment machine surface was measured and compared for different linear accelerators (Lonski et al. 
2012). This work demonstrated that the leakage dose from the treatment head varies not only between 
linacs from different manufacturers but even amongst different machine models from the same vendor. 
It was further demonstrated that, owing to additional shielding provided by the multileaf collimator banks, 
leakage dose along the x and y directions may vary considerably, and in fact dose beneath the MLC 
leaf bank was found to be approximately half that of the dose along the perpendicular direction. From 
this work it was concluded that dose from the linac reaching the patient plane may be reduced via 
judicious choice of collimator rotation thereby providing a relatively simple means of reducing out-of-
field dose to at-risk patients in cases where such collimator rotations are able to still provide similar 
treatment plan quality. Measurements at the patient plane would however be required to ascertain the 
consequences of this leakage dose at the linac surface to the patient.  
 
Since no such device was available, a collimated detector system was devised as part of this work 
which would provide focused measurements directed at points of interest at the linear accelerator from 
the patient plane. In this way, radiation contributions from directions other than a relatively narrow 
acceptance angle were excluded from assessment via shielding provided by the walls of the collimated 
device. High sensitivity thermoluminescent dosimeters (TLDs) were employed for their linear response 
and sensitivity to low radiation doses. Out-of-field dose from the linear accelerator was systematically 
mapped at the patient plane using the device and it was found that, for a variety of field sizes and gantry 
rotations, the leakage component did not exceed the manufacturer’s specification of 0.1 % dose at 
isocentre at 1 meter distance. The leakage dose was in fact determined to be closer to 0.01 %, with the 
highest dose originating from regions central within the linac head, attributable to the source of 
bremsstrahlung production within the photon target. This is consistent with the leakage dose measured 
in vivo and the 0.04 % proposed leakage correction determined in Chapter 2. Other points at the linac 
measured even lower doses of 0.0025 %, attributable to scatter within the gantry. This was the first 
systematic assessment of leakage dose from a medical linear accelerator performed at the patient 
plane, providing valuable data for estimating the leakage dose to out-of-field regions in patients 
undergoing external beam radiotherapy. 
 
Out-of-field dosimetry still stands as a unique and often complicated area of ongoing research in 
radiotherapy. Throughout this project a TLD system has been specifically refined to exploit the versatility 
of a unique TL material for use as an out-of-field dosimeter having applications in vivo and ‘in silico’ 
phantom studies. The system of TL dosimetry described herein has been subsequently adopted for use 
as a clinical in vivo dosimetry service at the Peter MacCallum Cancer centre, which treats approximately 
7,000 patients annually across its five campuses in the state of Victoria. Since the new TLD service 
was implemented, the use of LiF:Mg,Cu,P TL material has enabled several out-of-field dose 
measurements on patients undergoing radiotherapy. Over the last two years alone, 35 measurements 
were conducted at out-of-field locations as exploratory measurements to investigate dose to untargeted 
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healthy structures, equating to approximately 10% of all patient in vivo dosimetry measurements 
performed using TLD. Many of these measurements were requested by the treating clinician. Some 
60% of these out-of-field dose measurements were performed as routine quality assurance to verify 
dose to pacemakers. The remaining measurements were for dose verification to lens of the eye and 
other critical structures. While the focus of this project has been specific to breast cancer, there is 
considerable scope to expand the use of TLD as an out-of-field dosimeter to include other treatment 
sites in future.   
 
This thesis has demonstrated that commercial treatment planning systems in general underestimate 
the radiation dose, and therefore associated risk, at untargeted regions in radiotherapy for breast 
cancer. This effect worsens at locations further from the treatment region. A correction for leakage 
radiation derived directly from in vivo dosimetry has been proposed which compensates for limitations 
for commercial treatment planning systems. The physical and dosimetric challenges of performing TLD 
measurements at locations far from the field edge have been assessed within the unique radiation 
measurement conditions afforded in stereotactic treatments and determined to have minimal impact on 
measurement accuracy for the purposes of assessing leakage dose in vivo using the TLD handling 
processes described herein. The leakage component as measured in vivo is consistent with 
measurements performed directly at the linac head in a collimated detector system and found to be 
lower than the maximum allowable limit as prescribed by the International Electrochemical Commission. 
Although largely unaccounted for, the magnitude of the leakage radiation to which patients are exposed 
is generally considered low compared to doses absorbed closer to the field. It is in these higher dose 
regions in which second cancers occur. However, if our current understanding of the effects of these 
low radiation doses is to be improved, more accurate knowledge of the magnitude of these doses is 
required, which this theses has addressed. Furthermore, it is estimated that the leakage dose from a 
50 Gy treatment using standard tangents as measured in this work may cause an estimated 13 second 
cancer inductions annually in patients treated with radiotherapy across Australia. Increasing use of 
IMRT and VMAT techniques would need to be balanced against this associated risk and should only 
be used in cases where conventional plans are unable to achieve clinically acceptable dose 
distributions. Risks from exposure to leakage radiation are relatively low. In the intermediate and high 
dose regions, normal healthy tissues which are at higher risk include the contralateral breast, heart and 
skin. Deep inspiration breath hold for cardiac sparing is emerging as a promising technique to reduce 
heart dose. Future technologies such as the introduction of flattening filter free beam modalities have 
been explored in the context of breast radiotherapy and, if comparable plan quality can be achieved, 
may reduce the out-of-field dose compared to conventional beams, particularly to healthy regions 
adjacent to the treated volume, such as the contralateral breast. It is hoped the results of this work will 
be of service to the many patients and clinicians embarking on breast cancer management using 
radiotherapy, both now and into the future. 
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Appendix 
 
 
Assessment of leakage doses around the treatment 
heads of different linear accelerators 
 
 
This work aimed to directly assess radiation at the linear accelerator by positioning TLDs in contact with 
the linac surface. TLDs were placed along the waveguide and at the beam exit side of the collimator 
plate. Radiation doses arising during linac operation were compared for different field sizes and 
collimator rotations. Leakage dose at given points of interest were compared for different linac models 
from various manufacturers. Significant differences in leakage dose were found between various linac 
models, indicating that leakage contributions may be machine-specific. It was found that a single-energy 
linac produced the least leakage radiation. The highest leakage dose, measured to be 5 times that of 
the single-energy machine, was measured from a multimodality linac of a different manufacturer. This 
work highlights that differences in leakage dose between various manufacturers can be significant and 
that there is potential for patient-positioning strategies, linac choice and shielding strategies to reduce 
the leakage dose to patients. 
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Out-of-field doses to untargeted organs may have long-term detrimental health effects for patients treated with radiotherapy.
It has been observed that equivalent treatments delivered to patients with different accelerators may result in significant differ-
ences in the out-of-field dose. In this work, the points of leakage dose are identified about the gantry of several treatment
units. The origin of the observed higher doses is investigated. LiF:Mg,Cu,P thermoluminescent dosimetry has been employed
to quantify the dose at a several points around the linac head of various linear accelerators (linacs): a Varian 600C, Varian
21-iX, Siemens Primus and Elekta Synergy-II. Comparisons are also made between different energy modes, collimator rota-
tions and field sizes. Significant differences in leaked photon doses were identified when comparing the various linac models.
The isocentric-waveguide 600C generally exhibits the lowest leakage directed towards the patient. The Siemens and Elekta
models generally produce a greater leakage than the Varian models. The leakage ‘hotspots’ are evident on the gantry section
housing the waveguide on the 21-iX. For all machines, there are significant differences in the x and y directions. Larger field
sizes result in a greater leakage at the interface plate. There is a greater leakage around the waveguide when operating in a
low-energy mode, but a greater leakage for the high-energy mode at the linac face. Of the vendors investigated, the Varian
600C showed the lowest average leakage dose. The Varian 21-iX showed double the dose of the 600C. The Elekta Synergy-II
had on average four times the dose leakage than the 600C, and the Siemens Primus showed an average of five times that of
the 600C. All vendors show strong differences in the x and y directions. The results offer the potential for patient-positioning
strategies, linac choice and shielding strategies to reduce the leakage dose to patients.
INTRODUCTION
The increasing efficacy of cancer treatment is length-
ening patients’ lifetimes. An unfortunate corollary of
this is that secondary cancers have more time in
which to become manifest. Consequently, there is
much interest in out-of-field doses—i.e. doses given
to otherwise healthy anatomy outside of the treat-
ment field. Such doses arise due to both patient
scatter and leakage from the treatment linac. There
have been several interesting reviews published on
this topic(1–3). In particular, a recent paper analyses
the published data to identify the observed trends in
the out-of-field dose as they vary between different
linac models, treatment energies, field sizes, methods
(such as conformal or intensity-modulated radio-
therapy) and so on(4). In the latter work and an
earlier study within the context of out-of-field doses
in paediatric radiotherapy(5), a number of means of
significantly reducing the out-of-field dose to the
patient was observed, including delivering the treat-
ment with a (single-mode) Varian 600C rather than
a (multi-mode) Varian 21-iX, altering collimator
rotation and so on.
The present work determines the leakage around
the treatment head of several linac models for differ-
ent treatment energy, collimator rotation and field
size to identify the origin of observed differences in
the out-of-field dose at the patient plane.
Thermoluminescent dosimetry (TLD) using TLD-
100H dosemeters placed at key locations around
the linac gantry is used to map the leakage dose.
Photon doses from Varian 600C, Varian 21-iX,
Siemens Primus and Elekta Synergy-II accelerators
are investigated.
METHODS
Thermoluminescent dosimetry
Dose measurements at key locations around the
linear accelerators (shown in Figure 1a) were under-
taken using TLD. LiF:Mg,Cu,P TLD-100H chips
(Harshaw, KS, USA) were employed as they are
highly sensitive and exhibit less variation in response
with photon energy(6) than standard TLD-100
LiF:Mg,Ti. Uncertainties in the dopant concentra-
tion and the existence of unwanted impurities within
this TL material have been shown not to significant-
ly affect the photon–electron behaviour(7). TLD
calibration was performed in a clinical MV photon
beam at the depth of maximum dose in solid water,
using a 1010 cm2 field at 100-cm source-surface
distance. As such the detectors are calibrated to
# The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
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absorbed dose to water. Individual sensitivity factors
were used to correct the readings from each TLD
chip following all measurements. For each set of
measurements, a calibration group of five TLDs
were given 10 cGy. The average reproducibility of
TLD measurements was better than 2 % (1s). Using
multiple TLDs for calibration yielded an overall
uncertainty of 4 % at the 95 % confidence level for
a given dose reading. Each measurement was
performed with a pair of TLDs, the agreement of
which is illustrated in Figure 2, mounted in an
acrylic holder illustrated in Figure 1b. A read-out
was performed using a Harshaw 5500 automatic
TLD reader. For a detailed discussion on the micro-
dosimetry of LiF:Mg,Cu,P, the reader is referred to
the review by Olko (2006)(8).
Accelerators and parameters investigated
Measurements were undertaken for four different
linear accelerators: a Varian 600C, Varian 21-iX,
Siemens Primus and Elekta Synergy-II. Schematics
of the collimator design for various linacs is given
by Joosten et al.(9) The linacs used in the present
study are shown schematically in Figure 3. Beam
energy, collimator rotation and field size were also
varied. These parameters are summarised in Table 1
for reference. As the main goal was to quantify the
leakage dose, and not scatter, a phantom was not
present. TLDs were localised at several locations on
the external surfaces around the collimator head of
each linac. Because of the differing designs, mean-
ingful comparisons are made complex in some cases.
As such, a number of points about the linac head
may be considered ‘equivalent’ among the different
models and are indicated in Figure 1a. In addition
to these eight locations, a number of other points are
also investigated for the leakage dose around the
Varian 21-iX waveguide. The measurement points
are indicated in Figure 4 where the results are also
shown.
Measurements
Measurements were first taken to assess whether or
not the dosemeters were in the regions of adequate
build-up, following which the dose around the linac
head and waveguide was measured.
Attenuation
It is important to determine whether or not the
TLDs affixed to the linac are in the regions of
sufficient build-up for sensible interpretation of the
measured doses. To this end, measurements were
undertaken with various materials fixed to the
TLD holders; 29-mm blocks of low-density foam
(Styrofoam, density¼0.04+0.02 g cm23), alumin-
ium, brass and lead were employed. From the
Figure 2. In each measurement session, the out-of-field
doses were measured with two TLDs at each point of
interest; the figure demonstrates the agreement between the
TLD pairs (r2¼0.989). The line of identity indicates
perfect agreement.
Figure 1. (a) The schematic of the TLD locations placed around the linac head on the Varian 600C and 21-iX, Siemens
Primus and Elekta Synergy-II. (b) The schematic of the acrylic holder used to secure pairs of TLDs when affixed to points
of interest about the linac. The holder provides 3 mm of materials above and below the TLDs for buildup and backscatter.
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differential reading of the TLDs under the different
materials, it is possible to estimate the radiation
quality and to ensure that the actual maximum dose
is determined. Furthermore, experiments with lines/
arrays of TLDs at the nominal measurement points
(Figure 1a) were undertaken to ensure that the
measurements were not subject to misinterpretation if,
for instance, they were positioned, by chance, directly
beneath the joins between two shielding blocks.
Linac head
Measurements were made at points at the interface
plate (points 1–4 in Figure 1a) and around the
outside of the collimator cover (points 5–8). The
dose leakage patterns were compared for each linac
model for the measurement points in both the
presence and the absence (i.e. retraction) of x and y
jaws. In the case of the Siemens model, which
has no lower jaw pair, measurements made at the
interface plate investigate the effectiveness of the
multi-leaf collimator (MLC) leaves at attenuating the
primary beam. Measurements were conducted for
both an open (4040 cm2, 3434 cm2 for Elekta)
and a small (44 cm2, 33 cm2 for Elekta) treat-
ment field for each linac model in order to quantify
the influences of attenuation and scattering of the
primary beam by the collimators.
Waveguide
As bremsstrahlung photons are produced in the
linac waveguide, the dose leakage measurements
were made along the surface of the waveguide of a
Varian 21-iX machine. The waveguide also has
notably less shielding than the linac head. In the
case of the waveguide measurements, 50 cGy was
delivered to the isocentre with a 6-MV beam.
RESULTS
Each measurement point was assessed with two TL
dosemeters and averaged. The agreement between
each pair of TLDs is illustrated in Figure 2. As each
measurement point is represented by the pair of two
detectors 10 mm apart from each other, the data dem-
onstrate that the measured dose is not subjected to a
large local spatial variation between the two TLDs at
each measurement location. As can be seen from the
figure, this applies to the full range of dose observed.
To ensure that the TLD output may be interpreted
as dose, and that the measurements were not taken in
Figure 3. The schematic depicting the collimator design
for (a) Varian (21-iX and 600C), (b) Siemens Primus and
(c) Elekta Synergy-II machines. Components are not to
scale and the curved travel of the collimators is not shown.
MLC leaves were retracted for all measurements, the
arrangements depicted above are shown only for artistic
purposes.
Table 1. Overview of accelerators and parameters investigated.
Parameter Accelerator
Varian 600C Varian 21-iX Siemens Primus Elekta Synergy-II
Field size (cm2) 44, 4040 44, 4040 44, 4040 33, 3434
Collimator Rotn. (8) 0, 90 0, 90 0, 90 0, 90
Energy (MV) 6 6, 18 6, 18 6, 18
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build-up regions, sheets of foam, aluminium, brass
and lead were provided between the linac surface and
the TLD holder, and example results are shown in
Figure 5 for the 21-iX and 600C machines. The
results indicate that no additional build-up layers
(beyond that already provided by the acrylic TLD
holder) are necessary. This means that, in general, the
interpretation of measured doses is straightforward.
There is a notable spatial variation in the leakage
dose about the linac gantry. This is demonstrated in
Figure 4 for the 21-iX. There is a notable leakage
about the waveguide. This is also the case for the
(isocentric waveguide) 600C, though the greater
leakage was measured above the waveguide (i.e.
directed away from the patient).
Various systematic measurements have been made
for comparison. The dose (as a % of 5 Gy reference
dose) for each key treatment parameter and location
is presented in Figures 5–8.
Effects of distance from field edge
Dose measurements were made along the interface
plate (see Figure 9b) on an Elekta Synergy-II
machine operated at 18 MV for a 4040-cm2 field
with 500 MU delivered in the treatment field to de-
termine the behaviour of the out-of-field dose away
from the treatment field. The results suggest contri-
butions from increased attenuation path lengths and
1/r2 changes from scatter sources, indicated by the
decrease in the dose leakage along the interface
plate outward from the field edge. Figure 9a shows
the results of dose measurements at six separate
locations along the interface plate.
Beam quality
The results of attenuation measurements are plotted
in Figure 5a for a 6-MV beam and in Figure 5b for
an 18-MV beam. A 500-MU dose was delivered in
the treatment field. The measured dose is plotted as
a percentage of reference dose measurements (5 Gy
delivered to standard TLDs). The horizontal axis
shows measurement points 7, 3 and 4 after 29-mm
foam, aluminium, brass and lead, in addition to the
acrylic holder.
Figure 5a shows the decrease in TLD reading
expected for increasing attenuation if a 6-MV X-ray
beam is used. This indicates that the other measure-
ments for the 6-MV beam do indeed provide infor-
mation on maximum fluence. In the case of 18 MV,
similar conclusions can be drawn for points 4 and 7.
However, the results for brass and aluminium
Figure 4. The out-of-field dose measured at several key
points around the Varian 21-iX accelerator (indicated by
shaded red circles) for a 6-MV beam. The key indicates the
dose as a % of the isocentre dose (5 Gy). Note that the
highest measured doses are beneath the waveguide cover.
This figure appears in colour in the online version of
Radiation Protection Dosimetry.
Figure 5. Investigation of build-up conditions for TLDs affixed to the linac gantry with the use of various build-up
materials. The vertical axis shows the measured dose (as a percentage of the 5 Gy delivered to standard TLDs) while
the horizontal axis corresponds to the four different absorbers: foam (effectively air), aluminium, brass and lead—each of
29-mm thickness. These particular measurements were taken at (a) 6 and (b) 18 MVon the Varian 21-iX.
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(in Figure 5b) also indicate uncertainty about the
spectrum and/or the direction of radiation at
point 3. Therefore, the results for 18 MV must be
interpreted with caution.
Effects of field size
The dose leakage measured on the four different
linac models investigated is shown in Figure 6 for
both small and large fields with 500 MU delivered
in the treatment field. Doses are plotted as a percent-
age of standard TLDs (5 Gy delivered) for each
of the eight measurement locations illustrated in
Figure 1a.
Effects of MLC leaves
The results of average leakage dose values beneath
the interface plate are shown in Figure 7. TLDs
were placed at the interface plate at equal distances
Figure 7. The results for averaged dose measurements made beneath the collimator for each linac model using a 6-MV
beam and 4040-cm2 treatment field. Points 1 and 3 were located beneath the MLC leaves, while points 2 and 4 were at
908 to these. (b) The schematic depicting the two types of measurement locations. The shaded regions represent the
location of MLC leaves within the linac treatment head.
Figure 6. The out-of-field dose measured for a 6-MeV beam at eight different locations on the linac head of (a) Varian
21-iX, (b) Varian 600C, (c) Siemens Primus and (d) Elekta Synergy-II machines. The results obtained using a large and a
small field are shown for each measurement location.
P. LONSKI ETAL.
308
 at Peter M
acCallum
 Cancer Institute on January 16, 2013
http://rpd.oxfordjournals.org/
D
ow
nloaded from
 
89
away from central axis in the patient right, patient
left, and superior and inferior directions (corre-
sponding to points 1–4 in Figure 7b) and 500 MU
were delivered in the treatment beam. The MLC leaf
bank was in its retracted position. The vertical axis
shows the measured dose as a percentage of 5 Gy
delivered to standard TLDs. The horizontal axis
shows each linac model for two cases; points 2 and
4 were averaged to indicate the leakage dose beneath
the MLC leaf bank, as well as the x-jaws for all
models except for the Siemens Primus. Points 1 and
3 were averaged to obtain the leakage under
secondary collimators only (y jaws). The shaded
regions in Figure 7b indicate the location of MLC
leaf banks within the linac head.
Effects of beam energy
Leakage dose measurements made for both 6- and
18-MV beams are shown in Figure 8. The results
obtained using both beam energies are shown side
by side along the horizontal axis for each of the
three multimode machines. The vertical axis shows
the dose values as a percentage of the 5 Gy
Figure 9. (a) Dose measurements made at an increasingly larger distance from the field edge on an Elekta Synergy-II
machine. (b) The schematic depicting the measurement points.
Figure 8. Dose leakage measurements under varying energy for all multimode linacs for (a) small field beneath the
collimator, (b) large field beneath the collimator, (c) small field around the collimator and (d) large field around the
collimator.
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(500 MU) reference dose. The results labelled
‘beneath collimator’ refer to the average dose of
points 1–4, where ‘around collimator’ refers to aver-
aged points 5–8. Recall from Table 1 that a small
field is defined as 44 cm2 for all vendors except for
the Elekta Synergy-II (33 cm2) and a large field is
defined as 4040 cm2 except for the Elekta
Synergy-II (3434 cm2).
Waveguide measurements
Dose leakage measurements were made along the
waveguide of a Varian 21-iX machine as 500 MU
were delivered in the beam. The results show a
considerable variation in dose, with approximately
symmetrical behaviour about the centre as evident in
Figure 4. The largest doses were at the linac head
end. The leakage dose from the horizontal waveguide
is likely to be responsible for the notable difference in
the out-of-field doses to patients observed in a previ-
ous study(5). Doses directly beneath the central axis
of the waveguide were considerably lower than those
to either side. This presumably reflects the internal
structure providing source shielding.
DISCUSSION
These investigations were undertaken after a previ-
ous study in which significant differences in dose to
untargeted organs are found when using two differ-
ent linacs, operated at the same energy, to give the
same paediatric treatment(5). It was expected that,
for the two Varian units initially studied, the patient
scatter would be similar and hence differences in the
out-of-field dose would arise mostly due to leakage.
This hypothesis was strengthened by the fact that the
regions exhibiting the greatest difference between the
two linacs were those expected to be dominated by
the leakage rather than the patient scatter, i.e. .40
cm from the treatment field. In the present study,
the differences in leakage dose were quantified for
different linac designs, including those by the same
manufacturer. This is of course related to waveguide
orientation, shielding design and the nature of the
beam collimation system. It should be noted, before
discussing the results of this study, that manufac-
turers in general do not optimise medical linac
designs in terms of leakage minimisation. Rather,
focus is given to energy spectra, field shaping and so
forth, with a leakage reduction addressed to the
extent required by industry regulations. There are
advantages and disadvantages to different linac
designs, and these should be considered with respect
to different treatments. Only when a treatment can
be given that is entirely equivalent (in terms of the
efficacy of treating the primary disease) would a
lower leakage linac be preferentially selected.
The broad finding is that the Varian 600C, a
single-energy mode linac with isocentric waveguide,
generally exhibits the lowest leakage directed
towards the patient plane. Table 2 summarises the
findings and recommendations of this study.
One would expect, in a very general sense, that
the leakage may be a significant issue around the
bending magnet in the multimode linacs; however,
this region is well shielded and it transpires that the
horizontal waveguide is a more pronounced source
of leakage. Consider Figure 7, with reference to the
above discussion of the difference in the out-of-field
dose between the two Varian linacs observed in a
previous study. Specifically, note that the key points
1–4 about the linac face (indicated in Figure 1a)
on both the Varian 600C and 21-iX exhibit leakage
doses of the same order of magnitude (the latter is
on average about a factor of 2 higher). However,
leakage doses around the waveguide on the 21-iX
are the likely origins of the previously reported
difference in the out-of-field patient dose. With
this knowledge, manufacturers may be interested in
further shielding around the waveguide structure.
Furthermore, clinicians performing 6-MV treat-
ments on particular patients (e.g. paediatric
patients, patients with benign lesions etc.) may
select, when possible, to preferentially treat on a
single-mode linac such as the 600C so as to minim-
ise the out-of-field dose and associated risks. With
regards to the large differences relevant to the
changes in collimator orientation on the Varian
machines, this arises due to the collimator design.
The Varian linacs possess x and y collimating jaws,
and both have a tertiary micro-multileaf collimator.
The latter provides an additional attenuative layer
which functions to reduce the leakage dose along a
particular axis, which is why there are significant
differences between the x and y directions. For
treatments that do not require specific collimator
rotations, aligning the craniocaudal axis of the
patient with the direction of MLC leaf motion may
be a further means of the out-of-field dose
reduction.
The shielding and collimator design in the Elekta
Synergy-II differs from the Varian models and con-
sequently there are notable differences in the leakage
dose patterns. The Varian machines possess collimat-
ing jaws mounted orthogonally above one another,
downstream of which is the MLC. The Synergy,
however, uses the MLC to shape the field, with
downstream jaw collimators to back up the field.
The y jaws are mounted linearly with the MLC leaf
bank and never used for primary collimation (unlike
the Varian, which has jaws of equal thickness). As a
result of these dissimilarities, there are significant
(order of magnitude) differences in leakage in the x
and y directions. Furthermore, these are significantly
higher than the Varian leakage doses.
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Unsurprisingly, the shielding arrangement in the
Siemens Primus differs from the other models, but
there are also very significant differences in the colli-
mator design which are important to note, because
(of the linacs investigated) the Primus exhibits the
greatest mean leakage dose. It should be noted that
this is the case on average only; for larger fields, in
particular, the leakage is similar or less relative to
the other units. There are significant disparities in
the leakage dose in the x and y directions arising
from the notably different collimator arrangement.
The Varian and Elekta models incorporate jaw pairs
with an MLC for collimation, where the MLC leaf
bank lies in a plane parallel to the patient. The
Primus, however, incorporates an MLC composed of
vanes that move in an arc-like motion, above which
is a single jaw pair with arc-shaped geometries
capable of driving in and out of the field and rotat-
ing to match the field divergence. One side of the
linac face is sectioned out and consequently provides
less attenuative material, resulting in significantly
higher (order of magnitude) leakage doses. If the
nature of the treatment being given allows, it may be
possible to select a collimator rotation such that this
high-leakage region is directed away from the body
of the patient.
There are differences in the leakage dose when
operated at different nominal energies (in this work,
6 and 18 MV are compared). Around the waveguide,
there is a greater leakage in the low-energy mode.
From a priori knowledge of the accelerator design
and the behaviour of the charge particles within, this
is to be expected. The relative velocity, b, of elec-
trons in the waveguide when operated at 6 MV is
0.9969, while at 18 MV, b¼0.9996. As a result,
one would expect greater leakage radiation from the
waveguide when operating in the lower energy mode
as opposed to the higher energy mode, as a result of
the angular dependence of the bremsstrahlung
photons generated. Specifically, the emitted radiation
intensity in the lower energy case is about a factor of
3 less forward-peaked than in the higher energy case.
This means an increased fraction of photons direc-
ted ‘out’ (radially) of the waveguide. Furthermore,
and likely to be the more dominant effect, the pulse
frequency is higher in 6 MV to contend with the
poorer target efficiency (and to achieve the lower
energy, since the energy available is distributed
amongst the particles). This results in a higher
current of particles in the waveguide at 6 MV.
Under the collimators, however, an 18-MV beam
produces more leakage dose due to greater collima-
tor penetration, as expected. The leakage dose is up
to one and a half times greater in the case of the 21-
iX for an open field. These findings are strengthened
by Monte Carlo simulations of the Varian 21-iX in
both 6- and 18-MV mode (using a dosimetrically
matched EGSnrc(10, 11) model), whereby the latter is
Table 2. Summary of findings. In all cases, there are large differences in dose between the x and y directions.
Accelerator Average leakage dose
(all locations)
Comments
Varian 600C 0.15 (%) Lowest leakage of linacs studied
Strong differences in x and y directions
Align patient with MLC leaves to reduce dose
Varian 21-iX Average 2600C leakage Strong differences in x and y directions
Align patient with MLC leaves to reduce dose
Use 600C to reduce dose
Varian 21-iX
(18 MV)
Average 3600C leakage Strong differences in x and y directions
Align patient with MLC leaves to reduce dose
More leakage at linac face due to increased penetration through
collimators
Less waveguide leakage than at 6 MV
Elekta Synergy-II Average 4600C leakage Strong differences in x and y directions
Jaw thicknesses notably different
Use collimator rotation of 908 for couch at 08 to reduce leakage dose
to patient
Siemens Primus Average 5600C leakage Significantly different collimator design
Strong differences in x and y directions
Leakage similar to other linacs for larger fields
Orient sectioned-out region of linac face away from patient where
possible
Recommendations are given for a relative patient orientation so as to minimise the leakage dose intersected by the patient.
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found to result in a greater fluence of particles
transmitted through the collimator system.
CONCLUSION
Although the primary beam properties may be
matched to other linacs within a clinic, the leakage
around the gantry varies considerably from one linac
type to another, even for the same manufacturer.
This has previously been reported to result in signifi-
cant differences in the out-of-field dose and asso-
ciated risks of radiocarcinogenesis. Knowledge of
the leakage from a linac may be exploited in terms
of informing linac choice when treating particularly
susceptible patients, such as children, as well as
informing shielding designs. The complexity of
leakage patterns makes it hard to predict dose distri-
butions out of the field. In general, the Varian 600C
linear accelerator exhibited the least leakage dose.
All linacs investigated showed large differences in
the x and y directions—a result attributed to inher-
ent asymmetry of the MLC leaf bank. The Siemens
Primus machine showed the greatest average leakage
dose (up to five times that of the Varian 600C); the
Elekta Synergy-II delivered up to four times that of
the 600C and the 21-iX was on average nearly
double—despite being of the same manufacturer.
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